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Thesis abstract and outline  
The format of this thesis is as follows: a general introduction, a literature review, a research 
proposal, a systematic review, a general discussion, references and appendices. Both the 
literature review and systematic review (Chapters 2 and 4) have been published in peer-
reviewed journals and are presented in their original manuscript format, except that language 
had been adjusted into Australian English for consistency, and literature citations have been 
collated within the reference section. 
 The work presented herein explores how peripheral ultraviolet light applied to the skin can 
affect the central nervous system and behaviour, with a focus on the clinical translation to 
prevalent neurological disorders. First, the impact of solar irradiation on the integumentary 
system and evidence of skin-brain-communication pathways are introduced. This discussion 
builds the concept that peripheral UV signals arising in the skin may result in global 
manifestations via the brain (Chapter 1). The idea of skin-brain communication is further 
explored with a literature review linking sunbathing, UV exposure seeking and addictive 
behaviour (Chapter 2). In this chapter, a novel hypothesis is presented suggesting that UV-
induced inflammatory signalling may influence neuronal circuits to increase the addictive-like 
behaviours observed in frequent tanners (Chapter 2). This idea provides the basis for a research 
proposal (Chapter 3) detailing planned experimental work to investigate whether UV radiation 
influences mesolimbic dopaminergic systems within the brain, and if inflammation plays a 
substantial role. Chapter 3 is presented as a research proposal as the work could not be 
completed due to unforeseen circumstances, which significantly reduced my capacity to 
continue with the study. Appendices have been included to exhibit the pilot research that had 
commenced. The final research chapter (Chapter 4) focuses on the role of sun-induced or 
administered vitamin D and its influence on neurological health. This chapter presents a 
systematic review of published literature that investigates whether the presumed protective 
benefits from vitamin D, in neurodegenerative disease, is dependent on route of administration.   
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Chapter 1. General introduction: Ultraviolet radiation and the brain  
This thesis will explore how peripheral ultraviolet radiation (UVR) to the skin can 
influence central neurocircuitry, and presents a novel hypothesis of skin-to-brain signalling 
facilitated by the immune system from UV-damaged skin cells. The ubiquitous nature of 
sunlight means that almost everyone will have some level of UV exposure on a daily basis; 
which occurs exclusively through the contact with the eyes and skin (Juzeniene et al., 2011; 
Lucas et al., 2006). Regardless of these two peripheral ports of entry, it has become 
apparent that the impact of UVR extends beyond the site of contact, affecting the organism 
as a whole. Historically, this has been attributed to vitamin D production, however, growing 
evidence suggests other UV-skin related mechanisms could be at play (Autier et al., 2014; 
Becklund et al., 2010; Slominski, 2015). Therefore, the purpose of this thesis is to explore 
current evidence surrounding UV exposure on the skin and the downstream central effects, 
with emphasis on neurological disorders. 
This introductory chapter will provide the relevant background information on 
UVR and how it interacts with skin cells, as the primary point of contact initiating 
biological reactivity within the body. This chapter will also introduce the pertinent themes 
of neuroimmune communication explored throughout Chapters 2 and 3.  
1.1 Solar electromagnetic radiation has important implications for life on earth 
The sun produces an enormous quantity of electromagnetic energy including 
cosmic rays, gamma rays, x-rays, UVR, visible radiation and infrared radiation. The 
electromagnetic radiation produced exists on a continuum that can be visualised as a 
spectrum, segregated by wavelength (Figure. 1.1). All high-energy radiation, including 
cosmic, gamma and x-rays, are reflected or absorbed by the Earth’s atmosphere. 
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Consequently, ground level radiation is comprised of infrared (53%), visible (44%) and 
UVR (3%) (Holick, 2016; Slominski et al., 2018). Although UVR contributes the least 
percentage, it is the most energetic component of solar radiation at the Earth’s surface as 
there an  inverse relationship between wavelength and energy, thus lower wavelengths are 
higher in energy (Figure 1.1). UVR energy is highly biologically active, making it a key 
determinant of life on Earth, working as both an initiator and driver of evolution (Rapf and 
Vaida, 2016; Raven et al., 2008). Simple organic molecules harness the energy from UVR, 
converting photons of light into high-energy chemical bonds, generating molecular 
complexity. In this way, the energy of UVR is comparable to that of a covalent bond 
(Slominski et al., 2018; Rapf and Vaida, 2016).  Despite the immense changes to Earth’s 
atmosphere in the 3.7 billion years since life began, UVR continues to reach the Earth’s 
surface and affect living tissues  (Juzeniene et al., 2011; Lucas et al., 2006).  
Figure 1.1 The electromagnetic spectrum of radiation. This illustration is adapted 
from a figure created by Philip Ronan and Gringer released under a CC-BY-SA-3.0 
copyright via Wikimedia.  
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1.1.1 Ambient atmosphere influences the amount of ultraviolet radiation in the 
immediate environment  
The composition of the atmosphere in the immediate environment is heavily 
influenced by solar altitude and the intensity of sunlight; therefore, variables such as 
geographic location, season and time of day can all impact on the amount of ambient UVR 
in the immediate environment (Young, 2009). Moreover, UVR can be reflected, scattered 
and dampened by atmospheric particles, thus quantities also vary according to the amount 
of atmosphere UVR must pass through (D’Orazio et al., 2013; Diffey, 2002). As a result, 
UV concentrations are higher closer to the equator, at higher altitudes and when there is 
reduced cloud cover (D’Orazio et al. 2013). Also, countries in the southern hemisphere 
have greater levels of UVR compared to those in the northern hemisphere, as the Earth’s 
orbit brings the southern hemisphere closer to the sun during the summer months  (Gies et 
al. 2004). 
An ongoing public health concern is the depletion of the stratospheric ozone layer 
through excessive production of chlorofluorocarbons (CFCs). Living in an industrialised 
society has led to increased quantities of CFCs in the atmosphere, contributing to the 
detrimental chemical breakdown of the Earth’s protective shield (Diffey, 2003; Laube et 
al., 2014; Lucas et al., 2006). Consequently, the amount of UVR reaching the Earth has 
significantly increased. Despite the fact that cloud cover and low atmospheric pollution 
make it difficult to assess fluctuations in UVR levels, monitoring of the Swiss Alps where 
the atmosphere is much clearer, indicates that there are increased levels of UVR in the 
northern hemisphere (Willemse and Furger, 2016). A similar observation has also been 
recorded in the southern hemisphere through monitoring UVR levels in Australia (Gies et 
al., 2004). Increases in ambient UVR pose a serious health threat as it increases the risk of 
negative health consequences from overexposure.  
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1.1.2 Electromagnetic energy of solar radiation is biologically active 
Although UVR covers a small portion of the electromagnetic spectrum, spanning 
100-400nm, the biological effects vary enormously between wavelengths. Thus, UV 
energy is further divided into UV-A (320-400nm), UV-B (280-320nm) and UV-C (200-
280nm) regions (D’Orazio et al., 2013; Diffey, 2002). From solar radiation, only UV-A 
and UV-B wavelengths are relevant in today’s climate as the ozone layer and atmospheric 
oxygen completely filter out UV-C wavelengths. Much of the UV-B wavelengths are also 
filtered, resulting in the majority (94-97%) of ambient UVR being comprised of UV-A, 
while the remaining 6-3% consists of UV-B (Lucas et al., 2006). Both UV-A and UV-B 
wavelengths penetrate cutaneous tissue of humans and can be absorbed by cellular 
components; including nucleic acids, urocanic acid, amino acids and melanin precursors. 
The amount of UVR absorbed through the skin critically influences the biological effects 
(D’Orazio et al., 2013; Hönigsmann, 2002).  
Absorption of UV photons initiates biological reactivity, as photon energy carried 
in each wavelength is transferred to molecules within cells, causing chemical changes 
(Diffey and Kochevar, 2007). Each UV absorbing molecule, such as amino acids, 
nucleotides and porphyrins within skin tissue, are typically referred to as chromophores. 
These molecules absorb a unique combination of wavelengths, which could include either 
UV-A/UV-B or both (Young, 1997). Differences in the absorption characteristics of 
chromophores account for the diverse effects produced at different wavelengths (Diffey 
and Kochevar, 2007; Lee et al., 2013; Slominski et al., 2018). UV-B wavelengths are the 
most efficient at exerting biological alterations as the absorption spectra of many cellular 
structures, including DNA and urocanic acids are within the UV-B range (Budden and 
Bowden, 2013). This also means that UV-B photons are the most harmful. The efficiency 
of DNA, RNA and cellular proteins to absorb UV-B photons results in nearly all UV-B 
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radiation being absorbed within the upper layers of the epidermis (Holick, 2016). These 
cellular chromophores are less effective at absorbing UV-A radiation, therefore, UV-A 
penetrates more deeply through the skin, reaching the upper portion of the dermis. UV-A 
has a tenfold reduced efficiency compared to UV-B, evident by the difference in minimal 
erythema dose, which is the amount of radiation that will produce minimal erythema 
(redness) of an individual’s skin  (Heckman et al., 2013; Slominski et al., 2018). This large 
difference in magnitude of biological effect has been suggested to arise due to differences 
in the quantum mechanics of electron excitation within specific chromophores, as the 
photon energy from UV-A and UV-B wavelengths are similar (UV-A=3.10-3.94nm, UV-
B is 3.94-4.43nm) (Slominski et al., 2018). UV-C is profoundly mutagenic and would 
mostly be absorbed by chromophores within the upper layers of the epidermis, if UV-C 
was not blocked out by the ozone layer (Lee et al., 2013). 
When a biomolecule absorbs UVR it transforms from a “ground state” to an 
“excited state”, which is higher in energy. This is characterised by a change in the electron 
distribution surrounding the nuclear framework. Each molecule can only absorb photons 
with certain energies as the laws of quantum mechanics only allow specific energy gaps 
between the ground state and excited state (Diffey and Kochevar, 2007). As the energy of 
the photon is inversely related to wavelength, each chromophore has a unique absorption 
spectrum. The duration of the excited state is very brief and molecules will quickly return 
to the ground state by giving off light or heat energy or by undergoing a photochemical 
reaction. A photochemical reaction results in the creation of a photoproduct, as the 
chromophore is converted to a new molecule that now has a different structure (Holick, 
2011). An example of a photochemical reaction is the conversion of 7-dehydrocholesterol 
(7-DHC) to pre-vitamin D3, in which UV photons alter the structure of the carbon-carbon 
bonds (Holick, 2011).  
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1.2 Cutaneous responses to ultraviolet radiation exposure 
1.2.1 The structure and function of human skin  
The major recipient of UV energy is the skin. hence downstream systemic UV 
related changes likely arise from skin-messenger systems (Slominski, 2015). Skin tissue is 
the largest organ of the human body and is anatomically divided into two regions that are 
separated by a basement membrane (Swann, 2010). The outermost layer, sitting on top of 
the basement membrane, is the highly cellular epidermis (approximately 100-150µm) 
forming a protective barrier over the body’s surface. Directly beneath lies the dermis (2-
4mm), which is predominantly non-cellular but contains structural proteins such as 
collagen and elastin. The dermis also consists of cutaneous structures including hair 
follicles, nerves, sebaceous glands and sweat glands, as well as a small number of immune 
cells and fibroblast cells (D’Orazio et al., 2013; Lugo et al., 2011).  Below the dermis lies 
the hypodermis which is predominately composed of subcutaneous fat and houses the blood 
and lymphatic vessels destined for the skin (Hayward and Keatinge, 1981). 
The main cell type of the epidermis are keratinocytes (95%), which continually 
proliferate by division at the stratum basale (basal layer) on top of the basement membrane 
(Pincelli and Marconi, 2010). Non-proliferating keratinocytes transit through a series of 
well-defined layers, with cells progressing to become anucleated, keratin filled corneocytes 
that form the outer non-living layer, the stratum corneum (Figure 1.2). The highly stratified 
cells of the stratum corneum are joined by rigid tight junctions providing the major 
component of the skin’s physical barrier (Proksch et al., 2008). Normal epidermal turnover 
is under tight homeostatic control where desquamation (cell shedding) is balanced with cell 
division (Young, 1997). The DNA of keratinocytes is a major chromophore of UV-B, and 
repeated exposure results in mutations that contribute to the formation of non-melanoma 
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skin cancers (Nasti and Timares, 2012). Melanocytes and Langerhans cells are the next two 
prominent cell types of the epidermis, but exist in much smaller quantities. Melanocytes 
are also found within the basale layer and synthesise melanin pigments through 
melanogenesis. Melanin pigments are transferred to adjacent keratinocytes as melanosome 
particles where they contribute to skin colour. Melanin also provides the skin’s natural 
defence against UVR, absorbing UVR photons and dissipating the energy as heat (Lin and 
Fisher, 2007). Increased sun exposure results in increased melanin production, to protect 
against sun damage, better known as tanning (Koch et al., 2006; Videira et al., 2013). 
Langerhans cells are the immunocompetent cells of the skin located throughout the 
epidermis but most prominently within the stratum spinosum, directly above the stratum 
basale. Langerhans cells are the antigen presenting cells (APC) of the skin, with long 
dendritic structures, they provide the first line of immunological defence. Once Langerhans 
cells become activated, they migrate to skin draining lymph nodes and initiate the 
proliferation of T cells (Bennett et al., 2007). 
 
Figure 1.2. Histological section of human skin. The epidermis is divided into the stratum 
corneum, stratum granulosum, stratum spinosum and stratum basale (Hill, 2018).   
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1.2.2 Negative consequences of ultraviolet radiation exposure 
Sun-related health consequences have been closely examined, as UVR is known to 
have profound effects on skin physiology. One of the most immediate, acute responses to 
UVR exposure is erythema, or redness of the skin, which is a radiation type burn, also 
known as sunburn (Clydesdale et al. 2001). The sunburn response is highly inflammatory, 
driven by a cascade of cytokines, chemokines, vasoactive and neuroactive mediators that 
together facilitate vasodilation and cellular repair pathways (D’Orazio et al., 2013; De 
Gruijl, 1999; Ichihashi et al., 2003; Jans et al., 2006; Matsumura, 2002). If UVR doses 
exceed the threshold damage response, keratinocytes will activate apoptotic pathways 
resulting in cell death (Jans et al., 2006; Laethem et al., 2005).  
As mentioned previously, the UVR spectrum has distinct pathways of cell damage 
determined by wavelength. UV-B is responsible for direct damage as it is absorbed by 
cellular chromophores and therefore has the potential to critically interfere with processes 
necessary for cell viability (Sklar et al., 2012). DNA is one of the major UV-B 
chromophores, and damage arises through UV-B-induced cross-linking of pyrimidine 
bases, thymine and cytosine, resulting in DNA mutations. Double stranded RNA can also 
be affected and form uracil dimers. The most common DNA photoproducts are cyclobutene 
pyrimidine dimers and 6,3-pryimidine-pyrimidones. The accumulation of photoproducts 
alters the structure of DNA, consequently inhibiting DNA polymerases and arresting cell 
replication (Goodsell, 2001; Sklar et al., 2012; Zhao et al., 2010). Photo-reactivation and 
nucleotide excision repair can remove dimers from the DNA strand, however, the 
unrepaired dimers become mutagenic. It is believed that if certain genes, such as the p53 
tumour supressing gene, are affected this can lead to unregulated hyper-proliferation of 
epidermal cells and actinic keratosis.  Resulting in the formation of mutated cells that 
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undergo unregulated cellular differentiation, and can culminate in the formation of a skin 
cancer (Brash et al., 1991).  
UV-A radiation contributes to indirect photodamage through the formation and 
build-up of reactive oxygen species (ROS) leading to oxidative stress (Salmon et al., 2004). 
Free radical formation can also lead to DNA damage and increase the risk of skin cancers, 
as UVR penetrates into the layers of the dermis. Free radicals are responsible for the cross- 
linking of collagen and elastin fibres, resulting in sun damage and the formation of wrinkles 
(Schuch et al., 2017). UV-A may also have an effect of the immune system, increasing 
immune tolerance (Holick, 2016). Continued UVR exposure leads to adaptive skin 
responses such as increased dermal thickening and increased melanin production, aimed at 
reducing UV-induced harm (Schuch et al., 2017).   
1.2.3 Health benefits of ultraviolet radiation exposure 
The health benefits associated with UVR exposure have largely been attributed to 
photocutaneous production of vitamin D. The same part of the UV spectrum primarily 
responsible for DNA damage is also required for vitamin D photosynthesis. Thus, the 
deleterious and beneficial health effects of UV irradiation are inseparable intimately 
connected (Holick, 2011).  
During exposure to sunlight, epidermal 7-DHC absorbs UV-B wavelengths and is 
converted into the secto-steroid pre-vitamin D3, following a conformational change which 
breaks the B ring (Bikle, 2014; Zhang and Naughton, 2010). Pre-vitamin D3 then 
isomerises to D3 or, with continued UV irradiation, to by-products tachysterol and 
lumisterol (preventing overproduction of vitamin D and toxicity) (Holick et al., 1981). The 
inactive D3 exists the skin, bound to vitamin D binding protein (VDB), where it must 
undergo hydroxylation to become metabolically active (Juzeniene et al., 2011). The best 
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characterised pathway of vitamin D metabolism involves hydroxylation steps in the liver 
and then the kidney, however, numerous tissues have now been identified to contain the 
enzymes necessary for conversion of D3 to active vitamin D (calcitriol; 1,25 
hydroxycholecalciferol) (Bikle, 2000). 
Biologically activity vitamin D exerts it effects through binding to the vitamin D 
receptor (VDR), primarily located in the nuclei of target cells, which modulates gene 
transcription (Hossein-nezhad et al., 2013). Therefore, vitamin D influences several 
metabolic processes, including DNA repair, antioxidant activity and regulating cell 
proliferation and differentiation (Hossein-nezhad et al., 2013; Montecino et al., 2008). The 
VDR is found in nearly all organ systems, including the brain, indicating the widespread 
action of vitamin D on both physiological and pathological processes (Stocklin and 
Eggersdorfer, 2013).   
 
Sunlight is the major source of vitamin D for most people, contributing 
approximately 90% of the bioavailable vitamin D within body (Samanek et al., 2006). As 
such, eliminating sun exposure entirely would be detrimental to human health (Holick, 
2011; Wacker and Holick, 2013). Although vitamin D can be acquired through the diet, 
few foods contain enough vitamin D to maintain adequate levels (Holick, 2009). Deficiency 
of vitamin D, particularly in early life, has long been associated with poor bone health and 
development of Rickets or osteomalacia through malabsorption of calcium and phosphorus 
(Holick, 2011). However, in recent years, studies have demonstrated many non-classical 
roles for vitamin D in the immune, cardiovascular, muscular, reproductive and 
integumentary systems, as well as protecting against several cancers (Bikle, 2014; Garland 
et al., 2006; Norman, 2008; Zhang and Naughton, 2010). Although, randomised controlled 
trials do not consistently support the findings from observational and pre-clinical studies 
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that report an association between vitamin D status and reduced risk of disease. This begs 
the question as to whether vitamin D is a mere proxy for sun exposure. At present, research 
has been unable to distinguish if UV-related health benefits are solely attributable to 
vitamin D, or if other UV factors may be in play. 
1.2.4 New challenges of ultraviolet radiation related to skin pigmentation in the modern 
world 
The development of different skin pigmentation of humans has likely arisen due to 
selection pressures associated with exposure to UVR (Jablonski and Chaplin, 2017). This 
includes, for example, the migration of humans from areas of high ambient UVR to areas 
of lower ambient UVR,  the contrasting requirements of photo protection, and the necessity 
to receive sufficient sunlight for cutaneous vitamin D production (Jablonski and Chaplin, 
2010). Thus, people that inhabit regions closer to the equator, with higher UVR intensity, 
have darker skin pigmentation for protection from harm caused by UVR; while those at 
higher latitudes, with much less ambient UVR, have developed fair skin to maximise the 
production of vitamin D (Brenner and Hearing, 2008; Jablonski and Chaplin, 2010). 
However, in the modern world, this is not always the case. Rapid human migration in the 
last few hundred years, out of the areas in which our ancestors evolved, has meant that skin 
pigmentation is not necessarily suited to the environment in which we live. Dark-skinned 
populations migrating to areas of higher latitude has led to increased prevalence of 
conditions attributed to vitamin D deficiency (Kift et al., 2013; Pal et al., 2003). In contrast, 
fair-skinned populations that have migrated to areas with much higher UVR levels than 
where their ancestors evolved have experienced rapid increases in the incidence of skin 
cancers (Armstrong and Kricker, 2001; De Gruijl et al., 2001).  
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For this reason, people of the modern world are facing new challenges regarding 
sun avoidance and sun exposure in an environment they have not yet appropriately adapted 
to. This has resulted populations of people receiving more UVR than ever before, which 
could be contributing to yet unidentified pathological conditions, such as increased 
addictive-like behaviours observed in frequent tanners (Chapter 2) and increased incidence 
of skin cancers. Furthermore, at the opposite end of the spectrum, other people are not 
receiving sufficient sun exposure, and this appears to be correlated with an increased risk 
of chronic illness, infectious disease and increased mortality, assumedly due to insufficient 
vitamin D (Hoel et al., 2016). As such, the environmental burden of disease attributed to 
UVR is relevant across the globe, and UVR is concomitant with life on Earth. Thus, 
highlighting the need for ongoing research on the physiological responses to UVR.  
1.3 Skin-brain axis: How ultraviolet radiation “touches” the brain 
UVR exposure has been shown to affect mood, addictive behaviour, cognition and 
memory, indicating that external UVR can access neuronal circuitry and influence 
behavioural outcomes (Beecher et al., 2016; Dominiak et al., 2015; Fell et al., 2014; Keller 
et al., 2005). The principle pathway by which UV light applied to the skin has been thought 
to contribute to modulation of neuronal circuitry is via the actions of vitamin D (Holick, 
2011). However, recent developments suggest other systems, such as the neuroendocrine 
system, could be contributing to UV-induced modulation of behaviour (Skobowiat et al., 
2017; Slominski, 2015). This section will therefore explore the emerging evidence of 
potential pathways by which UVR exposure to the skin contributes to downstream 
modulation of neuronal circuitry.   
A growing body of literature suggests that UVR, through skin neuroendocrine 
systems (i.e. via the circulation and/or activating ascending neural pathways), can signal to 
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the brain; facilitated by the skin analogue of the hypothalamic-pituitary-adrenal (HPA) axis 
(Slominski et al., 2018; Zmijewski and Slominski, 2011). Organisation of this local 
“equivalent” HPA axis follows the same activation pattern as the central HPA axis, 
culminating in the production of glucocorticoids by the adrenal glands (Slominski et al., 
2013). In brief, noxious stimuli or stressors (such as UVR) are detected by skin cells, which 
enhance the cutaneous production or release of corticotrophin releasing hormone (CRH) 
from nerve endings (Slominski et al., 2001; Slominski et al., 2013). In turn, CRH triggers 
the subsequent secretion of adrenocorticotrophic hormone (ACTH) from the pituitary gland 
(Grammatopoulos and Chrousos, 2002; Slominski et al., 2013). ACTH, then circulates to 
the adrenal cortex contributing to the release of glucocorticoids, through the activation of 
glucosteriodogenesis from cholesterol (Miller and Auchus, 2011). Glucocorticoids can 
easily access the brain where they bind to receptors to influence neuronal signalling and 
behaviour, especially through altered glutamate neurotransmission in the prefrontal cortex 
and hippocampus, thereby influencing cognitive and emotional processing (Lupien et al., 
2009; Popoli et al., 2011). Experimental research in mice demonstrates that when UV-B is 
applied directly to the skin it triggers activation of both the local and central HPA axis, 
resulting in elevated levels of CRH, urocortin, ACTH, β-endorphin and corticosterone in 
plasma and brain tissue (Skobowiat et al., 2011; Skobowiat and Slominski, 2015). This 
indicates that UVR exposure is capable of activating a systemic stress response, centred in 
the HPA axis, which is initiated by skin cells (Skobowiat and Slominski, 2015). More 
recently, UV-B exposure has also been shown to activate the proopiomelanocortin (POMC) 
signalling pathway in the arcuate nucleus of the hypothalamus (Skobowiat and Slominski, 
2016). POMC is a precursor protein of numerous neuropeptides, including ACTH, α-
melanocyte stimulating hormone (α-MSH) and β-endorphin. Within the arcuate nucleus, 
these neuropeptides play a role in the regulation of feeding behaviour (Dutia et al., 2012). 
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Following UV-B application, dose-dependent increases in POMC gene expression, 
accompanied by increased plasma levels of α-MSH and β-endorphin, were observed in two 
genetically different strains of mice (Skobowiat and Slominski, 2016). Together, these 
findings emphasise that the brain is involved in translating peripheral UVR signals into 
systemic responses.  
Cutaneous exposure to UVR also contributes to alterations in the levels of 
peripheral proteins, peptides and small molecules, including vitamin D, melanin, β-
endorphin and nitric oxide (NO), both locally and within the circulation (Brenner and 
Hearing, 2008; Fell et al., 2014; Hart et al., 2011; Holliman et al., 2017). These small 
molecules, through similar mechanisms involving the circulation and/or ascending 
neuronal pathways, may likewise signal to the brain and influence neuronal signalling to 
alter behaviour. Preclinical studies have demonstrated that cutaneous UVR exposure 
contributes to elevated levels of β-endorphin (generated as a by-product in the cleavage of 
POMC), resulting in opioid-related increases in nociceptive thresholds. This effect could 
be  reversed with the opioid antagonist naloxone, and was abated in β-endorphin null mice 
(Fell et al., 2014). Recently, another study demonstrated that UVR triggered elevation of 
uranic acid in the blood, which in turn crossed the blood brain barrier (BBB), promoting 
the biosynthesis and release of glutamate within several areas on the brain (Zhu et al., 
2018). UVR exposure was subsequently correlated with enhanced performance in motor 
learning and recognition memory tasks in mice; an effect that could be blocked with the 
application of dipeptide glycyl-glycyl inhibiting urocanase within the neuron or with short 
hairpin RNA, preventing the enzymatic actions of urocanase (Zhu et al., 2018). This 
evidence further suggests a connection between peripheral and central systems invoked by 
UVR exposure on the skin.    
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1.4 The innate immune system facilitates peripheral-to-central communication 
The idea that events in the periphery, particularly those of an inflammatory nature, 
have profound influence on brain function has been widely accepted (for reviews see 
(Capuron and Miller, 2011; Dantzer et al., 2008; Quan and Banks, 2007; Watkins and 
Maier, 2000). Critically involved in host defence against invading pathogens, the innate 
immune system also has the ability to respond to endogenous factors initiated from cell 
stress/damage (Maier, 2003).  Thus, the innate immune system is a likely candidate to 
facilitate cross-talk between the skin and the brain following UVR exposure.  
Virtually all organs of the human body contain immunocompetent cells that express 
pattern recognition receptors (PRRs) for the detection of damage associated molecular 
patterns (DAMPs) released during tissue injury or infection (Bilbo and Schwarz, 2012). 
DAMPs are biomolecules that initiate and perpetuate inflammatory signalling cascades 
necessary for host defence. In response to inflammatory stimuli, activation of these 
signalling cascades result in bidirectional communication between the periphery and the 
brain (immune-to-brain communication), alerting higher centres to danger to implement an 
appropriate host response (Maier, 2003). Within the CNS, this process is mediated by glia 
cells which are a population of non-neuronal support cells (previously regarded as inert) 
that are now recognised to have an integral role in maintaining homeostasis and can 
influence neurotransmission (Ousman and Kubes, 2012). The  major resident immune-like 
cells of the CNS are microglia, which together with astrocytes and the pre- and post- 
synaptic neuron, form the tetrapartite synapse (De Leo et al., 2006). This structure is a key 
site of interaction in which each cell reciprocally signals to one another, enabling glial cells 
to mediate neuronal signalling and contribute to “neuroimmune communication”. The close 
proximity of the tetrapartite synapse means glial cells rapidly respond to disruptions in 
homeostasis, having a marked effect on neuronal signalling and behavioural adaptations; 
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for example, lethargy, anhedonia and fever experienced during times of sickness (Dantzer, 
2004; Kelley et al., 2003). However, as the periphery is virtually segregated from central 
tissue by the BBB, a physical impediment that restricts free access into the brain, immune-
to-brain communication relies on a network of highly sophisticated cell interactions 
involving hormones, neurotransmitters, and cytokines (Quan and Banks, 2007). 
So far, several mechanisms, acting in parallel, have been identified by which 
peripheral signals can access the brain (Figure 1.3). First, evidence suggests that blood-
borne cytokines can passively diffuse into the brain via regions lacking a contiguous BBB, 
including the circumventricular organs and the choroid plexus (Breder et al., 1988; Komaki 
et al., 1992; Saper and Breder, 1994). The close proximity and bidirectional neuronal 
projections from the circumventricular organs to the hypothalamus (McKinley et al., 1994; 
Silverman et al., 1981), hippocampus (Ciriello and Gutman, 1991) and amygdala 
(Silverman et al., 1981) suggest that circulating immune signals may be further projected 
into the brain via these connections (Quan, 2008).  Secondly, multiple endothelial-related 
mechanisms by which peripheral signals may enter the brain through an intact BBB have 
been identified. These include energy-dependent transport systems in which cytokines such 
as interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF) access the brain via saturable 
transport systems. Yet, it remains unclear whether the quantity of cytokines transported is 
sufficient to mediate behavioural adaptions (Banks et al., 1991). Peripheral leukocytes may 
cause increased immune signalling within the CNS, without physically crossing the BBB, 
through interactions with endothelial cells of the cerebral vasculature (D'Mello et al., 2013). 
Alternatively, adhesion molecules, such as ICAM (intracellular adhesion molecules) and 
VCAM (vascular adhesion molecules) allow passage of signals through the tissue (Wong 
et al., 2007). Endothelial cells also have the capacity to release immune-related molecules 
such as NO, prostaglandins, IL-1, and IL-6 (Fabry et al., 1993). Thus, blood-derived 
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cytokines may initiate release of cytokines into the CNS through peripheral binding, 
without physically entering. The aforementioned humoral and cellular pathways of 
immune-to-brain communication are dependent on blood-derived stimuli, circulating to the 
proximity of the CNS to initiate central neuroinflammatory processes. The final identified 
pathway provides a much faster mode of transmission, relaying information via the 
autonomic nervous system (Bluthe et al., 1994; Dantzer et al., 1998; McCusker and Kelley, 
2013). Locally produced cytokines are thought to directly stimulate primary afferent nerve 
fibres, such as the vagal nerve during abdominal or visceral infections, or the trigeminal 
nerve during orolingual infections. Signalling from these nerves in turn rapidly activates 
central pathways involved in sickness behaviours (Bluthe et al., 1994; Dantzer et al., 1998; 
McCusker and Kelley, 2013). Overall, these convergent pathways culminate in the 
production of inflammatory cytokines and the activation of glial cells within the brain, 
generating neuroinflammation, which is distinct from its peripheral source. This is a critical 
point to highlight as it is the presence of central cytokines and their direct contact with 
neuronal targets, facilitated by the tetrapartite synapse between glia and neurons, that elicits 
behavioural responses; regardless of the originating peripheral cytokine signals (Eyo and 
Wu, 2013; De Leo et al., 2006).  
The existence of these bidirectional communication pathways between peripheral 
and central tissues creates the opportunity for immune signalling to have broad implications 
on processes not normally associated with immune function. Furthermore, the potential for 
the immune system to manipulate neuronal circuits paves a pathway by which peripheral 
cutaneous UVR, which is inflammatory at both UV-A and UV-B wavelengths, could result 
in behavioural adaptions by affecting central circuitry. The relationship between cutaneous 
UVR and its effect on behaviour, potentially mediated by the immune system, has been 
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comprehensively reviewed as part of this research project. The following chapter presents 
this discussion in its peer-reviewed manuscript format.  
 
Figure 1.3 Schematic representation of neuroimmune communication. Inflammatory 
stimuli contribute to the release of circulating DAMPs that facilitate bidirectional 
communication between the peripheral tissues and the brain.  Several pathways have been 
identified by which peripheral signals may access central tissue to initiate 
neuroinflammation. A neuroinflammatory state can directly modulate neuronal 
transmission, via the tetrapartite synapse, resulting in immune-mediated behavioural 
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Chapter 2. Can neuroimmune mechanisms explain the link between 
ultraviolet light exposure and addictive behaviour? 
This chapter has been previously published in a peer-reviewed journal [Iacopetta K et al. 
(2018) Brain, Behaviour and Immunity].  
This thesis explores the relationship between UVR-induced skin signalling and its 
influence on brain function, asking the question of how UVR influences brain neuro 
circuitry in health and disease. In the following review paper, we have endeavoured to 
highlight that UVR seeking behaviour is comparable to other behavioural addictions, and 
that UVR exposure results in engagement of systems, such as the opioid and dopamine 
system, that are critical in the development of addiction. The concept of neuroimmune 
communication and its role in the development of addiction is introduced, and a novel 
hypothesis of alarmin-derived skin-brain signalling is presented. 
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A B S T R A C T
High ultraviolet (UV) light exposure on the skin acts as a reinforcing stimulus, increasing sun-seeking behavior
and even addiction-like sun seeking behavior. However, the physiological mechanisms that underlie this process
remain to be defined. Here, we propose a novel hypothesis that neuroimmune signaling, arising from in-
flammatory responses in UV-damaged skin cells, causes potentiated signaling within the cortico-mesolimbic
pathway, leading to increased sun-seeking behaviors. This hypothesized UV-induced, skin-to-brain signaling
depends upon cell stress signals, termed alarmins, reaching the circulation, thereby triggering the activation of
innate immune receptors, such as toll-like receptors (TLRs). This innate immune response is hypothesized to
occur both peripherally and centrally, with the downstream signaling from TLR activation affecting both the
endogenous opioid system and the mesolimbic dopamine pathway. As both neurotransmitter systems play a key
role in the development of addiction behaviors through their actions at key brain regions, such as the nucleus
accumbens (NAc), we hypothesize a novel connection between UV-induced inflammation and the activation of
pathways that contribute to the development of addiction. This paper is a review of the existing literature to
examine the evidence which suggests that chronic sun tanning resembles a behavioral addiction and proposes a
novel pathway by which persistent sun-seeking behavior could affect brain neurochemistry in a manner similar
to that of repeated drug use.
1. Introduction
Since the mid 20th century, it has become socially desirable and
acceptable in many cultures to have the “healthy tan” that comes with
sun exposure (Hunt et al., 2012). A tan develops as ultraviolet radiation
(UVR) triggers keratinocyte release of α-melanocyte stimulating hor-
mone (α-MHS) through p53-mediated transcriptional induction of the
proopiomelanocortin (POMC) gene, which results in increased synthesis
of the pigment melanin (Cui et al., 2007; Videira et al., 2013). Melanin
forms a protective barrier to absorb UVR, preventing DNA damage and
consequently causing the skin to darken (Bergenmar and Brandberg,
2001). While this may lead to the desired “healthy tan” effect, pro-
longed and repeated exposure to UV is a public health concern due to its
causal relationship to the development of skin cancer (Young, 2009).
The incidence of skin cancer continues to rise in many Westernized
nations including the United States, Canada, Australia, New Zealand
and numerous countries in Europe (Lucas et al., 2006). The increase of
skin cancer has been attributed to a multitude of factors, some of which
fall outside the locus of control of the individual, such as effects of
pollution damaging the ozone layer, increasing the amount of ambient
UVR (Diffey, 2003; Leary and Jones, 1993). However, the single biggest
risk factor continues to be behavioral: the willingness to be exposed to
UVR for the aesthetic purposes of achieving a tanned appearance
(Diffey, 2003; Leary and Jones, 1993). These behavioral choices can
include increased voluntary UVR exposure through sunbathing, an in-
creased amount of time spent outdoors participating in leisure activ-
ities, and changes in clothing styles exposing more skin (Diffey, 2003;
Leary and Jones, 1993).
The desire to tan has largely been attributed to appearance factors
acting as the primary reinforcement; that is, people believe they look
and feel better with a tan (Dennis et al., 2009). However, an increasing
body of literature is emerging indicating that UVR itself is a reinforcing
stimulus, acting to increase UV-seeking behaviors (Feldman et al.,
2004; Fell et al., 2014; Harrington et al., 2011a). Despite increasing
efforts to alter perceptions of tanning and increase awareness of the
damaging effects of UVR, frequent tanners are not deterred from
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2.1 Abstract  
High ultraviolet (UV) light exposure on the skin acts as a reinforcing stimulus, 
increasing sun-seeking behaviour and even addiction-like sun-seeking behaviour. 
However, the physiological mechanisms that underlie this process remain to be defined. 
Here, we propose a novel hypothesis that neuroimmune signalling, arising from 
inflammatory responses in UV-damaged skin cells, causes potentiated signalling within the 
cortico-mesolimbic pathway, leading to increased sun-seeking behaviours. This 
hypothesised UV-induced, skin-to-brain signalling depends upon cell stress signals, termed 
alarmins, reaching the circulation, thereby triggering the activation of innate immune 
receptors, such as toll-like receptors (TLRs). This innate immune response is hypothesised 
to occur both peripherally and centrally, with the downstream signalling from TLR 
activation affecting both the endogenous opioid system and the mesolimbic dopamine 
pathway. As both neurotransmitter systems play a key role in the development of addiction 
behaviours through their actions at key brain regions, such as the nucleus accumbens 
(NAc), we hypothesise a novel connection between UV-induced inflammation and the 
activation of pathways that contribute to the development of addiction. This paper is a 
review of the existing literature to examine the evidence which suggests that chronic sun 
tanning resembles a behavioural addiction and proposes a novel pathway by which 
persistent sun-seeking behaviour could affect brain neurochemistry in a manner similar to 
that of repeated drug use. 
2.2 Introduction 
Since the mid 20th century, it has become socially desirable and acceptable in many 
cultures to have the “healthy tan” that comes with sun exposure (Hunt et al., 2012). A tan 
develops as ultraviolet radiation (UVR) triggers keratinocyte release of α-melanocyte 
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stimulating hormone (α-MHS) through p53-mediated transcriptional induction of the 
proopiomelanocortin (POMC) gene, which results in increased synthesis of the pigment 
melanin (Cui et al., 2007; Videira et al., 2013). Melanin forms a protective barrier to absorb 
UVR, preventing DNA damage and consequently causing the skin to darken (Bergenmar 
and Brandberg, 2001). While this may lead to the desired “healthy tan” effect, prolonged 
and repeated exposure to UV is a public health concern due to its causal relationship to the 
development of skin cancer (Young, 2009). 
The incidence of skin cancer continues to rise in many Westernised nations 
including the United States, Canada, Australia, New Zealand and numerous countries in 
Europe (Lucas et al., 2006). The increase of skin cancer has been attributed to a multitude 
of factors, some of which fall outside the locus of control of the individual, such as effects 
of pollution damaging the ozone layer, increasing the amount of ambient UVR (Diffey, 
2003; Leary and Jones, 1993). However, the single biggest risk factor continues to be 
behavioural: the willingness to be exposed to UVR for the aesthetic purposes of achieving 
a tanned appearance (Diffey, 2003; Leary and Jones, 1993). These behavioural choices can 
include increased voluntary UVR exposure through sunbathing, an increased amount of 
time spent outdoors participating in leisure activities, and changes in clothing styles 
exposing more skin (Diffey, 2003; Leary and Jones, 1993). 
 The desire to tan has largely been attributed to appearance factors acting as the 
primary reinforcement; that is, people believe they look and feel better with a tan (Dennis 
et al., 2009). However, an increasing body of literature is emerging indicating that UVR 
itself is a reinforcing stimulus, acting to increase UV-seeking behaviours (Feldman et al., 
2004; Fell et al., 2014; Harrington et al., 2011a). Despite increasing efforts to alter 
perceptions of tanning and increase awareness of the damaging effects of UVR, frequent 
tanners are not deterred from engaging in tanning behaviour (Montague et al., 2001), 
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particularly among adolescents and young adults (Cokkinides et al., 2006; Guy et al., 2015; 
Livingston et al., 2003). In fact, although public knowledge regarding the dangers of sun 
exposure greatly increased between 1986 and 1996, sun burning and regular use of tanning 
beds also increased (Robinson et al., 1997).  
Remarkably, survey studies have revealed that frequent tanners are well informed, 
often displaying higher levels of knowledge regarding the risk of UVR than their non-
tanning peers (Poorsattar and Hornung, 2007). An overwhelming majority, more than 90% 
of past and current tanners surveyed, revealed that they believed that skin cancer was a 
possible consequence of tanning. The same study also identified that 81% of past tanners 
and 53% of current tanners did not believe that tanning beds were safe (Knight et al., 2002), 
indicating that tanners know the dangers of tanning. Frequent tanners are more likely to be 
informed about UV-induced skin damage but are also more likely to believe that tanned 
skin improves appearance and protects against subsequent UV damage (Grange et al., 
2015). Even having a hereditary risk of cancer was not enough to prevent the use of tanning 
beds in a sub-population of young adults (Bergenmar and Brandberg, 2001). 
Therefore, despite a growing awareness of the danger associated with overexposure 
to UVR and the increased risk of skin cancer or having watched a family member face a 
deadly cancer, frequent tanners are not deterred from engaging in tanning behaviour. In this 
way, continuing to tan resembles behaviours associated with substance use or gambling 
disorder when there is a loss of control of a behaviour despite being aware of the potential 
dangers. The person is not able to change the behaviour even when adverse consequences 
arise that are clearly aggravated by the use (American Psychiatric Association, 2013; 
Kourosh et al., 2010; Nolan and Feldman, 2009). 
While the exact mechanisms that may lead to tanning dependence are still unknown, 
this paper reviews the evidence that chronic UV exposure has physiologically reinforcing 
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effects comparable to addiction and proposes a novel hypothesis by which UV light could 
affect brain neurochemistry via cutaneous-brain inflammatory signalling. 
2.3 Evidence to suggest that tanning is comparable to behavioural addictions  
People who tan frequently can exhibit signs of psychological and physical 
dependence that parallel those seen in other addictive disorders suggesting a form of 
behaviour addiction (Poorsattar and Hornung, 2007; Stapleton et al., 2017). For example, 
using diagnostic screening tests, such as the CAGE (cut down, annoyed, guilty, eye-opener) 
questionnaire (Ewing, 1984), originally developed for alcohol dependence, as well as 
criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 
adapted for tanning behaviour, it was discovered that approximately 70% of both frequent 
outdoor (Warthan et al., 2005) and indoor (Harrington et al., 2011b) tanners met the 
modified criteria for addictive disorders or dependence. Specifically, frequent tanners 
continued to tan despite attempts to stop, showed persistent tanning in the presence of 
adverse consequences and neglected other responsibilities to maintain a tan (Harrington et 
al., 2011b; Warthan et al., 2005). Collectively, these behaviours show significant 
resemblance to the characteristics that define addictions such as gambling disorder 
(American Psychiatric Association, 2013). In support of this, a survey of 325 American 
college students, using the Structured Interview for Tanning Abuse and Dependence 
(SITAD), discovered that 10.8% and 5.4% of this population met criteria for tanning abuse 
and dependence, respectively. These rates are comparable to those reported for alcohol 
(5.8%) and alcohol or any illicit drug dependence (7.7%) in this age group (Hillhouse et 
al., 2012). 
Moreover, when we consider individual difference in behaviour it appears that 
factors such as age of initiation and frequency of the tanning behaviour correlate with 
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difficulty to cease tanning among adolescents (Zeller et al., 2006), similar to what we see 
in drug dependence. Those who were 14 to 15 years old at the time of the initiation were 
more likely to report difficulty in stopping the behaviour compared to 16 to 17 year olds 
(Zeller et al., 2006). This parallels other high-risk activities, such as gambling, smoking 
and alcohol abuse, in which age of initiation is inversely correlated with success of quitting 
(Abdolahinia et al., 2012; Guttmannova et al., 2011; Khuder et al., 1999; Rahman et al., 
2012). 
Mechanistically, it is important to consider whether there are similarities in the 
biological basis of the effects of UVR exposure and the development of compulsive tanning 
with that of behavioural addictions. Frequent tanners indicated that besides aesthetic appeal 
(90%), tanners wanted to feel good (69%) and relax (56%) (Harrington et al., 2011b). 
Although the perception of a good appearance may be reinforcing, the latter two responses 
are comparable to what is reported by those with substance use disorders as reasons for 
drug or alcohol use (Titus et al., 2007). But are the tanners addicted to UVR exposure, or 
mainly the relaxing nature of the activity? A study by Feldman et al. (2004) highlighted 
that frequent tanners show a preference for UV tanning beds compared to identical non-
UV beds, based solely on subjective feeling (Feldman et al., 2004). This suggests that the 
UV light may have physiologically reinforcing effects separate from aesthetic motivation 
alone.  
However, is there any evidence that there is similar engagement of the mesolimbic 
dopamine or opioid system in frequent tanning, as is seen with other forms of addiction? 
Dopamine efflux follows administration of amphetamines (Di Chiara and Imperato, 1988), 
alcohol (Melendez and Rodd-Henricks, 2002) and cannabinoids (Jianping et al., 1990). 
Increased synaptic dopamine is also implicated in multiple behaviours that can become 
addictions, such as overeating (Avena et al., 2009), gambling (Bergh et al., 1997) and 
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sexual behaviour (Balfour et al., 2004). Aubert et al. (2016) showed an increase in 
dopamine efflux in addicted tanners in response to UVR compared to sham UVR, while 
such changes were not seen in infrequent tanners (Aubert et al., 2016). Interestingly, a pilot 
study using SPECT (single photon emission computed tomography) imaging to measure 
regional cerebral blood flow (rCBF) during a (blinded) session with either UVR or sham 
UVR in frequent tanners demonstrated that during the UVR session, tanners had a 
significant increase in rCBF in the left striatum, indicating activation of this dopamine rich 
region (Harrington et al., 2011a). These changes were accompanied by a decrease in the 
subjective desire to tan. Similarly, emerging evidence suggests that the reinforcing effects 
of UVR may be mediated by the opioid system, specifically through β-endorphin (Fell et 
al., 2014; Kaur et al., 2005; Kaur et al., 2006). b-endorphin is an endogenous opioid peptide 
with high affinity for the µ-opioid receptor (Volkow and McLellan, 2016), the same 
receptor responsible for producing the analgesic and euphoric properties from exogenous 
opioid derivatives, including drugs of abuse (Akil et al., 1998). UVR exposure in rodents, 
as well as cultured human cells, triggers release of b-endorphin as a by-product of the 
physiological processes that contribute to tanning (Fell et al., 2014). Daily exposure to 
UVR for a period of 6 weeks was associated with elevated plasma levels of b-endorphin in 
rodents. This was accompanied by increases in pain related thresholds, an effect that could 
be reversed with systemic administration of opioid antagonist, naloxone, and was abated in 
b-endorphin null mice. Administration of naloxone following chronic daily UV exposure 
resulted in numerous signs of opioid withdrawal in mice under experimental conditions. 
This included increased wet dog shake, paw tremor, teeth chatter and rearing. Furthermore, 
chronically UV-irradiated mice conditioned with naloxone in a black box developed 
conditioned place aversion for the black box during the postconditioning preference testing. 
Conversely, naloxone conditioning in the black box had no effect on mock UV-irradiated 
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mice, demonstrating that chronic UV exposure imparts an opioid-like physical dependence 
sufficient enough to guide behaviour. Finally, cross tolerance between UV-exposure and 
morphine developed, as evidenced by the fact that higher doses of morphine were required 
to produce comparable analgesia between mice that had received chronic UV-irradiation 
compared to mock UV (Fell et al., 2014).  
Taken together, evidence supports that tanning is a form of behavioural addiction, 
with similar impacts on brain neurotransmission as other types of addiction. However, the 
physiological mechanisms that link UVR with an increase in addictive-like behaviour are 
still unclear. In order to understand this, it is necessary to look at other aspects of addiction 
pathophysiology, including the role of the immune system in this process. 
2.4 Why the immune system is relevant to addiction  
A major development in addiction research in recent years has been the discovery 
that immune signalling within the central nervous system significantly influences signalling 
pathways responsible for reward processing (Hutchinson and Watkins, 2014). Research by 
Hutchinson et al. (2012) has demonstrated that a pro-inflammatory state increases the 
vulnerability to addiction. Inflammatory mediators (e.g. cytokines and chemokines) are 
able to change the pharmacodynamic actions of drugs (Hutchinson et al., 2008; Narita et 
al., 2006). For example, morphine reward behaviours are modulated through central 
immune signalling. Direct injection of an astrocyte-conditioned medium into the nucleus 
accumbens (NAc) leads to heightened morphine conditioned place preference, indicative 
of drug preference in rodents (Narita et al., 2006). Conversely, blocking the 
proinflammatory response from glia prevents morphine and oxycodone conditioned place 
preference (Hutchinson et al., 2008; Hutchinson et al., 2012).  
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 It has been demonstrated that these effects occur through Toll-like receptors 
(TLRs), particularly TLR4 (Jacobsen et al., 2014), which are located on the cell membrane 
of glial cells. Opioid activation of TLR4 contributed to drug reinforcement, as 
pharmacological blocking of TLR signalling, along with the use of genetic knock out 
animals, suppressed opioid-induced conditioned place preference and decreased levels of 
extracellular dopamine (Hutchinson et al., 2012). Similarly, another study demonstrated 
cocaine interacts with TLR4 and induces pro-inflammatory signalling heightening the 
rewarding properties of cocaine (Northcutt et al., 2015). Systemic administration of cocaine 
led to upregulation of pro-inflammatory cytokine interleukin-1b (IL-1b) within the ventral 
tegmental area (VTA), yet blockade of either TLR4 or IL-1b signalling suppressed cocaine 
induced increases of dopamine concentrations within the NAc highlighting the importance 
of TLR signalling in cocaine reinforcement (Northcutt et al., 2015).  When a drug of abuse 
binds at a TLR4 receptor, it facilitates glial activation and increases the production and 
release of pro-inflammatory cytokines. Pro-inflammatory cytokines are capable of altering 
neuroexcitability impacting on neuronal output as they upregulate the surface expression 
of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-
methyl-D-aspartate) receptors, increasing spontaneous neurotransmitter release and 
glutamate transmission (Stellwagen et al., 2005; Viviani et al., 2014). Furthermore, tumour 
necrosis factor (TNF)-α contributes to endocytosis of GABAA receptor, resulting in fewer 
surface receptors and decreased inhibitory strength (Stellwagen et al., 2005). Therefore, 
TLR4 activity may amplify changes in neuronal activity induced by drugs of abuse, such 
as increased opioid and dopamine signalling, and contribute to their rewarding properties 
(Hutchinson et al., 2012; Grace et al., 2014). Taken together, this suggests that the 
rewarding, and possibly addictive, effects of some drugs require stimulation not only of 
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neuronal but also of immune-like cell functioning (Coller and Hutchinson, 2012; 
Hutchinson and Watkins, 2014). 
Inflammation also plays a role in the onset and maintenance of binge eating 
behaviour, which is now listed in the diagnostics for addiction disorders (Corcos et al., 
2003; Holden and Pakula, 1996).  Binge eating and excessive consumption of certain foods 
can produce behaviours and changes in the brain that resemble an addiction-like state, 
involving adaptations to both the dopamine and opioid systems similar to that seen with 
drugs of abuse (Bello and Hajnal, 2010; Corwin et al., 2011). Abdominal obesity-associated 
inflammation is suggested to affect neural circuits that may promote addictive behaviours 
leading to self-perpetuating cycles associated with food intake (Heber and Carpenter, 
2011).  Hypothalamic levels of IL-18, as well as the IL-18 receptor systems, were down 
regulated in an animal model of binge eating (Alboni et al., 2017), providing supporting 
evidence that inflammatory mediators in specific brain regions can contribute to the onset 
of maladaptive behaviour.  
Given the role of the immune system not only in the vulnerability to drugs of abuse, 
but also in behavioural addictions, such as binge eating, it is reasonable to hypothesise that 
immune system activation may also be a key factor in the addictive-like behaviours shown 
by frequent tanners.  
2.5 Ultraviolet radiation exposure damages skin cells contributing to release of 
endogenous danger signals (“alarmins”) that activate the immune system 
A growing body of evidence demonstrates that UVR damages skin cells, leading to 
apoptosis, necrosis and pyroptosis (unexpected inflammatory cell death) of epidermal cells 
following exposure (D’Orazio et al., 2013; De Gruijl, 1999; Ichihashi et al., 2003; Jans et 
al., 2006; Matsumura, 2002). UV-B wavelengths (290-320nm) are the most cytotoxic to 
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cells, as they are directly absorbed by DNA (Schuch et al., 2017). The energy from UV-B 
causes bond opening of DNA nitrogenous bases, allowing adjacent bases to join together 
via covalent bonding to form a cyclobutane ring of pyrimidine dimers (Jans et al., 2006; 
Zhao et al., 2010).  Single bonds between two carbon atoms and the cyclobutane ring may 
also form, which results in the “6-4 (T-C) photoproduct” (Zhao et al., 2010).  UV-induced 
single and double strand breaks occur rapidly, and it has been estimated that each skin cell 
might experience 50-100 reactions per second of exposure (Goodsell, 2001). The disruption 
of the DNA structure ultimately effects gene sequencing, impacting on cell viability (e.g., 
transcription and replication) (Sklar et al., 2012).  UV-A wavelengths (320-400nm) are less 
damaging, but can penetrate more deeply, causing indirect photodamage through the 
creation of reactive oxygen species (ROS) and oxidative stress (Salmon et al., 2004). With 
increasing levels of UVR and the accumulation of photoproducts cell DNA is 
compromised, forcing cells to either initiate cellular repair pathways or undergo apoptosis 
or pyroptosis (inflammatory cell death) (Jans et al., 2006).  
Damaged skin cells immediately begin secreting danger signals that “sound the 
alarm,” recruiting immune cells through the release of chemokines and cytokines. 
Unexpected cell death results in the spillage of intracellular contents into the extracellular 
space, further exacerbating distress signals (Rock and Kono, 2008). These endogenous 
mediators are collectively known as “alarmins”.  Examples of alarmins include adenosine 
triphosphate (ATP), uric acid, ROS, DNA, and DNA-binding proteins, such as high 
mobility group box 1 (HMGB1), heat shock proteins (HSPs), inflammatory cytokines and 
S100 proteins, all of which can be rapidly released from cells during infection or tissue 
injury, including UVR (Cayrol and Girard, 2014; Chan et al., 2012; Roh et al., 2008).  
Numerous studies have shown that alarmins are released from skin cells following 
stimulation with UVR (Byrne et al., 2011; Johnson et al., 2013; Takai et al., 2011; 
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Yoshizumi et al., 2008). For example, UV-B radiation induced the release of ATP from 
HaCat (human keratinocytes) cells (Takai et al., 2011). ATP levels were significantly 
elevated within the culture medium after 1-minute following 100mkJ/cm2 of UV light 
exposure. Release of ATP was determined to occur via maxi-anion channels and anion 
transporters (Takai et al., 2011). A separate study demonstrated that UV-induced ATP 
release likely contributes to synthesis of IL-6, as administration of a purinergic (P2) 
receptor antagonist blocking ATP release inhibited the expression of IL-6 in UV-irradiated 
normal human epidermal keratinocytes (NHEK) cells (Inoue et al., 2007).  
Moreover, acute exposure to UVR (300J/m2 UV-B) stimulated the release of 
HMGB1 and pro-inflammatory cytokines, including IL-1b, TNF-α, and IL-6, from human 
keratinocytes (Johnson et al., 2013).  While levels were low in the non-irradiated cells, they 
began to increase 12 hours post-UV and were highest 24 hours following UV exposure. 
Similarly, Yoshizumi and colleagues (2008) demonstrated that a low dose of UVR 
(100mkJ/cm2) significantly increased concentrations of IL-6, interferon (IFN)-γ and TNF-
α, while a higher dose of UVR (400mkJ/cm2) further compounded the inflammatory 
response, also increasing the release of IL-1β, granulocyte-colony stimulating factor (G-
CSF) and chemokines IL-8 and macrophage inflammatory protein (MIP)-1 from cultured 
HaCaT cells (Yoshizumi et al., 2008). HMGB1 release from epidermal keratinocytes and 
corresponding inflammation has also been shown to be elevated in a murine model 
(Johnson et al., 2013; Yoshizumi et al., 2008). 
IL-33 has also been identified as an endogenous alarmin released from murine 
keratinocytes and dermal fibroblasts (in vivo) as well as human skin explants and cells 
derived from normal human skin (ex vivo) (Byrne et al., 2011). Both protein and mRNA 
expression of IL-33 were increased at 24 hours following exposure to solar simulated UV 
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light; conversely no expression of IL-33 was observed in non-irradiated skin samples 
(Byrne et al., 2011).    
HSPs are another group of alarmins which are constitutively expressed in human 
skin under normal conditions, including HSP27, 60, 70, 90, 110 and therefore are assumed 
to have a critically important role in maintaining fundamental cutaneous processes (Jonak 
et al., 2009). There is some debate as to whether UV exposure itself, rather than increases 
in temperature, is responsible for increased expression of HSPs from epidermal 
keratinocytes and melanocytes (Muramatsu et al., 1992; Muramatsu et al., 1993; Trautinger 
et al., 1993). A more recent study reported that UV exposure increased expression of 
HSP70 in cultured human dermal fibroblast, yet the same increase was not observed in the 
epidermal cell types. Both keratinocytes and melanocytes displayed high baseline levels of 
HSP70 protein expression but this was not upregulated following UV exposure (Roh et al., 
2008). UV-A has been shown to induce HSP72 mRNA and protein expression through 
what appears to be caused by oxidative damage (Keyse and Tyrrell, 1989; Tyrrell, 2000). 
 Inflammatory doses of UV trigger cutaneous production of uric acid, as 
demonstrated in both in vitro and in vivo models (Leighton et al., 2013). Using a murine 
keratinocyte cell line, doses of 60mkJ/m2 UV lead to substantial increases in the level of 
uric acid measured in the supernatant between 1 and 2 hours following irradiation (Leighton 
et al., 2013). Similarly, in an in vivo model, C57BL/6 mice irradiated with 80mkJ/m2 of 
UV had significantly elevated skin levels of uric acid when compared to un-irradiated 
controls (Leighton et al., 2013).   
Lastly, as mentioned above, UVR is a known inducer of ROS, which are generated 
in skin tissue through photo-activation of endogenous photosynthesisors such as 
porphyrins, riboflavin and quinones (Marrot and Meunier, 2008). ROS include superoxide, 
hydrogen peroxide, singlet oxygen and hydroxyl radical, which have been shown to initiate 
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signalling pathways indicative of cell damage and apoptosis (Black and Lambert, 2001; 
Tyrrell, 1995), demonstrating an alarmin role for ROS following UV-B exposure.  
Data from the above studies provide evidence that physiologically relevant doses 
of UV delivered both in vivo and in vitro stimulate the secretion and release of alarmins 
and pro-inflammatory mediators that contribute to a hyper-inflammatory state. Once in the 
extracellular space, alarmins work similarly to the exogenous pathogen associated 
molecular patterns (PAMPs) and together they fall under the broader category of damage-
associated molecular patterns (DAMPs), leading to further exacerbations of the 
inflammatory response (Bianchi, 2007). 
2.6 Alarmins contribute to inflammation through binding to pattern recognition 
receptors such as TLR4, leading to downstream release of pro-inflammatory products 
Alarmins released during UV stress must alert the immune system of danger in 
order to promote repair, thereby initiating an inflammatory response through the activation 
of specific pattern recognition receptors (PRR) which are present on surrounding epidermal 
keratinocytes/melanocytes (Miller, 2008). Receptors from these families may also be found 
within dermal tissues on endothelial cells of the microvasculature, as well as on stromal 
cells, such as fibroblasts and adipocytes (Miller, 2008).  Activation of PRRs can stimulate 
a multitude of responses, including cell differentiation, cell death, or secretion of anti- or 
pro-inflammatory mediators (Ojcius and Saïd-Sadier, 2012). The particular PRRs of 
interest in the pro-inflammatory pathway are the TLR family and nucleotide-binding 
oligomerisation domain (NOD)-like receptors (NLRs), both of which contribute to an 
enhanced inflammatory state. 
TLRs are transmembrane glycoproteins that all contain two main signalling 
domains.  Firstly there is an ectodomain of leucine-rich repeat (LRR) motifs that are able 
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to specifically recognise components on DAMPs (Akira et al., 2001). The second is a 
cytoplasmic domain, containing a toll/interleukin receptor (TIR) responsible for initiating 
several intracellular signalling cascades (Akira et al., 2001). These signalling cascades 
include activation of transcription factor nuclear factor (NF)-kB, which is a key factor in 
stimulating the expression of genes involved in immune responses such as cytokines, 
chemokines and co-stimulatory and adhesion molecules (Miller, 2008).  
 NLRs are another family of PRRs that can also recognise microbial peptides and 
intracellular alarmin signals, initiating host defence pathways via the NF-kB response and 
inflammatory caspases (Nasti and Timares, 2012). Activation of NLR stimulates the 
formation of the inflammasome, comprised of a sensor, an adaptor and a zymogen 
procaspase-1, and leads to caspase-1 activation. Caspase-1 is responsible for the maturation 
and release of IL-1β (Feldmeyer et al., 2007; Johnson et al., 2013). Induction of IL-1β 
expression and its release can subsequently induce the expression of additional 
inflammatory mediators, therefore further amplifying the inflammatory response (Nasti and 
Timares, 2012).  
The direct link between UVR and activation of TLRs and NLRs is yet to be fully 
established, but reports indicate that both receptor families are likely contributors to UV-
induced inflammatory processes (Nasti and Timares, 2012).  Endogenous DAMP signals 
that bind to TLRs include HSP60, HSP70, gp96 (from the HSP90 family), fibrinogen, 
heparan sulfate, b-defensins, HMGB1 and mRNA which initiate signalling pathways and 
stimulate pro-inflammatory cytokine production through receptor ligation (Erridge, 2010; 
Miller et al., 2011; Tsan and Gao, 2004).  Whereas, ATP, uric acid and ROS can initiate 
inflammation via activation of the inflammasome complex (Chen et al., 2013; Leighton et 
al., 2013; Martinon et al., 2006; Tschopp and Schroder, 2010). As discussed in the previous 
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section, many of these endogenous DAMP signals are alarmins released from UV-damaged 
skin cells.   
2.7 Peripheral TLR4 activation can influence neuronal signalling and alter behaviour 
through immune-brain communication pathways  
The evidence discussed so far has demonstrated that UVR induces an inflammatory 
response in the skin, through the release of endogenous alarmins. We have also discussed 
how inflammatory signalling plays a role in addiction, building the foundation for the 
hypothesis that an alarmin driven mechanism may contribute to the addictive-like 
behaviour observed in frequent tanners through TLR4. Therefore, it is important to now 
consider how peripheral TLR immune signalling may influence higher brain centres.   
Currently, no direct evidence of a UV-alarmin-brain pathway exists. However, 
parallels can be drawn to the immune-to-brain communication pathways associated with 
the sickness response, in which peripheral TLR4 activation, contributes to behavioural 
adaptions following infection (Hines et al., 2013). The sickness response describes the set 
of profound behavioural changes that occur with illness, including increased anhedonia, 
malaise, loss of locomotion and anorexia. Sickness behaviours result from an independent 
neuroinflammatory state initiated by endogenous inflammatory mediators (Dantzer, 2004). 
Once thought to be unfortunate side effects of illness, this shift in behaviour is now 
recognised to be a highly adaptive and organised strategy of cytokine-dependent signalling 
cascades that promote homeostasis (Dantzer, 2001). 
 The brain monitors peripheral immune responses by several pathways that act in 
parallel. Firstly, there is a humoral pathway, in which peripheral TLRs in macrophage-like 
cells residing in the circumventricular organs and the choroid plexus respond to circulating 
DAMPs. As this area of the blood-brain-barrier is “leaky”, it enables direct increases in 
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neurokine signalling through volume diffusion (Saper and Breder, 1994). In a second, 
neural pathway, locally produced cytokines may activate primary afferent nerve endings, 
such as the vagus nerve, contributing to behavioural change via neural mechanisms 
(McCusker and Kelley, 2013; Van Dam et al., 1993). A third pathway, consists of cytokine 
transporters across endothelial cells at the blood-brain-barrier, allowing pro-inflammatory 
cytokines to gain access to the brain via saturable transport systems (Banks et al., 1991). A 
fourth pathway involves binding of inflammatory cells to adhesion molecules, such as 
ICAM (intracellular adhesion molecules) and VCAM (vascular adhesion molecules) on the 
endothelium of blood-brain barrier vessels, enabling cells to migrate through the tissue 
(Wong et al., 2007). Finally, peripheral endogenous signalling may communicate across 
the blood-brain-barrier through peripheral leukocytes as they roll along and adhere to 
cerebral vasculature (D'Mello et al., 2013). Engagement of these immune-to-brain 
communication pathways ultimately stimulates the “activation” of glial cells, which are the 
non-neuronal support cells of the central nervous system (CNS) responsible for the central 
production of inflammatory cytokines  (Jacobsen et al., 2014; Laflamme and Rivest, 1999). 
As glia are anatomically co-localised at the tetrapartite synapse, a key site of interaction 
between astrocytes, microglia and neurons, they enable bidirectional communication 
between cells, facilitating “neuroimmune communication” (De Leo et al., 2006; Eyo and 
Wu, 2013). Therefore, glial cells have the ability to rapidly respond to perturbations in 
either peripheral or central homeostasis and directly influence neuronal activity, critical for 
regular physiological function as well as pathological states (Milligan and Watkins, 2009) 
Cytokines in the brain can function as part of an integrated network of signal 
amplification inducing potent effects on neural pathways, ultimately directing behavioural 
output (Capuron and Miller, 2011). For example, it was demonstrated that an illness 
response stimulated by systemic administration of an endotoxin (lipopolysaccharide; LPS) 
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caused significant elevations of dopamine release in the NAc, despite decreased intracranial 
self-stimulation on ascending rate-intensity functions (Borowski et al., 1998). This study 
provides a specific example of a TLR4-mediated illness response affecting central 
dopamine release, a key neurotransmitter involved in reinforcing behaviour, within the 
NAc (Sulzer, 2011).  Another study reported that peripheral administration of recombinant 
IL-1b, IL-2 and IL-6 contributed to alterations in norepinephrine, serotonin and dopamine 
activity within multiple brain regions that were cytokine specific (Zalcman et al., 1994). 
Hence, there is already good evidence to demonstrate that immune stimuli of diverse 
origins can modify behaviour, paving the way for UVR as an immune stimulus to cause 
adaptations in reward behaviours. 
Each of these examples of immune-brain signalling provide a potential mechanism, 
by which UV-mediated alarmin signalling may influence neurotransmission and 
behavioural outcomes. Therefore, it is hypothesised that UV-induced alarmin activation of 
TLRs, either peripherally or centrally, directs neurotransmission and may drive an 
addictive-like behavioural response (Figure 2.1). 
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Figure 2.1 A schematic representation of the proposed immune-to-brain signalling 
pathways that may be induced by UVR. UVR damages skin cells, resulting in the 
production of “alarmins”. Alarmins are DAMP signals that serve to alert the immune 
system of danger and are detected by immune competent cells, leading to stimulation of 
pro-inflammatory cytokines and chemokines. Based on identified pathways of peripheral 
to central communication, pro-inflammatory mediators released from peripheral 
macrophages and monocytes or alarmins could access the CNS via the following pathways: 
1) Humoral pathway - Circulating DAMPs and pro-inflammatory cytokines may activate 
TLRs on the perivascular macrophages to access the brain through leaky regions of the 
blood-brain-barrier, such as the choroid plexus and circumventricular organs (CVO’s). 
Within neuronal tissue, the activation of endothelial cells leads to the subsequent release of 
second messengers such as prostaglandins (PGE2) and nitric oxide (NO). 2) Neural 
pathway – Peripheral pro-inflammatory cytokines may stimulate afferent nerve endings 
such as the vagus nerve, which are then relayed within the brain. 3) Cellular pathway - 
peripheral leukocytes can adhere to cerebral vasculature signalling across the blood-brain 
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monocyte chemoattractant protein-1 (MCP-1), which is principle for the recruitment of 
monocytes within the central nervous tissue. These immune-to-brain signalling pathways 
contribute to the activation of glial cells (astrocyte and microglia). Glia, together with the 
pre- and post-synaptic neurons, form the tetrapartite synapse, enabling bidirectional 
communication between cells. Activation of glia is characterised by higher concentrations 
of inflammatory mediators, creating a neuroinflammatory environment which impacts on 
the excitation of neurons (increased AMPA and NMDA receptors, increased glutamate in 
the synapse, downregulating of GABA). Increased inflammatory signalling at 
neuroanatomical sites associated with addiction, the mesolimbic dopamine pathway, could 
contribute to enhanced reinforcement increasing addictive-like behaviour. 
2.8 We don’t like being sick, so why do we “like” UV exposure? 
Our understanding of the immune system is ever evolving, and it has become 
apparent that the one response fits all approach may not be true in every situation. 
Therefore, it is important to note that immune responses are context specific and will vary 
according to the stimulus (Graeber, 2010). Key factors, such as neuroanatomy and the 
heterogeneity of the immune system, significantly affect how a peripheral immune 
response can initiate a central response (Hutchinson and Watkins, 2014). This means that 
peripheral immune responses do not simply cause pan-glial reactivity but, through discrete 
and selective pathways, may lead to distinct behavioural phenotypes; such as eliciting an 
illness response in one situation and contributing to the development of addiction in another 
(Hutchinson and Watkins, 2014).  
In the case of sickness behaviours, there is a significant insult to the peripheral 
immune system, which requires an adaptive response, affecting multiple behavioural 
(anhedonic, appetite, mood) and physiological (fever) outcomes (Liu et al., 2014). This 
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response is pro-inflammatory, and relies upon TLR activation of peripheral immune cells 
significantly increasing circulating inflammatory products, as the blood-brain barrier 
largely prevents endotoxins from readily entering the CNS (Quan and Banks, 2007). This 
anatomical barrier immediately limits direct glial activation, ensuring a slower, but more 
graded glial response. Conversely, recreational substances, such as opioids and alcohol, 
can readily penetrate the blood-brain barrier, activating glia directly (Stevens et al., 2013). 
Alarmins signals may also activate glia directly, as they can readily enter neuronal tissue 
through humoral pathways or they may be released within the CNS directly as a result of 
neuroinflammation (Bianchi, 2007). Direct access of alarmins to glia means that alarmins 
can function akin to neurotransmitters and therefore act at sub-inflammatory levels much 
lower in magnitude than an illness response (Hutchinson and Watkins, 2014).  
Furthermore, the physiological responses to UV exposure are not mutually 
exclusive or occurring independently of one another (D’Orazio et al., 2013). The 
hypothesis presented here builds on the evidence that together neuroimmune signalling and 
opioid/dopamine signalling produce a heightened response, which may contribute to the 
addictive-like behaviour observed in certain individuals following UV exposure.  
Interestingly, recent work by Petrulli and colleagues (2017) demonstrated a synergistic 
effect between immune activity and dopamine stimulants (Petrulli et al., 2017). Intravenous 
administration of LPS contributed to elevated stimulant-induced dopamine concentrations 
in the striatum (detected with PET scan) of human subjects, when compared to those 
receiving placebo.  Yet, despite elevated circulating inflammatory cytokines, the negative 
behavioural effects typically observed during an illness response, such as fatigue, were not 
present (Petrulli et al., 2017). These findings suggest that there may be a synergistic effect 
between stressors leading to immune system activation and increased dopamine signalling, 
with the presence of inflammation perhaps increasing addiction potential. Such a finding 
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could have significant implications for tanning addiction, as chronic UV exposure may lead 
to similar stressor-induced immune activation, and, consequently, increases in central 
dopamine signalling, although this hypothesis remains to be empirically tested.  
It is also interesting to note that in instances of both illness response and drug abuse, 
the resulting inflammation would be much more transient than the inflammatory response 
initiated from UV-damage, and would be resolved, under normal conditions, when the 
stimulus was removed. Comparatively, the inflammatory response triggered by UV 
exposure would presumably be much lower, but with increased frequency, due to the 
ubiquitous nature of sunlight. This is of particular relevance in countries where the UV 
index is high, and people tan frequently. Constant UV exposure would provide low grade, 
everyday stimulation of cell stress signals; an effect that would be even further increased 
in frequent tanners. This could have significant ramifications for basal glial priming 
reactivity (linked to priming of heightened responses) and could contribute to the 
maladaptive addictive-like behaviours demonstrated by frequent tanners.  
There is still a great deal unknown regarding the hypothesised link between UV 
exposure and behavioural changes. However, there are significant converging lines of 
evidence that can direct future research. The sun-tanning literature demonstrates that people 
who are exposed to UV, present with signs of withdrawal, signifying dependence 
(Harrington et al., 2011b; Warthan et al., 2005). The physiological process of tanning is a 
trigger for b-endorphin production, which has the capacity to activate neuronal signalling 
within key brain regions that have been associated with addiction (Fell et al., 2014; Volkow 
and McLellan, 2016). Given the new insights into neuroimmune modulation and the role 
of glia in facilitating dependence (Hutchinson et al., 2012), combined with the hypothesised 
UV-DAMP signal to the brain, the opportunity for a new neuroimmune contributor exists. 
Therefore, it is possible that UV induced alarmin signalling, which arises in the skin 
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following UV exposure, could be contributing to glia activation and play a part in the 
addiction-like behavioural phenotype observed following UV exposure.  
2.9 Conclusion 
Our hypothesis outlined in the current review posits that UV exposure causes 
behavioural modifications in those who tan frequently and that this behaviour is 
comparable to that which is seen in drug addiction. UVR activates components of the 
mesolimbic dopamine pathway, indicating that dopamine neurotransmission may be a key 
target for UV-mediated behavioural adaptions. UVR also leads to elevations in the opioid 
neuropeptide β-endorphin, suggesting involvement of opioid neurocircuitry systems as 
well.  
To date, a direct mechanism by which UVR can influence neurotransmission to 
modify behaviour is still to be identified. However, recent advances in neuroimmunology 
point to a possible mechanism by which UV exposure could influence central neurokine 
signalling. A chronic alarmin-mediated process derived from repeated UV-initiated cellular 
damage is hypothesised to lead to TLR/NLR activation, causing the peripheral release of 
pro-inflammatory cytokines. These alarmins and pro-inflammatory cytokines could 
penetrate or translate the CNS, where they may cause activation of central TLRs and other 
inflammatory receptor systems, translating to a state of glial reactivity. This glial activation 
would then lead to enhanced opioid and dopamine signalling within the mesolimbic 
circuitry, facilitating addiction-like behaviours in frequent tanners. Further research is 
required to investigate the novel cutaneous-to-brain immune mediated hypothesis 
presented here, as a potential mechanism explaining the addictive-like behavioural 
adaptions observed with frequent tanning and UV exposure. If found to be clinically 
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applicable, these hypotheses also point to the need to expand the range of interventions and 
services available in the public health programs used to promote sun smart behaviours. 
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Thesis aims and hypotheses  
The work contained in this thesis aimed to understand how UV light applied to the skin has 
the capacity to influence neuronal circuitry and affect neurological outcomes. Thus, this 
work investigates cutaneous responses to UVR and the potential skin-induced signalling 
molecules that communicate from peripheral to central tissue.  Chapter 3 focuses on an 
immune mediated-mechanism, whereas Chapter 4 explores the contributions of vitamin D.  
Chapter 3. Do UV-induced alarmin stress signals influence dopaminergic brain 
pathways and increase motivation? 
Given the recent advances in the field of neuroimmunology demonstrating that heightened 
immune signalling has the capacity to modify behavioural outcomes (Hutchinson and 
Watkins, 2014; Narita et al., 2006), it is plausible that UV-induced inflammatory signalling 
could be a contributing mechanism for the increased UV-seeking phenotype observed in 
frequent tanners. Therefore, the aims of the first study were to:  
1. Develop and optimise a novel apparatus using fibre optic technology for the safe 
and targeted exogenous delivery of UV light to the skin of Sprague Dawley rats 
(275-400g).  
2. Determine the alarmin profile in the skin, blood, spinal cord and brain tissue 
following UVR exposure at different levels/intensities of exposure.  
3. Characterise both the peripheral and central UV-induced immune profiles through 
the measurement of inflammatory markers from the blood, spinal cord and brain.  
4. Examine dopamine-related behaviours and dopamine levels within the nucleus 
accumbens using operant conditioning boxes paired with microdialysis and 
immunohistochemistry.  
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As UVR is a potent inducer of cell damage, it was hypothesised that UV exposure will 
contribute to an immune response and the release of endogenous alarmins that will impact 
on dopamine neurocircuitry. Further, this will contribute to alterations in dopamine 
neuronal signalling that increase behavioural output in a test of motivational drive.  
Chapter 4. Are the protective benefits of vitamin D in neurodegenerative disease 
dependent on route of administration? A systematic review. 
UV light is also responsible for the cutaneous production of vitamin D and this may be 
another pathway connecting peripheral UV with central changes. Several studies indicate 
that sun exposure mitigates neurological disease and is protective against the risk of 
neurodegeneration, an effect that has largely been attributed to synthesis of vitamin D 
(Annweiler et al., 2011; Duan et al., 2014; Landel et al., 2016; Munger et al., 2006; Shen 
and Ji, 2015). To investigate a role for vitamin D in neurodegenerative disease a systematic 
review was completed that aimed to:  
1. Determine if neuroprotective benefits from vitamin D in neurogenerative disease 
are dependent on route of administration (exogenous or endogenous) by reviewing 
published literature available on PubMed, Embase and PsycInfo.  
It was hypothesised that if vitamin D was the sole mediator of UV related protective 
benefits, then synthetic vitamin D supplementation would either improve disease outcomes 
or reduce disease risk.  
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Chapter 3. Do UV-induced alarmin stress signals influence dopaminergic 
brain pathways and increase motivation? 
This chapter describes the proposed experimental work designed to investigate if 
UVR influences dopaminergic systems within the brain to increase motivated behaviour; 
and if this is driven, at least in part, by alarmin signalling arising from UV-damaged skin 
cells. The chapter is written as a research proposal and includes a brief project summary 
and discussion of the two main research questions. The project aims, and hypotheses are 
then presented which are followed by a detailed outline of the methodology and analysis 
techniques that have been carefully considered and planned. This chapter is written in this 
format as the work was not completed due to unforeseen circumstances, which significantly 
reduced my capability to undertake the research. Progress of the work that had commenced 
can be viewed in the Appendices.  
3.1 Brief summary  
This project will examine if alarmin cell stress signalling arising from UV damaged 
skin cells contributes to increased reinforcement or motivation, through the analysis of 
operant choice behavioural paradigms and dopamine levels within the nucleus accumbens 
(NAc).  
The proposed study design will use a dose-response-like application of graded UVR 
concentration applied directly to the skin of the scapular region of Sprague Dawley rats. 
The first aim is to investigate whether a correlation exists between cutaneous alarmin 
production and behavioural modifications. Tissue analysis for levels of alarmins, secondary 
markers of inflammation and dopamine will be performed on the skin, blood, spinal cord 
and brain using a combination of immunohistochemistry, molecular pathology and high-
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performance protein liquid chromatography (HPLC). An acute effect will be recorded 
following a single UV exposure, whereas a chronic effect will be measured following daily 
exposure for a period of 28 days. This study will use the well-validated concurrent choice 
procedure (Randall et al., 2012) to investigate how UVR impacts effort-related choice 
behaviour. Additionally, to further consolidate findings, a second microdialysis study is 
proposed to measure the levels of dopamine in cerebrospinal fluid from the NAc within a 
freely moving animal.  
3.2 Research questions 
3.2.1 Is UVR associated with increased motivational output and the continued engagement 
in operant lever pressing? Does this correlate with elevated production of alarmins and 
immune activation? 
Rationale: People who tan frequently can exhibit signs of psychological and physical 
dependence suggesting that UVR has a reinforcing effect associated with increased 
motivation for sun-seeking behaviour (Feldman et al., 2004; Fell et al., 2014; Harrington 
et al., 2011a). As such, tanning may present as a form of behavioural addiction with similar 
impacts on neurocircuitry to other types of addiction, particularly affecting the mesolimbic 
dopamine pathway (American Psychiatric Association, 2013; Aubert et al., 2016; Kourosh 
et al., 2010; Nolan and Feldman, 2009). The dopamine neurotransmitter is heavily 
associated with the development of addiction, due to its involvement in the neurocircuitry 
of motivation and associative learning (Salamone and Correa, 2012). Dopamine is known 
to increase the motivation to seek rewarding stimuli, or the “wanting” component of 
addiction with dopaminergic drive increasing as addiction develops (Berridge et al., 2009). 
Increases in dopamine efflux have been observed in frequent tanners following exposure 
to UVR (Aubert et al., 2016), thus it is reasonable to hypothesise that UVR stimulation of 
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dopaminergic pathways may play a critical role in the behavioural modification observed 
with frequent tanning.  
To date, the physiological mechanisms by which peripheral UVR could be driving 
behavioural change via secondary neuronal signalling have yet to be defined. However, 
recent developments in addiction research and the discovery of an immune contribution to 
addiction pathophysiology, open the possibility for previously unidentified signalling 
pathways (Hutchinson and Watkins, 2014). Solid evidence shows that vulnerability to 
addiction is increased during a pro-inflammatory state and that inflammatory mediators 
change the pharmacodynamics of illicit substances (Hutchinson et al., 2008; Narita et al., 
2006). As UVR has the capacity to initiate inflammatory cascades and the release of 
endogenous alarmins (Byrne et al., 2011; Johnson et al., 2013; Takai et al., 2011; 
Yoshizumi et al., 2008), this may be one potential pathway by which UVR could affect 
central circuits and alter behavioural outcomes. Therefore, this project proposes to 
investigate the effects of cutaneous UVR on alarmin expression (in the skin, blood, spinal 
cord and brain) and if this correlates with increased performance in a test of motivated 
behaviour using the progressive ratio/concurrent choice procedure (Randall et al., 2012).   
The progressive ratio/concurrent choice procedure is a well validated behavioural 
test capable of detecting alterations in dopamine expression, particularly within the NAc 
(Randall et al., 2012; Salamone et al., 1997). In this task, experimental animals are given 
the choice to engage in lever pressing (that is continually demanding more effort by 
increasing the number of required lever presses) for a highly desirable sugar pellet or to 
consume the concurrently available, less palatable standard chow (Randall et al., 2012). 
Administration of dopamine antagonists produces a dramatic shift in the choice behaviour 
of animals resulting in decreased lever pressing for the preferred chow and considerable 
increases in consumption of the freely accessible chow (Koch et al., 2000; Salamone et al., 
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2001). Whereas, elevated levels of dopamine within the NAc, such as through 
administration of amphetamines or knock down of dopamine transporters, contributes to 
decreased performance in motivation under a progressive ratio schedule of reinforcement 
(Zhang et al., 2003). Consequently, using this behavioural paradigm, sensitive to dopamine 
alterations in conjunction with UVR exposure, will shed light on whether UVR affects 
neurocircuits in a manner similar to other dopamine manipulators. This will test the 
hypothesis that UV exposure will contribute to the release of endogenous alarmins and this 
will have a central effect increasing behavioural output during a test of motivated choice 
behaviour.   
3.2.2 Is UV exposure associated with increased dopamine within the nucleus accumbens in 
a dose dependent manner? 
Rationale: In addition to behavioural modifications attributed to UVR, it is also important 
to consider the neurotransmitter signalling underlying any adaptations to motivated 
behaviour and provide evidence of such change. As mentioned in the previous section, 
mesolimbic dopamine is the most likely candidate as it plays a key role in several 
behavioural functions related to motivation (Bromberg-Martin et al., 2010). Moreover, the 
mesolimbic dopaminergic pathway is also heavily associated with the development of 
addiction with dopamine efflux implicated in drug/alcohol abuse as well as a number of 
behaviours that can become addictions (Avena et al., 2009; Balfour et al., 2004; Di Chiara 
and Imperato, 1988). In addition, mesolimbic activation and dopamine increases have 
already been recorded in frequent tanners following tanning sessions. Firstly, a study using 
SPECT imaging to measure rCBF during a session with either UVR or sham UVR in 
frequent tanners, demonstrated that during the UVR session, tanners had a significant 
increase in rCBF in the left striatum (Harrington et al., 2011a). Another group reported 
dopamine efflux occurred in frequent tanners, but not in infrequent tanners after UVR 
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administration. This effect that was diminished when using sham UVR light, in which UV 
wavelengths were blocked (Aubert et al., 2016), providing further support that dopamine 
could be the key neurotransmitter involved in modifying behaviour following prolonged 
UV exposure. Dopamine neurotransmission is also known to be sensitive to inflammatory 
signalling and therefore may respond to increases in circulating alarmins induced by UVR. 
Increased efflux of in vivo dopamine from the NAc was observed following peripheral 
injections of the inflammatory stimulant lipopolysaccharide (LPS) (Borowski et al., 1998). 
This suggested that in addition to illness-induced behavioural modifications, inflammatory 
stimuli can also provoke alterations in neurotransmitter release along the mesolimbic 
pathway. Therefore, this project will investigate if UV light can influence dopamine 
signalling, testing the hypotheses that UVR exposure will increase dopamine levels within 
the NAc in a dose dependent manner. 
3.3 Aims 
1. Develop and optimise a novel apparatus using fibre optic technology for the safe 
and targeted exogenous delivery of UV light to the skin of Sprague Dawley rats 
(275-400g).  
2. Characterise the alarmin immune response in skin, blood, spinal cord and brain 
tissue following exposure to different durations of UV light.  
3. Characterise the peripheral and central UV-induced immune profiles by measuring 
inflammatory markers from the blood, spinal cord and brain.  
4. Examine dopamine related behaviours and dopamine levels within the NAc of 
Sprague Dawley rats by monitoring performance in motivated behavioural task 
(concurrent choice behaviour) paired with analysis of microdialysis and 
immunohistochemistry.  
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3.4 Hypotheses 
1. UVR exposure will contribute to an immune response and the release of 
endogenous alarmins from irradiated skin cells. 
2. This UV-induced alarmin signalling will contribute to central alterations 
effecting dopamine levels within the NAc. UV-triggered dopamine efflux will 
occur in a dose-dependent manner.  
3. Any increases in dopamine will affect behavioural output and contribute to 
increased performance in the progressive ratio/concurrent choice behavioural 
paradigm used to test motivated behaviours.  
3.5 Experiment 1: Examine the effect of daily ultraviolet exposure on motivational 
drive and determine ultraviolet induced alterations in the alarmin response in rodents 
Overview: The aim of this study is to investigate the alarmin response generated from 
graded concentrations of chronic dermal UVR and if this correlates to a change in 
dopaminergic-driven behaviour. This will allow us to determine whether UVR alters 
neuronal processing causing a change in behaviour. The behavioural test used for this study 
will follow the protocol published by Randall et. al 2012, using a progressive 
ratio/concurrent choice paradigm, in which the animal can either lever press (with 
increasing effort) for a desired high carbohydrate pellet or consume freely accessible 
standard chow (Randall et al., 2012).  
Rats (n =50; 10/group) will be trained on the concurrent progressive/chow feeding 
procedure as described in section 3.7.3 below. The sample size (n=10/group) has been 
selected from a power analysis using a standardised effect size of 1.4 (signal/noise ratio), 
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believed to provide the study with sufficient power (80%) for statistical analysis, as there 
is no preliminary data to guide group size estimates.  
UVR exposure will be administered using a between-groups design, with each rat 
receiving only one exposure condition. Rats will be randomly assigned to receive either 0, 
0.5, 1, 2 or 4 kJ/m2 UVR delivered via a newly designed UV apparatus, that will guide UV 
light directly onto the skin (described in section 3.7.2). Immediately following UVR 
exposure, rats will be placed within an operant conditioning chamber where they will begin 
the progressive ratio concurrent choice feeding session, as a test of motivated behaviour. 
Behavioural measures to be recorded include the total number of lever presses/pellets 
received within the 30-minute period and the amount of freely accessible chow consumed. 
UVR exposure and choice behavioural testing will be performed daily for a period of 28 
days. At completion of the experiment animals will be humanely sacrificed and tissue 
collected for further analysis. Half of the animals from each group (n=5) will be prepared 
for immunohistochemistry (IHC) and serial sections from the brain/spinal cord will be 
stained using specific antibodies to measure the presence of alarmins (HMGB1, IL-1b, IL-
33) and immune activation (CD68, CD3, RAGE and TLR4 receptors) within key regions 
of interest. The remaining animals (n=5) will be prepared for molecular pathology and 
protein quantification using the western blot technique and enzyme-linked immunosorbent 
assay (ELISA) for markers of protein expression and immune activation (based on results 
from IHC).  
3.6 Experiment 2: Determine the effect of ultraviolet exposure on the levels of 
dopamine within the nucleus accumbens 
Overview: The aim of this study is to investigate the effects of graded concentrations of 
chronic UV light on dopamine levels within the NAc, using microdialysis sampling to 
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detect changes in neurotransmitter levels. This will shed light on whether UVR influences 
dopaminergic transmission within the NAc. 
Rats (n =50; 10/group) will be implanted (unilaterally) with a 10-mm microdialysis 
guide cannula (described in section 3.7.8) to allow sampling of cerebrospinal fluid (CSF) 
from the NAc to measure dopamine concentration. This group size has been selected based 
on previous microdialysis experiments and is expected to provide sufficient statistical 
power (see (Collins-Praino et al., 2012; Ishiwari et al., 2004). 
UVR exposure will follow the same protocol as Experiment 1, using a between 
groups design and random assignment of either 0, 0.5, 1, 2 or 4 kJ/m2 UVR, to be 
administered with the UV apparatus. Rats will be exposed to UVR daily for 28 days but 
microdialysis samples of CSF will only be collected on days 1, 7, 14 and 28. On sampling 
days, animals will have a concentric dialysis probe inserted through the guide cannula. 
Artificial CFS (aCSF) will then be continually perfused through the microdialysis tubing 
at a flow rate of of 2.0 µL/min. Prior to UVR exposure, flowing CSF will be sampled every 
30-minutes until seven baseline samples are collected.  Animals will then be fitted with the 
UV apparatus and receive their daily dose of UVR. During which time, animals will remain 
in the microdialysis chamber and CSF sampling will continue for a 6-hour period with 
samples collected every 30-minutes. CFS samples will be analysed for dopamine content 
using reverse-phase HPLC with electrochemical detection. Food and water will be 
available ad libitum within the microdialysis chamber. 
3.7 Proposed methodology 
This section describes the general procedures to be utilised for the preceding 
experiments. However, as this is a new research design at the University of Adelaide, pilot 
experiments will be necessary to determine key experimental parameters.  
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3.7.1 Animals  
Male Harlan Sprague Dawley rats weighing between 275-400g will be used for all 
experiments. Sprague Dawley rats have been selected as they have been previously used 
by our lab to explore behavioural consequences of inflammatory signalling. This strain is 
also regularly used in behavioural studies and in addiction research, therefore ensuring the 
results of this study will be comparable to other published data within the field (Hutchinson 
et al., 2012; Randall et al., 2012). Rats will be housed in a temperature (23±3°C) regulated 
facility and subject to a 12 h light/ 12 h dark cycle. Animals will have ad libitum access to 
chow and water in the home cage unless assigned to the progressive ratio behavioural 
groups in which animals will be food deprived to 85% of their free feeding body weight 
for initial training purposes. Rats will be fed supplemented chow throughout the 
behavioural study, with ad libitum access to water in the home cage. Hair from the scapular 
region will be continually removed using an electric shaver throughout the study period to 
allow for direct UVR exposure on the skin. All experimental procedures will be performed 
in accordance with the National Health and Medical Research Council Australian Code for 
the care and use for scientific purposes (8th edition, 2013) and the University of Adelaide 
Animal Ethics Guidelines, and approved by the University of Adelaide Ethics Committee.  
3.7.2 Ultraviolet  light apparatus  
To best investigate the effects of different UV light concentrations, a novel UV light 
apparatus will be employed to allow for the safe and targeted delivery of UVR. This design 
guides light directly onto a small portion of shaved skin, serving to eliminate unnecessary 
exposure to sensitive areas of the animal (ear, paws and eyes) and to ensure the precise 
delivery of exact quantities of UVR by eliminating external variables that might affect the 
amount UVR received. Furthermore, the advanced fibre optic technology available also has 
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the capacity to obtain a reflection-absorption spectrum, providing information of irradiance 
projected back off the skin which main serve to provide additional insights on skin related 
changes following exposure to UVR.     
The design consists of a lightweight titanium dispersing cone that is to be worn by 
the animal (embedded within a fabric vest) projecting light on to the shaved scapular region. 
The dispersing cone is connected with fibre optic cables to a plasma laser-driven light 
source (Eq-99, Energetiq Technology Inc., Wilmington, MA, United States), emitting 
wavelengths of light that are comparable to those emitted from sun as recorded at sea level. 
However, as this apparatus employs a new method for delivery of UV light, pilot 
experiments will be needed to identify the appropriate concentration of UVR to in order to 
address the specific research questions. The proposed intensities of UV light have been 
based on peer-reviewed literature and include 0, 0.5, 1, 2 and 4 kJ/m2 of UVR. These 
intensities have been selected to create a dose-response like regime and to represent a range 
from minimal to mild sunburn (Grimbaldeston et al., 2007; Yoshizumi et al., 2008). 
Each exposure session will last the duration of the 30-minutes, however, the 
manipulation of UVR intensity will be achieved by using a UV filter (blocking all 
wavelengths below 400nm) to create “sham” UVR. The length of UVR exposure needed 
to fulfil each intensity, determined in minutes, will be calculated and the UV filter applied 
for the remainder of the 30-minutes session. The reflection-absorption measurement will 
be recorded daily prior to removal of the UVR filter at the beginning of the exposure session 
and then again once UVR exposure has ceased. This recording will be used to detect a 
potential shift in the amount of light that is absorbed/reflected by skin tissue. All exposure 
will take place inside an operant conditioning chamber, with the optic fibre cable extending 
from the top of the box. The animal will be able to move freely inside the chamber.  
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3.7.3 Behavioural testing 
UVR-induced changes to motivated behaviour will be assessed using a progressive 
ratio/concurrent choice protocol. In this behavioural test, animals will have the choice to 
lever press for highly derisible sugar pellets or to eat the freely accessible standard rodent 
chow. However, the number of responses needed to release a sugar pellet are progressively 
increased throughout the test, thus continually more effort is demanded before a sugar pellet 
can be obtained providing a measurable outcome of motivated behaviour (Randall et al., 
2012; Yohn et al., 2015). This test will be conducted daily within an operant conditioning 
chamber (28x23x23 cm3; Med Associates Inc; Fairfax, VT, United States) and run for the 
duration of 30-minutes.  
Initially, rats will be trained to lever press using a continuous fixed ratio (FR) 
reinforcement schedule for approximately one week, and then, will be shifted to the 
progressive schedule used by (Randall et al., 2012). In brief, the FR schedule will gradually 
be increased from FR1-FR5 (FR1- one lever press, one sugar pellet, FR5-five lever presses, 
one sugar pellet) across the training week. Once the animal has associated lever pressing 
with the delivery of a sugar pellet the progressive schedule will be introduced. 
Commencing with FR1, every time 15 reinforcements are obtained, the number lever 
presses needed will be increased by one additional response (FR1x15, FR2x15, FR3x15…). 
If a ratio is not completed within 2 minutes, a “time-out” feature will deactivate the 
response lever for the remainder of the session. Upon reaching a stable baseline of 
responses (approx. 4 weeks), chow will be introduced. Weighed amounts of standard rodent 
chow will be concurrently available on the floor of the chamber, the animal will now have 
the choice of eating freely available chow or to engage in lever pressing for sugar pellets, 
therefore testing motivational drive. Chow intake will be determined by weighing any 
remaining food (including spillage). Rats will be trained on the on the progressive schedule 
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for an additional 4 weeks, after which daily UVR exposure will commence in conjunction 
with operant testing.  
3.7.4 Tissue collection 
Prior to UVR exposure, animals will be anesthetised to perform a tail-vein bleed 
from which plasma will isolated and used to determine baseline levels of circulating 
alarmins (such as HMGB1, IL-1b, IL-33) and vitamin D. At cessation of behavioural 
testing animals will be humanely sacrificed for tissue collection including skin, blood, 
spinal cord and brain.  
Firstly, skin samples will be acquired from the irradiated site and a proximal non-
irradiated site using a 4mm punch-tool. Half of the samples from each location will be post-
fixed in 10% neutral-buffered formalin (overnight at 4°C) in preparation for histological 
analysis. This will include routine hematoxylin and eosin (H&E) staining to detect UVR 
induced changes to skin integrity, cell type and cell number. Immunohistochemistry will 
also be performed using antibody staining to detect markers of immune activation. The 
primary antibodies of interest include HMGB1, IL-1b and IL-33, as these have been 
categorised as alarmins and have been shown by other research groups to alter their 
expression following UVR induced damage to keratinocytes (Byrne et al., 2011; Johnson 
et al., 2013; Yoshizumi et al., 2008). The remaining tissue will be snap frozen in liquid 
nitrogen to be stored for protein quantification and western blot analysis. Next, blood 
samples taken directly from cardiac tissue will be collected in EDTA tubes and the plasma 
used to measure potential UVR induced changes to both alarmin and vitamin D 
concentrations. Lastly, following skin and blood collection, half of the animals from each 
group will undergo transcardial perfusion with 10% neutral-buffered formalin, fixing the 
tissue for histological analysis and immunohistochemistry. The brain and spinal cord will 
 59  
 
be analysed for the presence of alarmins (HMGB1, IL-1b, IL-33) and immune activation 
(CD68, CD3, RAGE and TLR4 receptors). The remaining animals will be perfused with 
0.9% saline, to remove tissue of blood, and then the brain and spinal cord will be removed  
and snap frozen in liquid nitrogen. Brain and spinal tissue will undergo western blot, ELISA 
and multiplex analysis for protein expression of range of inflammatory markers including 
HMGB1, IL-1b, IL-33 and TLR4 and RAGE receptors. The data obtained from cutaneous 
and blood samples will be analysed first and will help determine the alarmin markers to be 
examined centrally. 
3.7.5 Histological analysis  
In preparation for H&E histological analysis of treatment groups, fixed samples 
must undergo tissue processing during which water is removed and replaced with paraffin 
wax, enabling thin sections to be cut and viewed microscopically. Firstly, tissue samples 
will be placed in processing cassettes and then systematically transferred through a series 
of baths gradually increasing in ethanol content (70-100%), dehydrating the tissue of water. 
Samples will then be submerged in the clearing agent xylene, necessary to remove the 
ethanol from the tissue to allow the paraffin wax to infiltrate the tissue. After processing is 
complete, samples will be externally embedded in wax with sections orientated so all layers 
of the skin can be identified. Once the wax has solidified, serial sections will be cut using 
a rotary microtome (4µm) and mounted onto albumin-coated slides, followed by routine 
H&E staining. In brief, sections will be dewaxed with xylene and rehydrated through 
graded ethanol. Tissue sections will then be stained using Harris Hematoxylin (three 
minutes) before being placed in 0.5% ammonia (one minute) to enable bluing. Finally, 
sections will be stained with eosin (four minutes) and prepared for cover slipping, 
progressing through ethanol and xylene once again. After which, cover slips will be 
mounted, and the slides scanned with a NanoZoomer (Hamamatsum Photonics, Shizuoka 
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Pref., Japan). Tissue analysis will be performed on scanned images using NanoZoomer 
Digital Pathology software view.2 (Histalim; Montpellier, France) and ImageJ software 
(Schneider et al., 2012). 
3.7.6 Immunohistochemistry 
Immunohistochemistry (IHC) will be performed to determine the presence of 
alarmins (HMGB1, IL-1b, IL-33) and immune activation (CD68, CD3, RAGE and TLR4 
receptors) using antibody staining. Each antibody will have a specific IHC protocol, 
recommended by the manufacturer, which will be used as a first point of reference. 
Although protocols may vary slightly, a general indirect IHC procedure using avidin is as 
follows: 
Prepared tissue samples that have been fixed in in formalin and embedded within 
paraffin wax will be cut using a microtome (4µm) and mounted onto SuperFrost® glass 
microscope slides (Menzel-Glaäser; Braunschweig, Germany). Following dewaxing and 
rehydration steps, antigen retrieval will then be completed, necessary to break the amino 
cross-links that form during fixation to “unmask” the antigenic site of interest. This is 
commonly performed using heat treatment (such as within a microwave or pressure cooker) 
and will need to be optimised for each antibody. Generally, slides are submerged in a buffer 
solution (citrate, EDTA or Tris-EDTA) and then maintained at boiling temperatures for a 
set period of time (e.g 10 minutes). Slides must then be cooled to room temperature and 
endogenous peroxidase activity blocked using a 3% solution of hydrogen peroxide/ 
methanol. Further blocking of non-specific staining is required to reduced background 
interreference which can be achieved with the use of a blocking buffer, such as 10% normal 
horse serum (NHS). After the blocking stages are complete, slides are then incubated with 
the primary antibody, diluted in blocking buffer, within a humid chamber (typically 
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overnight). Incubation with the corresponding biotinylated secondary antibody is then 
applied followed by avidin horseradish peroxidase solution, which will further amplify the 
signal. Staining is then developed using 3,3’ Diaminobenzidine (DAB) and slides are 
counterstained with hematoxylin and prepared to have coverslips applied. Once the 
coverslip mounts have dried, the slides can then be scanned using the NanoZoomer 
(Hamamatsu Photonics, Shizuoka Pref., Japan) and images analysed with NanoZoomer 
Digital Pathology software view.2 (Histalim; Montpellier, France) and ImageJ software 
(Schneider et al., 2012).  
3.7.7 Molecular pathology 
3.7.7.1 Tissue processing 
In preparation for molecular pathology, skin tissue will be frozen in liquid nitrogen 
and crushed to a fine powder using a mortar and pestle and then sonicated with RIPA 
(radioimmunoprecipitation assay) buffer. Soft tissue samples will be homogenised and 
sonicated using RIPA, without the need for prior crushing. Homogenised samples will then 
be separated using a centrifuge set at 4°C/14,000 RPM and the supernatant collected. Total 
protein concentration will be calculated using a Pierce™ BCA protein assay (ThermoFisher 
Scientific; Waltham, MA, USA) at 750nm absorbance.  
3.7.7.2 Western blot  
The western blot will be used to detect and analyse modified protein quantities 
between treatment groups (determined from IHC), modelling techniques that have been 
previously published by our lab (Arulsamy et al., 2018). Briefly, gel electrophoresis will 
be performed using Bolt 4-12% Bis-Tris Plus gels (ThermoFisher Scientific; Waltham, 
MA, USA), loading 50ug of protein per well. Gels are then run at 150V for between 30-45 
minutes (determined by the molecular weight of the protein of interest) and then to a PVDF 
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(polyvinylidene difluoride) membrane using the iBlot 2 Dry Blotting System 
(ThermoFisher Scientific; Waltham, MA, USA). Next, the membranes are repeatedly 
washed (3x5 minutes) using tris-buffered saline with tween 20 (TBST). Before progressing, 
the membranes will be submerged in Ponceau S red solution (Sigma-Aldrich; NSW, 
Australia) for five minutes, so that protein lanes can be visualised. All excess Ponceau S 
will be removed by rinsing the membrane with distilled water. Antibody staining will then 
be performed with primary and secondary antibodies in 1X iBind solution using the iBind 
Western System (ThermoFisher Scientific; Waltham, MA, USA). The specific antibodies 
selected will be based on results from IHC analysis but are expected to include markers for 
HMBG1 IL-1b, IL-33 and TLR4 and RAGE receptors. Imaging of western blots will take 
place using an Odyssey Infrared Imaging System (model 9120; software version 3.0.21) 
(LI-COR Inc; Lincoln, NE, United States) at a resolution of 169µm. Analysis will then be 
performed using ImageJ software (Schneider et al., 2012).  
3.7.7.3 Enzyme-linked immunosorbent assay (ELISA) 
UV-induced changes to cytokines, chemokines and other soluble biomarkers of 
interest will also be measured through the use of ELISA kits. The specific biomolecules to 
be measured with an ELISA have yet to be determined, however prior analysis of IHC and 
western blot will guide selection. Once identified, the appropriate ELISA kits will be 
utilised, following the manufacturer’s specifications. A standard ELISA protocol, as 
presented on the ThermoFisher Scientific website, is as follows:  
Prepared standard and tissue samples (50-100µL) will be added to a pre-coated 96-
well plate and left to incubate at room temperature for a period of two hours. Specific 
biotinylated primary antibodies are then applied to each well, incubating for 60-minutes. 
Next, streptavidin horseradish peroxidase conjugate (100µL), which will bind to the biotin 
on the primary antibody, is added with an incubation period of 30-minutes.  So far, in 
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between each of these preceding steps, the incubating solution must be adequately decanted 
and the plate washed, either using a squirt water bottle or plate washer. In the final 
incubating stage, a chromogenic colouring solution (100µL) is added to visualise substrates 
and must develop in the dark for 30-minutes. Lastly, a stop solution (100µL) is applied, 
preventing further colour development and absorbance can be read using a plate reader. 
Experimental data is then calibrated against the standard curve corresponding to each 
protein of interest.  
3.7.8 Microdialysis and high-performance protein liquid chromatography (HPLC) 
To investigate the effects of UVR on real-time levels of dopamine within the NAc, 
samples of CSF will be collected through microdialysis and screened using HPLC. Which 
will provide robust recordings of dopamine activity during UVR exposure to give a clear 
overview of UVR induced alterations to the dopaminergic system.  
 To facilitate sample collection, a microdialysis probe will be surgically implanted 
following well validated protocols (Collins-Praino et al., 2012; Ishiwari et al., 2004). 
Firstly, animals will have a 10mm guide cannular (Bioanalytical Systems Inc; Lafayette, 
IN, United States) unilaterally inserted into the NAc. To ensure correct placement of the 
cannula, a stereotaxic apparatus will be used with the upper incisor bar set at 5.0mm above 
the interaural line. The NAc can be located using the following coordinates: 8 mm anterior 
from bregma, 1.8 mm lateral from the midline, 6.8 mm ventral from the skull surface. Guide 
cannulae are then secured to the skull with stainless steel screws and polycarboxylate 
cement. The cannula will be counterbalanced and its integrity will be maintained by 
inserting a stylet in-between probe insertion. Animals will be allowed sufficient recovering 
time following cannula insertion.  
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On sample collection days, the stylet will be removed and a concentric dialysis 
probe (2.0 mm active surface; Bioanalytical Systems Inc; Lafayette, IN, United States) 
inserted through the guide cannula of each animal. The tip of the probe will extend 2.0 mm 
beyond the cannula with the active surface placed within the NAc. Artificial cerebrospinal 
fluid (aCSF; 147.2 mM NaCl, 2.4 mM CaCl2, 4.0 mM KCl) will then be continually 
perfused through connecting polyethylene tubing (flowrate of 2.0µL/min) with dialysis 
samples collected every 30-minutes. Seven baseline samples will be collected initially, 
prior to UVR exposure, to establish baseline levels of dopamine. UVR exposure will then 
be administered (0.5-4 kJ/m2) and samples will continue to be collected every 30-minutes 
for up to six hours. Samples will be frozen, until analysis for dopamine content using 
reverse-phase HPLC with electrochemical detection (ESA Inc.; Chelmsford, MA, United 
States), following the methods developed by (Phillips and Cox, 1997). 
3.8 Significance  
The high levels of UVR in many countries across the globe are largely unavoidable, 
with almost everyone having some level of exposure on a daily basis. Increases in migration 
have also seen a rise in people dwelling in in environments which they are not genetically 
suited for and there has been a dramatic shift in clothing and lifestyle habits, greatly 
increasing the potential for harm attributed to UVR (Diffey, 2003; Leary and Jones, 1993; 
Jablonski and Chaplin, 2017). While there are benefits associated with sun and UVR 
exposure for vitamin D synthesis, there are numerous people receiving substantial 
quantities of UVR, beyond the necessary daily requirements (Diffey, 2003; Leary and 
Jones, 1993). Consequently, this dramatic increase in sun exposure enhances the known 
risks of UVR (e.g. skin cancer, cataracts, immune deficiency) but may also bring about new 
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UVR associated pathologies (e.g. behavioural addiction), with major consequences for 
public health. 
Already, strong evidence suggests that UVR can act as a reinforcing stimulus, 
increasing sun-seeking behaviour in frequent tanners (Iacopetta et al., 2018). Yet, more 
research is needed to develop concepts further. Given that dopamine neurotransmission is 
a key target in addiction development, dopamine signalling along the mesolimbic pathway 
is a likely candidate for UV-mediated behavioural adaptions. By pairing sophisticated UVR 
administration technology with a test of motivated behaviour (sensitive to dopamine) and 
microdialysis sampling to monitor dopamine levels (within the NAc), the proposed 
research project will provide robust evidence to determine if UVR alters mesolimbic 
dopamine neurotransmission. This may provide new insights on the role of dopamine in 
the reinforcing properties of UVR. Furthermore, taking into consideration that 
neuroimmune modulation is also associated with the development of addiction, this project 
will look at the possible interaction between UV-induced inflammatory signalling and 
dopamine neurotransmission. The recent advances in addiction research have verified that 
inflammatory signalling can increase vulnerability to addiction through glial cell 
modulation. Therefore, UV-induced alarmin signalling arising from UV damaged skin cells 
may be the driving force behind the addictive-like behavioural adaptions observed with 
frequent exposure to UVR. By monitoring production of alarmin signalling at the site of 
contact, in the circulation, and within central tissue, it will be possible to determine if 
peripheral UV-induced inflammatory signals are relayed to the brain.  This may shed light 
on a possible mechanism by which UVR can influence behavioural outcomes. If there is a 
correlation between immune activation and dopaminergic modification this could have 
further ramifications for understanding how the immune system contributes to addictive 
and motivational behaviours. And, if found to be clinically applicable, this work may 
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translate to the public health domain highlighting the need for broader interventions and 
services that promote sun-smart behaviour.  
Overall, UVR-related research is of great significance to the population at large due 
to the global presence of UVR within the environment and the potential for harm associated 
with overexposure/avoidance.  
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Chapter 4. Are the protective benefits of vitamin D in neurodegenerative 
disease dependent on route of administration? A systematic review 
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In conjunction with inflammation and cell damage, skin exposure to UVR, at the 
same damage-inflicting wavelengths, is necessary for cutaneous production of vitamin D. 
For this reason, vitamin D and UV are virtually inseparable and vitamin D is closely 
imbedded with UV-related research. Moreover, it has been suggested that sun exposure 
attenuates several neurological diseases through the vitamin D pathway. This chapter 
presents a systematic review of the literature to address whether the presumed 
neuroprotective benefits attributed to vitamin D in neurological disease are equivalent 
concerning endogenous or exogenous derived vitamin D, teasing apart UVR and vitamin 
D in this context.    
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4.1 Abstract 
Background: The clinical and pre-clinical exploration of the therapeutic properties of 
vitamin D have significantly increased in the past decade, owing to the growing associative 
evidence suggesting vitamin D is neuroprotective. However, whether depletion of vitamin 
D contributes to the onset of neurological disorders or is a symptom of neurological disease 
has yet to be defined. Much remains unclear about the causal role of vitamin D and the 
method of use and forms of vitamin D.  
Objectives: We sought to quantitatively assess if neuroprotective benefits from vitamin D 
in neurodegenerative diseases are dependent on route of administration: comparing the 
effect of endogenously sourced vitamin D from UV exposure to exogenously derived 
vitamin D through synthetic supplementation.  
Design: We systematically searched PubMed, Embase and PsycInfo databases, which 
included both pre-clinical and clinical studies investigating vitamin D in neurodegenerative 
diseases. Articles were subject to strict inclusion criteria and objectively assessed for 
quality. Additionally, Medline data was analysed to identify trends in topic publications 
and linguistic characteristics of papers. 
Results: From a total of 231 screened articles, we identified 73 appropriate for review 
based on inclusion criteria: original studies that investigated vitamin D levels or levels of 
vitamin D supplementation in neurodegenerative diseases or investigated past/present sun 
exposure in disease cohorts. Results indicate there is insufficient evidence to 
comprehensively reflect on a potential neuroprotective role for vitamin D and if this was 
dependent on route of administration. The majority of current data supporting 
neuroprotective benefits from vitamin D are based on pre-clinical and observational 
studies.  Solid evidence is lacking to support the current hypothesis that the beneficial effect 
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of UV exposure results from the synthesis of vitamin D. Sun exposure, independent of 
vitamin D production, may be protective against multiple sclerosis, Parkinson’s disease and 
Alzheimer’s disease. Yet, further research is required to elucidate the beneficial mechanism 
of actions of UV exposure. The literature of vitamin D and amyotrophic lateral sclerosis 
was limited, and no conclusions were drawn. Therefore, in cases where UV-derived 
vitamin D was hypothesised to be the beneficial mediator in the neuroprotective effects of 
sun exposure, we propose results are based only on associative evidence. 
Conclusion: On the basis of this systematic review, strong recommendations regarding 
therapeutic benefits of Vitamin D in neurodegenerative disease cannot be made. It is 
unclear if vitamin D mediates a protective benefit in neurodegenerative disease or whether 
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4.2 Background 
Neurodegenerative disorders are incurable and debilitating conditions that result in 
the progressive deterioration and/or death of neurons within the brain and spinal cord 
(Przedborski et al., 2003). Examples include multiple sclerosis (MS), Parkinson’s disease 
(PD), Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) and Huntington’s 
disease. Research suggests that vitamin D or increased sun exposure may have a positive 
impact in reducing the risk of development/progression of neurodegenerative disorders 
(Koduah et al., 2017). Relevant observational studies indicate that patients with a 
neurodegenerative disease tend to have lower levels of serum vitamin D compared to 
healthy controls. Furthermore, several studies have suggested that sun exposure attenuates 
disease course through influence on vitamin D production (Annweiler et al., 2013; 
Annweiler et al., 2011; Duan et al., 2014; Landel et al., 2016; Munger et al., 2006; Shen 
and Ji, 2015). Presently, the association between vitamin D and neurodegenerative disease 
remains to be defined and greater understanding is required to elucidate on administrative 
method and form of vitamin D for potential protective benefits. 
Vitamin D has two distinct forms, vitamin D3 or cholecalciferol and vitamin D2 or 
ergocalciferol, which are derived through distinct pathways (Thacher and Clarke, 2011). 
The major source of vitamin D for most people is vitamin D3, generated in the skin through 
conversion of 7-dehydrocholesterol from skin cell membranes mediated by ultraviolet 
(UV) light (Bikle, 2014; Zhang and Naughton, 2010). However, changes in lifestyle and 
increased life expectancy have contributed to widespread vitamin D insufficiency due to a 
lack of adequate sun exposure, therefore increasing the use of synthetic vitamin D 
supplementation (Anderson, 2005; van Schoor and Lips, 2017).  Vitamin D3 can also be 
acquired in the diet from animal sources (e.g. meat, oily fish, egg yolk and liver) via 
absorption through the gastrointestinal tract (Crowe et al., 2011; Zhang and Naughton, 
 73  
 
2010). Conversely, Vitamin D2 is derived from fungi or yeast and can only be obtained 
exogenously through dietary intake (Japelt and Jakobsen, 2013; Zhang and Naughton, 
2010). Few foods naturally have substantial quantities of vitamin D2; therefore, dietary 
vitamin D2 is primarily obtained through oral supplementation (Rapuri et al., 2004). Both 
vitamin D3 and D2 can be produced synthetically as supplements, with vitamin D2 
remaining the major form of synthetic vitamin D produced commercially (Houghton and 
Vieth, 2006). 
Presently, while vitamin D2 and D3 are typically considered equipotent at raising 
serum metabolite levels (Thacher and Clarke, 2011), the evidence for this is contradictory. 
Studies suggest that vitamin D2 is inferior to vitamin D3 in raising serum levels of 
25(OH)D in all primate species, including humans (Armas et al., 2004; Marx et al., 1989; 
Trang et al., 1998). Moreover, the subtle differences in chemistry between the two forms 
of vitamin D result in lower binding affinity of vitamin D2 for the plasma vitamin D binding 
protein (DBP). Furthermore, an additional oxidation reaction being required for vitamin 
D3 to be biologically deactivated, suggesting vitamin D2 is more rapidly metabolised than 
vitamin D3, resulting in a faster rate of clearance from the circulation (Horst et al., 1986). 
However, in contrast, recent studies have presented evidence that vitamin D2 is as effective 
as vitamin D3 in sustaining serum vitamin D levels (Holick, 2011; Rapuri et al., 2004). 
Similarly, it is unclear whether vitamin D derived from oral supplementation is equivalent 
to vitamin D synthesised in the skin from UV exposure. In fact, we have not been able to 
identify a single study that addresses this question.  
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4.2.1 Possible mechanisms by which vitamin D may contribute protective benefit within 
neurodegenerative disease 
Several metabolic pathways by which vitamin D may influence neurological 
outcomes have been proposed (see reviews (Fernandes de Abreu et al., 2009; Koduah et 
al., 2017)). These largely surround the hypothesis that vitamin D modulates gene 
transcription factors, through interactions with the vitamin D receptor (VDR), which result 
in neuroprotective benefits by simultaneously targeting different factors that lead to 
neurodegeneration (Mpandzou et al., 2016). For example, vitamin D inhibits the synthesis 
of inducible nitric oxide synthase (iNOS), a catalyst for the free radical nitric oxide which 
can damage cells (Garcion et al., 2002). Vitamin D also increases stimulation of gamma-
glutamyl transpeptidase, which is an enzyme important in the synthesis of the antioxidant, 
glutathione, that protects from cell damage by neutralising free radicals (Garcion et al., 
2002). Lastly, vitamin D can act as a neurotrophic factor, stimulating glial cells to produce 
nerve growth factor (NGF), glial cell derived nerve growth factor (GDNF) and 
neurotrophin 3 (NT3) (Neveu et al., 1994; Naveilhan et al., 1996; Musiol and Feldman, 
1997), potentially beneficially contributing to growth and protection of neurons, which is 
critical for the prevention of diseases such as AD and PD, where neuronal cell death is 
prominent.  
Animal models and neuronal cell culture have been instrumental in the investigation 
of potential molecular mechanisms by which vitamin D supplementation may confer 
protection against neurodegeneration, demonstrating that serum vitamin D or the active 
vitamin D metabolite may prevent neurotoxicity.  One study found that vitamin D treated 
macrophage cells from AD patients had increased amyloid beta (Ab) uptake and clearance 
as well as protection from apoptosis compared to untreated cells (Masoumi et al., 2009). 
More recently, a study using a neuroblastoma cell line also identified that vitamin D altered 
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Ab production and degradation in vitro as well as in ex vivo vitamin D deficient mouse 
brains (Grimm et al., 2017). Effects were mediated through alterations to the Ab–producing 
enzymes BACE1 and γ-secretase, suggesting that vitamin D supplementation may have 
therapeutic benefits for AD prevention (Grimm et al., 2017). 
Another possible pathway by which vitamin D may beneficially protect against 
neurological disease is through modulation of the innate and adaptive immune systems 
(Dankers et al., 2016). Vitamin D has general immunosuppressive properties that may serve 
to protect the brain from inflammatory damage, such as that which occurs with MS (Prietl 
et al., 2013). Recent in vivo experimental work, using experimental autoimmune 
encephalomyelitis, an animal model of MS, has linked vitamin D to the metabolic and 
signalling pathways critical in the differentiation of naïve CD4+ T cells (Zeitelhofer et al., 
2017).  Vitamin D administration was linked with downregulation of pathogenic T helper 
(Th) cells which are critical in the development of experimental autoimmune 
encephalomyelitis, suggesting that vitamin D provide protective benefit in MS (Zeitelhofer 
et al., 2017).   
Finally, animal models of PD have also demonstrated that vitamin D administration 
results in elevation of central dopamine levels compared to controls through enhancing 
GDNF expression (Smith et al., 2006; Wang et al., 2001). Animals that were pre-treated 
with vitamin D, prior to disease induction, showed diminished decreases in tyrosine 
hydroxylase (TH), the rate-limiting enzyme for the production of dopamine, within the 
substantia nigra, suggesting that vitamin D may have utility for the protection of dopamine 
neurons in PD (Sanchez et al., 2009). 
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4.2.2 Gaps in current evidence surrounding therapeutic benefit of vitamin D   
Given that vitamin D has gained increased attention from diverse areas of 
biomedical research and geographical ecological evidence linking UV with disease (Grant, 
2016), many groups have pursued vitamin D research and numerous studies have been 
published suggesting that: 1) vitamin D insufficiency leads to increased risk of neurological 
disease and 2) there are potential benefits of therapeutic vitamin D supplementation for 
these diseases (Shen and Ji, 2015). However, researchers are still elucidating whether 
depletion of vitamin D contributes to the onset of neurological disorders or is a symptom 
of neurological disease. As yet, a clear link between vitamin D and neurodegenerative 
disease has not been firmly established and the literature often reports conflicting results as 
to whether or not vitamin D has therapeutic benefits in these conditions (Annweiler et al., 
2011; Kragt et al., 2009; Mosayebi et al., 2011; Suzuki et al., 2013; Zheng et al., 2018).  
Additionally, two other key points of controversy in the research exist; 1) whether 
different forms of vitamin D are equally beneficial for neurodegenerative disease and 2) 
whether vitamin D derived from oral supplementation is equally beneficial as that derived 
directly from UV exposure. 
The aim of this systematic review is firstly to establish a context for vitamin D and 
neurodegenerative diseases within the broad field of literature over the last few decades 
through preforming an analysis on MeSH terms, looking at word frequency and charting 
trends over time. Secondly, a traditional systematic review approach, using PRISMA 
guidelines, will specifically address if the neuroprotective effects of vitamin D in 
neurodegenerative disease are dependent on route of administration. 
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4.3 Methods 
4.3.1 Corpus data analysis and visualisation 
To identify trends in the topic of publications and linguistic characteristics of 
papers, Medline data was analysed. Data containing article summary data, including 
abstracts, titles, MeSH terms, author keywords, and journal names, were extracted from 
PubMed using the defined search terms as seen in Table 1 (section a. only). Trends were 
then analysed using the Biopython v1.69 (Cock et al., 2009) library via Python 2.7.  
Abstracts were word tokenized (split into single words) and converted to lowercase. Stop 
words (common grammar terms like “and” “is” “was”) and punctuation were removed. All 
words were converted to word-stems (i.e. running -> run) using the LancasterStemmer 
algorithm in Natural Language Toolkit (NKLT).  
The bag-of-words approach was then used to sum incidences of each word in the 
vocabulary for each document, yielding a sparse matrix with word counts per word, per 
abstract. The bag-of-words transforms the dataset, where each row represents a separate 
document (abstract), and each column contains words mentioned across all documents. 
Each cell in the dataset records the frequency of each word in the document, thus generating 
a sparse matrix.  
Term frequency inverse document frequency (TFIDF) transformation was further 
applied to correct total term frequency by accounting for the number of documents that 
mention each term. From this analysis, higher weights were given to terms that were 
repeatedly mentioned across documents rather than the number of times within documents. 
This was implemented using the Transformer function in scikit.learn. 
Nouns were extracted from the sentence structure using part of speech tagging via 
pos_tag in NLTK. Noun tagged words were identified as singular nouns (nouns should all 
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be singular after word stemming). Word frequency was performed on / keywords/ MeSH 
terms/ authors/ nouns from stemmed bag-of-words transformed abstracts. Noun trends 
were compiled from the most frequent nouns (see graph) identified from abstracts from 
1964-2015.  
To investigate the contextual use of descriptors of direction-weighted words, such 
as “increase,” “decrease” and “association”, the body of abstracts was first searched for 15-
word phrases containing the target words using concordance analysis, which, as much as 
possible (with the exception of end of text or abstract), tries to place the target word in the 
middle of the 15-word phrase. For example, "an effective treatment strategy to decrease 
fatigue and improve quality of life in patients with MS. Objective” (Achiron et al., 2015). 
N-gram analysis, which takes a body of text and breaks it up into “n” word chunks, 
was then applied to turn these 15-word phrases into bi-grams and tri-grams. Bi-grams and 
tri-grams were thus obtained from each phrase and passed through a frequency analysis.  
Word2Vec approximates word similarity through contextual information via eigen 
distances between each word. For example, similarities between “king” and “male” would 
hold true for “queen” and “female” due to the relative context (distance) between these 
words across documents. Word2vec was applied to stemmed word vectors using the 
Word2Vec function from gensim. Most similar words to each target word were obtained 
using the most_similar function in gensim.  
4.3.2 Search strategy for systematic review 
The following systematic review was prepared following the PRISMA approach to 
ensure quality of research and minimise the risk of bias (McInnes et al., 2018). In order to 
identify all eligible studies, we performed a literature search of PubMed, Embase and 
PsychINFO databases for all papers published in English up until April 2016. Search terms 
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included “vitamin D” and related words combined with those used to identify 
neurodegenerative disease in the titles or abstracts. No limits were used in the searches. 
The exact search strings used are depicted in Table 1.  In addition, the reference list of each 
included article was manually searched to identify additional eligible studies.  
4.3.3 Systematic review publication selection criteria 
The search results were imported into EndNote and duplicates were deleted. The 
potentially eligible studies were identified by screening titles and/or abstracts, and/or the 
full text of references. Studies were eligible for inclusion if they (i) were original studies 
investigating an association between vitamin D levels or vitamin D supplementation with 
neurodegenerative disease and reported a neurological outcome (for example, improved 
disease symptoms); or (ii) looked at past or present sun exposure in neurodegenerative 
disease cohorts. Studies were excluded if they (i) were about vitamin D but did not have a 
neurological/clinical outcome; (ii) did not adequately provide a measure of vitamin D or 
specifically state month/time spent outdoors; (iii) pilot studies that did not have significant 
power to measure clinical outcomes; (iv) were case reports/expert options; or (v) were 
review articles.  
4.3.4 Systematic review publication data extraction 
The following data were extracted from each included study: (i) study 
characteristics (first author, year of publication, study design); (ii) principal aim and 
hypothesis and (iii) whether the outcome supported the hypothesis. Vitamin D was assessed 
for a protective effect.  
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Table 1. Search terms 
a. PubMed  
 Vitamin d* [tw] OR vitamin D [mh] OR vit D*[tw] OR ergocalciferol [tw] OR 
cholecalciferol [tw]  
OR Ultraviolet [tw] OR ultra violet [tw] OR UV [tw] OR UV-A [tw] OR UV-B [tw] OR sunlight 
[tw] OR sun exposure [tw] 
AND Parkinsonian disorders [mh] OR parkinson* [tw] OR alzheimer* [tw] OR dementia [tw] OR 
dementia [mh]  OR lewy body dementia [tw] OR huntington* [tw] OR motor neuron disease 
[mh] OR motor neuron disease [tw] OR multiple sclerosis [mh] OR multiple sclerosis [tw] 
OR prion disease [mh] OR prion disease [tw] OR progressive supranuclear palsy [tw]  OR 
PSP [tw]  OR vascular dementia [mh] OR vascular dementia [tw] OR multiple system 
atrophy [mh] OR multiple system atrophy [tw] OR spinocerebellar ataxia [mh] OR  
spinocerebellar ataxia [tw] OR spinal muscular atrophy [tw] OR friedreich* [tw] 
b. Embase 
 ‘Vitamin d’:ab,ti OR ‘vitamin D’:ab,ti OR ‘Vit D’:ab,ti OR 'ergocalciferol':ab,ti OR 
cholecalciferol:ab,ti  
OR 'ultraviolet radiation’:ab,ti OR 'ultraviolet radiation':ab,ti OR ultra violet:ab,ti OR UV OR 
UV-A OR UV-B OR 'sunlight':ab,ti OR 'sunlight':ab,ti OR 'sun exposure':ab,ti 
AND ‘Parkinsonian disorders’ OR parkinson*:ab,ti OR ‘dementia’:ab,ti OR ‘diffuse Lewy body 
disease':ab,ti OR Huntington*:ab,ti OR 'motor neuron disease':ab,ti OR ‘multiple 
sclerosis’:ab,ti OR 'prion disease’:ab,ti OR 'progressive supranuclear palsy':ab,ti OR 
'multiinfarct dementia':ab,ti OR 'Shy drager syndrome':ab,ti OR 'spinocerebellar 
degeneration':ab,ti OR 'spinal muscular atrophy’:ab,ti OR 'friedreich ataxia':ab,ti 
c. PsychINFO 
 Vitamin d OR vitamin D OR vit D OR ergocalciferol OR cholecalciferol  
OR Ultraviolet radiation OR ultraviolet radiation OR Ultra violet OR UV OR UV-A OR UV-B 
OR sunlight OR sunlight OR sun exposure 
AND Parkinsonian disorders OR Parkinson* OR dementia OR diffuse Lewy body disease OR 
Huntington* OR motor neuron disease OR multiple sclerosis OR prion disease OR 
'progressive supranuclear palsy OR multiinfarct dementia OR shy drager syndrome OR 
spinocerebellar degeneration OR spinal muscular atrophy OR Friedreich ataxia 
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4.4 Results  
4.4.1 Corpus data analysis summary  
4.4.1.1 Description of the vitamin D field of research  
To establish the context in which this systematic review was conducted, an analysis 
of MeSH term frequency was performed to provide an overview of the state of play and 
trends in the literature (Figure 4.1a). In the last three decades, there have been more human 
studies compared to pre-clinical studies, with females featured in marginally more papers 
than males. To date, there has been a predominance of UV rather than vitamin D and dose 
response studies, with risk factors, disease progression, retrospective and cohort studies 
having higher prevalence than treatment outcomes from PubMed’s classification system. 
These data perhaps indicate higher associative rather than experimental or clinical studies.  
Deeper natural language processing analysis from the abstract corpus allowed 
exploration of the frequency of the use of nouns in abstracts yielding high rates of the use 
of “vitamin” and “d” and terms most frequent throughout most abstracts. This is 
substantiated by the “bag of words” (BOW) approach to vectorised language processing 
and term TFIDF analysis. To correct for potential small groups of abstracts that had higher 
incidences of particular words, a TFIDF transformation was used on the BOW matrix. This 
yielded a reduction of gaps between “vitamin” and “MS”, the second most mentioned term 
(Figure 4.1c), thus implying that MS is an important descriptor for a majority of abstracts, 
and hence the predominance of the field focusing on this pathology.  
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Figure 4.1. Frequency distributions of top 5 MeSH keywords (a.) Lemmatised words 
(b.) Term frequency inverse document frequency transformed words (c.) and noun 
frequency (d.). 
Finally, to visualise the vitamin D research trends over time, we plot incidence of 
selected nouns across time (Figure 4.2). “p”(value) was plotted as a baseline mention, as it 
should be a stable descriptor of papers, i.e. a proportional number of papers would mention 
p-values. Frequency distribution of nouns increased in general across time, with the 
exception of “dopamine,”which had lower values in recent years. Mentions of “(vitamin) 
d” had the highest growth across nouns investigated, followed by MS. There were also 
increased trends in “disease”, “PD” (Parkinson's disease), “AD” (Alzheimer's disease) and 
“(vitamin) d3”, showing potential increasing correlations between vitamin d research and 
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disease states. Of note is the profound increase of publications in the field in the last decade, 
highlighting the timely nature of this systematic review. 
 
 
Figure 4.2. Trends in selected noun mentions in abstracts across time. 
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4.4.2 Systematic review search outcomes 
The outcomes of the PRISMA screening process are provided in Figure 4.3. The 
initial search yielded 5107 articles. Of these, 2440 were immediately excluded (1660 were 
identified as duplicates and 780 were review papers), leaving 2667 articles for screening 
based on title and abstract. An additional 2436 were excluded, as they were not relevant to 
the research question. 231 articles underwent full text review, resulting in 73 articles 
eligible for inclusion. Of these, 12 articles were flagged as having a potential conflict of 
interest, which have been outlined in each table.   
To aid in the targeted review and interpretation of the broad fields covered by this 
systematic review, eligible articles were then segregated into the following disease types 
for further analysis and discussion; MS (n=46); PD (n=12); AD (n=10) and ALS (n=5). All 
articles were separated into clinical and pre-clinical subgroups for further analysis. Study 
characteristics are summarised in Tables 2-10.  
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Figure 4.3. Flow diagram outlining the study selection process. *Inclusion criteria 
were original studies that investigated vitamin D levels or vitamin D supplementation in 
neurodegenerative diseases or investigated past/present sun exposure in disease cohorts. 
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4.4.3 Multiple sclerosis  
A total of 46 articles relevant to MS were included from the search. Of these, 21 
articles reported a protective benefit improving disease outcomes that was attributed to 
vitamin D. The study characteristics from the identified articles relevant to MS can be found 
in Tables 2-5. Tables were organised according to study type; Table 2 lists pre-clinical 
studies (n=16); Table 3 documents retrospective case control studies (n=7); Table 4 details 
cross-sectional studies (n=9) and Table 5 lists the prospective clinical trials (n=14).  
4.4.3.1 Pre-clinical studies 
The 16 pre-clinical studies identified herein, predominately induced MS symptoms 
in rodents using the experimental autoimmune encephalomyelitis (EAE) model, injecting 
antigenic compounds that cause demyelination of neurons creating an MS-like pathology 
(Adzemovic et al., 2013; Becklund et al., 2010; Farias et al., 2013; Garcion et al., 2003; 
Nashold et al., 2000; Nashold et al., 2013; Nataf et al., 1996; Pedersen et al., 2007; Sloka 
et al., 2015; Soleimani et al., 2014; Spach and Hayes, 2005; Spach et al., 2006; Wang et 
al., 2015b; Wang et al., 2012; Wang et al., 2013). One of the pre-clinical studies used the 
toxin induced demyelination model, injecting lysophosphatidyl choline (LPC) in the 
hippocampus (Tarbali and Khezri, 2016). A potential relationship between MS and vitamin 
D was then investigated by either oral/intraperitoneal or gavage vitamin D3 metabolite 
supplementation (n=11), (Adzemovic et al., 2013; Farias et al., 2013; Garcion et al., 2003; 
Nashold et al., 2000; Nashold et al., 2013; Nataf et al., 1996; Pedersen et al., 2007; Sloka 
et al., 2015; Soleimani et al., 2014; Spach and Hayes, 2005; Tarbali and Khezri, 2016) 
through UVR induced epidermal vitamin D production (n=3), (Becklund et al., 2010; Wang 
et al., 2015b; Wang et al., 2013) and lastly using knockout animals devoid of either vitamin 
D receptor or enzymes that convert active vitamin D3 (n=1) (Wang et al., 2012).  
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Of the eleven studies using vitamin D supplementation, three studies specifically 
looked at the protective effects of vitamin D prior to EAE induction, manipulating vitamin 
D3 levels in the diet before EAE inoculation (Adzemovic et al., 2013; Spach and Hayes, 
2005; Spach et al., 2006). In the first two studies, animals were treated with either 0, 2, 
10IU/gram (Adzemovic et al., 2013) or 0, 1, 5µg/day (Spach and Hayes, 2005) of vitamin 
D3 for 3-8 and 4 weeks respectively. These two studies identified that vitamin D therapy 
was beneficial in preventing or reducing clinical symptoms of MS in the EAE model only 
in the juvenile/adolescent age groups (Adzemovic et al., 2013) and in female mice (Spach 
and Hayes, 2005). Other tested groups that were not significant include adult animals that 
were supplemented with vitamin D3 for 8 weeks (Adzemovic et al., 2013) and 
ovariectomised or intact or castrated males (Spach and Hayes, 2005). In a subsequent study 
by Spach et al (2006), using a similar protocol of 1 ng/day vitamin D3 for 4 weeks prior to 
EAE induction, similar results were observed with a reduced effect only in the female mice. 
However, when given pre-treatment with active vitamin D (50 ng for females and 100 ng 
for males) before EAE induction, both males and females had lower incidence of EAE and 
improved clinical outcomes (Spach et al., 2006). The remaining nine studies provided 
vitamin D treatment at varying stages of disease onset as detailed in table 4 (Farias et al., 
2013; Garcion et al., 2003; Nashold et al., 2000; Nashold et al., 2013; Nataf et al., 1996; 
Pedersen et al., 2007; Sloka et al., 2015; Soleimani et al., 2014; Spach et al., 2006; Tarbali 
and Khezri, 2016). Although outcome measures were different, including clinical score 
analysis, measure of inflammatory markers and the degree of re-myelination, all nine 
studies reported that vitamin D therapy improved disease outcomes or reduced 
inflammation in EAE models of MS when compared to control animals. It is noteworthy, 
that one study, which supplemented vitamin D via both gavage and intraperitoneal routes, 
found vitamin D to be protective only when administered at higher doses and via gavage. 
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Low dose gavage and intraperitoneal injections had no significant benefit on clinical 
outcomes (Farias et al., 2013).  
Three pre-clinical studies investigated the potential protective effects from 
increasing vitamin D via UVR in suppressing disease severity in the EAE mouse model of 
MS. All three studies irradiated mice with either 2.5, 5 or 10kj/m2 of UVR for 7 days prior 
to EAE immunisation and then continued UVR exposure for up to 30 days (Becklund et 
al., 2010; Wang et al., 2015b; Wang et al., 2013). Although UV-B suppressed EAE, all 
three studies concluded that the observed UV-B mediated suppression occurred 
independently of vitamin D, as circulating serum vitamin D levels were not elevated. 
Therefore, vitamin D3 was determined as not being protective in these studies, contrary to 
the conclusions drawn from the previously reviewed pharmacological manipulation 
studies.  
Interestingly, in the study using genetic knockout animals, vitamin D had the 
opposite effect and was reported as necessary for the development of EAE (Wang et al., 
2012). Genetically modified mice lacking the vitamin D receptor showed markedly 
suppressed EAE, and mice with insufficient vitamin D had partially suppressed EAE when 
compared with wild type animals. These unexpected results indicate that vitamin D may 
have a potential role in the development of elements of the immune system that are required 
for the autoimmune disease EAE.  
4.4.3.2 Case-control studies 
This review identified seven case-control studies eligible for inclusion in the 
analysis and these are summarised in Table 2b. The case-control studies retrospectively 
investigated lifestyle factors such as sun exposure (Baarnhielm et al., 2012; Bjornevik et 
al., 2014; Dalmay et al., 2010; Espinosa-Ramirez et al., 2014; Islam et al., 2007; Kampman 
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et al., 2007; Van Der Mei et al., 2003) and diet (Kampman et al., 2007) in MS patients 
(n=2371) compared to controls (n=4445) and investigated whether activities associated 
with increased vitamin D were protective in decreasing the risk of MS. All studies 
questioned participants on specific time periods during childhood and adolescence. 
However, one study also reported on sun exposure in the last 5 years (Espinosa-Ramirez et 
al., 2014). Questionnaires were completed comprised of self-report measures (Kampman 
et al., 2007; Bjornevik et al., 2014) or through interviews (Dalmay et al., 2010; Espinosa-
Ramirez et al., 2014; Islam et al., 2007; Van Der Mei et al., 2003). 
The majority (n=6) of these case-control articles reported that increased sun 
exposure and time outdoors during childhood and adolescence was associated with 
decreased risk of developing MS (Bjornevik et al., 2014; Dalmay et al., 2010; Islam et al., 
2007; Kampman et al., 2007; Van Der Mei et al., 2003). Two studies demonstrated a dose-
response like effect, in which higher sun exposure was associated with decreased relative 
risk (Islam et al., 2007; Kampman et al., 2007). These data suggest that sun exposure, 
postulated to be mediated by elevating vitamin D levels, was beneficial in reducing the risk 
of disease. Contrary to the results reported in the three UVR pre-clinical studies that suggest 
UVR had a protective effect independent from vitamin D. Another study, investigating UV 
exposure in the past 5 years found similar results, reporting increased UVR decreased the 
risk of MS (Baarnhielm et al., 2012). This study also suggested that the protective benefit 
from UV may be mediated by pathways independent of vitamin D as adjusting for a variety 
of confounding factors, including vitamin D serum levels at inclusion of the study, did not 
affect the strength of the association (Baarnhielm et al., 2012). Two studies demonstrated 
a dose-response like effect, in which higher sun exposure was associated with decreased 
relative risk (Islam et al., 2007; Kampman et al., 2007). The remaining case-control study 
found no association between past or current sun exposure and the risk of development of 
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MS and reported that MS patients spent more time in sunlight compared to controls both 
during adolescence and in the past 5 years. 
4.4.3.3 Cross-sectional studies 
The search identified nine cross-sectional studies eligible for inclusion that were 
relevant to MS (see table 4). Three cross-sectional studies investigated MS cohorts by 
comparing self-report data of life style factors, including past and present sun exposure, 
with geographic location/latitude (McDowell et al., 2011a; McDowell et al., 2011b)  or 
residential solar estimates (Jelinek et al., 2015). All studies showed a positive correlation 
between increased past sun exposure and improved disease outcomes, concluding that sun 
exposure was likely to be a key environmental factor to modulate disease. One cross-
sectional study compared relapsing MS with progressive MS, reporting vitamin D related 
sun exposure influenced disease types independently. Increased sun exposure in the past 
10 years was protective in relapsing MS, whereas increased sun sensitivity or the likeliness 
to burn was associated with increased hazard in progressive MS (D'Hooghe M et al., 2012).   
The five remaining studies similarly used questionnaire information on lifestyle 
factors related to vitamin D exposure in MS cohorts, but also measured current serum 
vitamin D metabolites. Two studies found support for a protective effect of vitamin D (Van 
Der Mei et al., 2007; Mandia et al., 2014), while one study reported mixed results (Lucas 
et al., 2011) and two studies found no association between vitamin D and disease (Hejazi 
et al., 2014; Gelfand et al., 2011). 
Of the two studies that showed a protective benefit of vitamin D, one study 
specifically looked at the effect of vitamin D on disease severity rather than risk and found 
that increased sun exposure and adequate vitamin D was associated with relatively mild 
MS for a sample population of 131 MS patients (Mandia et al., 2014). Consistent with this, 
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the second article in support of vitamin D showed that lower levels of serum vitamin D 
were associated with reduced sun exposure and increased disability in MS patients 
compared to control participants (Van Der Mei et al., 2007). The article which reported 
mixed results reported that increased lifetime sun exposure was associated with reduced 
risk of MS. However, vitamin D and current sun exposure were independent of each other, 
suggesting that another possible UV-related factor was involved in protection from MS 
disease aetiology (Lucas et al., 2011) consistent with the three pre-clinical studies that used 
UVR (Wang et al., 2015b; Wang et al., 2012; Wang et al., 2013). Of the two cross-sectional 
studies that found no association between vitamin D and disease, the first looked at self-
report data of dietary intake of multiple vitamins, including vitamin D, and sun exposure 
but found no significant difference between patients and controls. Serum sampling from all 
participants showed low antioxidant level and vitamin D insufficiency (Hejazi et al., 2014). 
The final cross-sectional study investigated the correlation between disease severity and 
circulating vitamin D within an African American study population. The study reported 
that vitamin D was not associated with disease severity, as MS patients had higher serum 
vitamin D compared to control subjects, but this was primarily attributed to differences in 
place of dwelling associated with climate and geography (Gelfand et al., 2011). 
4.4.3.4 Prospective studies 
Fourteen prospective clinical articles were identified as eligible for inclusion; 
summary data can be observed in table 5. Five (n=5) longitudinal cohort studies (Kragt et 
al., 2009; Knippenberg et al., 2014; Loken-Amsrud et al., 2012; Munger et al., 2004; 
Simpson Jr et al., 2010), eight (n=8) double blind randomised controlled trials (Achiron et 
al., 2015; Derakhshandi et al., 2013; Golan et al., 2013; Kampman et al., 2012; Mosayebi 
et al., 2011; Shaygannejad et al., 2012; Stein et al., 2011a) and one (n=1) non-blinded 
clinical trial (Farsani et al., 2015) were included.  
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Three of the five longitudinal cohort studies measured serum vitamin D levels of 
MS patients every 6 months, with follow up periods of 6 months, (Kragt et al., 2009) 2.3 
years (Knippenberg et al., 2014) and 3 years (Simpson Jr et al., 2010). The first study (Kragt 
et al., 2009) compared MS patients with controls, whereas the latter two (Knippenberg et 
al., 2014; Simpson Jr et al., 2010) only included MS patients. The first two studies reported 
that higher circulating levels of vitamin D were associated with decreased MS-related 
disability and relapse rate (Kragt et al., 2009; Simpson Jr et al., 2010). The third 
longitudinal study examined separate disease characteristics including depression, anxiety, 
fatigue and cognition and found that higher reported sun exposure, rather than vitamin D 
levels, was associated with improved depressive and fatigue symptoms. No effect was 
observed between sun exposure, vitamin D and cognition (Knippenberg et al., 2014).  
The remaining two longitudinal cohort studies reported mixed results (Loken-
Amsrud et al., 2012; Munger et al., 2004).  One study investigated vitamin D status by 
correlating levels to lesion development, determined by MRI, for 6 months preceding 
interferon-β (IFN-β) treatment and then an additional 18 months thereafter. Vitamin D was 
associated with a reduced odds ratio for lesion development prior to IFN-β, however, once 
treatment began there was no association between disease activity and vitamin D (Loken-
Amsrud et al., 2012). The final study used data acquired from the nurses’ health study 
cohorts, in which food frequency/dietary intake questionnaires were distributed every four 
years. During the 20-year follow up period 173 cases of MS had developed. It was 
identified that women who supplemented with vitamin D had a 40% lower risk of 
developing MS compared to women who did not take supplementation. No protective 
benefit was observed from dietary vitamin D intake and the risk of developing MS (Munger 
et al., 2004).   
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The non-blinded clinical trial reported that intramuscular supplementation with 
vitamin D in MS patients resulted in a reduced mean average of expanded disability status 
scale (EDSS), attributed to increased interleukin-10 gene expression. This study was 
performed over an 8-week period and serum samples were analysed for gene expression 
and markers of inflammation against serum samples from health controls. This data was 
later correlated with EDSS scores (Farsani et al., 2015).  
The remaining eight randomised controlled trials were all double-blinded and 
predominately used supplementation with oral vitamin D3 capsules (Achiron et al., 2015; 
Derakhshandi et al., 2013; Golan et al., 2013; Kampman et al., 2012; Shaygannejad et al., 
2012; Soilu-Hänninen et al., 2012). However, one study supplemented via intramuscular 
injection (Mosayebi et al., 2011) and one study supplemented with vitamin D2 (Stein et al., 
2011a). All except one study, that reported an improvement in fatigue impact score 
(Achiron et al., 2015), found no therapeutic advantage of vitamin D therapy on clinical 
outcomes of MS compared to controls. Five studies looked specifically at the EDSS and 
found no effect between treatment groups; (Achiron et al., 2015; Golan et al., 2013; 
Mosayebi et al., 2011; Shaygannejad et al., 2012; Soilu-Hänninen et al., 2012); other 
measures included relapse rate (Golan et al., 2013; Shaygannejad et al., 2012) and MRI 
lesion size (Soilu-Hänninen et al., 2012; Stein et al., 2011a). All studies had relatively low 
sample sizes, ranging from 11-80 participants. Importantly, results were not suggestive of 
a vitamin D related protective effect on MS outcomes. 
In summary, these data indicate that a clear role for a neuroprotective benefit from 
vitamin D in MS cannot be established. The pre-clinical and observational data are in 
support for protective/therapeutic benefit from vitamin D, however, this same positive 
trend is not observed within results from prospective clinical trials of MS patients. 
Furthermore, there is only minimal data supporting the UV-vitamin D conversion link for 
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beneficial actions of sun exposure in MS. Rather, there appears to be a sun or UV specific 
factor–independent of vitamin D that may mediate the sun exposure benefits related to MS. 
4.4.4 Parkinson’s disease 
Tables 6 and 7, respectively, describe the pre-clinical and clinical study 
characteristics of all identified studies from the described search specific to PD.  Twelve 
studies were included, with nine articles in support of a positive or beneficial effect of 
vitamin D in either decreasing disease risk or improving clinical outcomes in PD.  The 
twelve articles were categorised as either pre-clinical studies using animal models of 
disease (n=6) or clinical studies involving retrospective case control studies (n=3), cross-
sectional studies (n=2) and prospective controlled trials (n=1). 
4.4.4.1 Pre-clinical studies 
The six pre-clinical studies applied a vitamin D intervention to rodent models of 
PD, in which dopaminergic neurons in the substantia nigra were lesioned with neurotoxin, 
either 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyidine 
(MPTP), inducing PD-like symptoms, in order to investigate the effects of vitamin D on 
dopamine (DA) neuron integrity as indicated by TH expression. With the exception of one 
study, that dosed with 100µg 6-OHDA (Smith et al., 2006), all lesions were induced with 
similar doses. Studies using 6-OHDA (Cass et al., 2014; Kim et al., 2006; Sanchez et al., 
2009; Wang et al., 2001) used either 8ug or 12ug compared to studies using MPTP (Dean 
et al., 2012; Kim et al., 2006) that dosed with 15 or 20g. Four studies supplemented vitamin 
D3 (1µg/ml/kg/day) through intraperitoneal injections for seven days prior to the 
neurotoxic lesion (Kim et al., 2006; Sanchez et al., 2009; Smith et al., 2006; Wang et al., 
2001). The study by Smith et al. (2009) also included a long-term treatment group that 
received a further 28 days of vitamin D treatment post lesion. One study supplemented 
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vitamin D3 (either 1 or 0.3µg/ml/kg/day) via subcutaneous injection for eight days 4 weeks 
post lesion (Cass et al., 2014). The final study restricted vitamin D intake with a vitamin D 
depleted diet for 6 weeks before exposing animals to the neurotoxin MPTP (Dean et al., 
2012). 
All five studies that supplemented with vitamin D3 reported increased DA or TH 
levels within the substantia nigra tissue, indicting reduced neuronal damage sustained from 
neurotoxic injury; functional tests were not performed (Cass et al., 2014; Kim et al., 2006; 
Sanchez et al., 2009; Smith et al., 2006; Wang et al., 2001). Vitamin D was determined as 
protective against the onset/severity of PD in rodent models (Cass et al., 2014; Kim et al., 
2006; Sanchez et al., 2009; Smith et al., 2006; Wang et al., 2001). However, of these, one 
study did report mixed results, finding vitamin D treatment was only protective in the long-
term group that received vitamin D supplementation both before and after lesion (Smith et 
al., 2006). This study also used different neurotoxins and species between each group, 6-
OHDA in rats for the short-term group and MPTP in mice for the long-term group, which 
makes it difficult to draw conclusions between treatment groups. Importantly, however, the 
study that eliminated vitamin D from the diet prior to MPTP injury observed no difference 
in the susceptibility of DA neurons to injury and the development of PD symptoms between 
groups (Dean et al., 2012) indicating that vitamin D deficiency may not contribute to the 
development of disease. 
4.4.4.2 Case-control studies 
The three case control studies retrospectively analysed lifestyle factors and dietary 
habits as indictors of vitamin D levels in PD patients, with a total population size of 949 
patients and 1426 control participants. Of these, only one study identified that increased 
vitamin D levels may be protective by decreasing the risk of developing PD. This study 
reported that increased outdoor physical activity and higher total vitamin D intake were 
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inversely associated with the risk of PD by calculating the odds ratio for separate quartiles 
(of hours/week and intake/day), showing significant decreasing trends of P=0.002 and 
P=0.011 respectively (Zhu et al., 2014). However, when investigating a potential joint 
effect of vitamin D and physical activity on risk of PD, significance was lost, suggesting 
that both outdoor physical activity (and, hence, UV exposure) and vitamin D may act 
independently (Zhu et al., 2014). The remaining two studies did not report significant 
correlations between indicators of vitamin D levels and the risk of PD between patient and 
control subjects, using occupational sunlight as an indicator of vitamin D in one study 
(Kwon et al., 2013) and the consumption of dairy products containing vitamin D in the 
other (Miyake et al., 2011). 
4.4.4.3 Cross-sectional studies 
The two cross-sectional studies had a pooled population of 1099 patients and 730 
control participants. These two studies primarily measured vitamin D status of participants 
by sampling serum metabolites of vitamin D2 and D3 (Wang et al., 2016) or D3 only (Wang 
et al., 2015a; Wang et al., 2016) to investigate the association between serum vitamin D 
and PD within the sample population. One study also recorded sunlight exposure and 
vitamin D intake from participants (Wang et al., 2015a). Both studies reported an 
association between vitamin D deficiency and PD, as PD patients had lower serum vitamin 
D, irrespective of D2 or D3, than controls, indicating that low serum vitamin D levels are 
significantly associated with an increased presence of PD in cross-sectional studies. 
4.4.4.4 Prospective study 
The most robust study, the prospective clinical intervention study, supported a 
neuroprotective effect of vitamin D in existing PD patients. The effect of vitamin D3 
supplementation on the disease progression of PD was investigated using a 12-month 
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double blind, placebo-controlled trial in 104 PD patients (Suzuki et al., 2013). Patients were 
divided into a treatment group (n=56) receiving 1200 IU of vitamin D3 daily in the form 
of an oral capsule and a control (n=58) receiving a matched placebo. The average time 
since diagnosis for each group was 24 months and 13 months, respectively. Importantly, it 
was found that the vitamin D3 supplementation group had significantly reduced symptom 
scores, determined by treating neurologists, on both the modified Hoehn and Yahr (H&Y) 
scale and the Unified Parkinson’s disease rating scale (UPDRS), which are used to 
determine severity of symptoms in PD patients. 
In summary, the data suggest a stronger association between adequate vitamin D 
and reduced risk of PD compared with the MS results; however, few studies met the 
inclusion criteria. Moreover, pre-clinical study designs varied significantly in PD models 
as well as treatment regimens making it difficult to draw hard conclusions. Retrospective 
study designs only show that vitamin D deficiency is associated with disease, but cannot 
provide evidence directly connecting vitamin D with disease risk or progression. Similarly, 
although the pre-clinical data showed that vitamin D therapy may improve disease 
outcomes, the lack of ample clinical data (there has only been the single prospective clinical 
intervention trial to date) means it is not possible yet to determine if this can be successfully 
translated clinically. Additionally, results from this systematic review cannot determine 
whether the source of vitamin D (i.e. oral supplementation or UV exposure) is influential 
in disease onset/progression.  
4.4.5 Alzheimer’s disease and dementia 
Tables 8 and 9 detail the study characteristics of all pre-clinical and clinical studies 
identified from the search specific to AD. A total of ten studies were included in the final 
analysis. Of these, eight studies supported vitamin D having a protective effect in the 
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progression of AD and the remaining two studies did not conclude a positive benefit from 
vitamin D treatment. Articles were separated into pre-clinical studies (n=5) and clinical 
studies (n=5), including three cohort studies and two randomised controlled trials.  
4.4.5.1 Pre-clinical studies 
The five pre-clinical studies used rodent models of AD; two studies used transgenic 
animals with characteristic gene defects consistent with familial AD; one study used the 
AβPP-PS1 transgenic mouse model (Yu et al., 2011) whereas the remaining two used 
intracerebro-ventricular (ICV) injection of Aβ 1-42 to induce AD-like symptoms 
(Taghizadeh et al., 2014; Taghizadeh et al., 2011). All five pre-clinical studies looked at 
the effects of vitamin D on AD by adjusting levels of vitamin D3 available in the diet; using 
normal rodent chow with standard vitamin D levels, or either rodent chow fortified with 
increased vitamin D or chow that had been depleted of vitamin D.   
The three studies using transgenic rodent models of AD all investigated long-term 
vitamin D treatment outcomes on cognitive and memory performance, brain inflammation 
and amyloid plaque formation in transgenic animals compared to wild-type control 
animals. All studies reported positive outcomes from vitamin D treatment at conclusion of 
their studies (Bennett et al., 2013; Landel et al., 2016; Yu et al., 2011). The first study, over 
a 7-month period, fed chow enriched with vitamin D2-button mushroom (VDM) or 
depleted chow to APPswe/PS1dE9 mice, and demonstrated that VDM contributed to 
significantly improved scores in memory and learning tests in wild-type animals and to a 
lesser extent VDM transgenic animals (Bennett et al., 2013). There were also decreases in 
the number of plaques and markers of inflammation in transgenic mice fed the VDM diet 
compared to the control diet (Bennett et al., 2013). Similarly, the study by Landel et al. 
2016, in which 5XFAD transgenic mice were fed either high or low vitamin D diets for a 
period of 8 months, also reported that vitamin D improved functional outcomes compared 
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to control, with the wild type animals showing the highest improvement in cognitive tasks 
as well as decreased signs of inflammation (Landel et al., 2016). Finally, the third study 
assessed the impact of vitamin D on the formation of amyloid plaques in the AβPP-PS1 
transgenic mice and showed that increased vitamin D3 levels (12IU/g) correlated with 
reduced amyloid plaque formation in this model (Yu et al., 2011).  
The final two pre-clinical studies, performed by the same research group, used 
intracerebroventricular injection of Aβ 1-42 to induce AD like symptoms. One study 
reported vitamin D3 to be beneficial by demonstrating that oral vitamin D3 
supplementation (200ng/rat/d) restored suppressed synaptic plasticity in Aβ 1-42 -induced 
rats (Taghizadeh et al., 2014). Conversely, an earlier study using higher doses of vitamin 
D3 (1000ng VD3/100g chow) to ameliorate deficits induced by Aβ 1-42 in spatial 
performance found no significant benefit from vitamin D treatment (Taghizadeh et al., 
2011). 
4.4.5.2 Longitudinal cohort studies 
The search identified three longitudinal cohort studies investigating vitamin D and 
AD that were eligible for inclusion. Two studies concluded that low serum vitamin D levels 
were positively correlated with the risk of developing AD and Non-Alzheimer’s dementia 
(NAD) (Annweiler et al., 2011; Afzal et al., 2014). The third study reported dietary vitamin 
D intake at baseline was inversely associated with the onset of AD, suggesting that lower 
levels of vitamin D intake at baseline was associated with lower risk of AD (Annweiler et 
al., 2012).  
The first study analysed stored baseline plasma samples, taken from participants 
(n=10,118) from the Copenhagen City heart study, for levels of the vitamin D metabolite 
25(OH)D in order to investigate the association between serum vitamin D and the later 
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development of either AD or vascular dementia (Afzal et al., 2014). During the 30-year 
follow up period, 418 people were diagnosed with AD and 92 people with vascular 
dementia. The combined endpoint of AD and vascular dementia showed that reduced 
plasma 25(OH)D at baseline was associated with increased risk of disease within the cohort 
population, suggesting that vitamin D is protective and reduces the risk of disease. The 
second cohort study, consisting of only female participants, measured serum vitamin D 
levels to determine if vitamin D deficiency was predicative of developing NAD within a 7-
year time frame (Annweiler et al., 2011). This study analysed stored serum samples from 
40 participants in the EPIDOS Toulouse longitudinal study. Participants were divided into 
two groups, determined by level of vitamin D deficiency. At the end of the 7-year period, 
data on cognitive status (i.e. no dementia, or AD, or NAD) were reported and correlated to 
baseline vitamin D metabolite levels. This study demonstrated that baseline serum vitamin 
D deficiency was predicative of the onset of NAD within a 7-year period among older 
women, also supporting that vitamin D may have a protective effect in preventing disease. 
The final study was published by the same research group again using the EPIDOS data 
set, however, this study investigated if baseline dietary vitamin D intake was an 
independent predictor of the onset of dementia among the cohort of women (Annweiler et 
al., 2012). This study categorised the participants into three groups according to the onset 
of dementia (no dementia, Alzheimer’s Disease or other dementias) within the 7-year time 
frame. Baseline dietary vitamin D was then estimated for each participant from the self-
report food frequency questionnaire. Higher dietary vitamin D intake was associated with 
a lower risk of developing AD among older women.  
4.4.5.3 Prospective studies 
Two prospective randomised controlled trials investigated if vitamin D treatment 
improved cognitive scores in patients with mild-moderate dementia with conflicting results 
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(Gangwar et al., 2015; Stein et al., 2011b). The first study included a population of 
outpatient participants receiving the same regimen of medical treatment for their dementia, 
supplementing one group with additional vitamin D. A total of 80 participants were 
randomly divided into treatment (n=40) and control (n=40) groups. All participants had 
low cognitive scores at baseline, determined by scores <24 on the mini mental state 
examination (MMSE), and were vitamin D deficient with serum vitamin D levels of <30 
ng/ml before the study began. The treatment regime included oral granules of vitamin D3 
(4000IU/d). After 6 months of supplementation, MMSE scores were significantly higher 
in the treatment group compared to controls, supporting that vitamin D3 has a beneficial 
effect on cognitive functions in an elderly population. The second trial was shorter in 
duration and supplemented with oral capsules of vitamin D2. All participants received low 
doses of vitamin D2 (1000IU/d) for a period of 8 weeks, then were randomly allocated to 
high dose (6000IU/d) vitamin D2 or placebo for a subsequent 8 weeks (Stein et al., 2011b). 
All participants had mild-moderate AD determined by MMSE scores between 12 and 24 
recorded by an occupational therapist. At the conclusion of the study, no significant 
differences were observed in MMSE scores between treatment groups. Therefore, it was 
concluded that high dose has no protective benefit compared to low dose vitamin D (Stein 
et al., 2011b).  
In summary, there again were few studies available to comprehensively reflect on 
a potential neuroprotective role for vitamin D in AD and if this was dependent on route of 
administration. The included studies predominately suggest that AD is associated with low 
serum vitamin D levels and increasing serum vitamin D supplementation may improve 
disease outcome; however, further research is required to better understand this 
relationship. No studies investigated the impact of sun exposure on neurological outcomes 
in AD.  
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4.4.6 Amyotrophic lateral sclerosis  
Table 10 lists the study characteristics of all identified studies from the described 
search specific to ALS. A total of five studies were included in the final analysis consisting 
of pre-clinical studies (n=4) and a longitudinal cohort study (n=1).  
4.4.6.1 Pre-clinical studies  
All four pre-clinical studies tested potential therapeutic benefits of vitamin D 
treatment for ALS by manipulating vitamin D in the diet of G93A transgenic mice with a 
mutation in the SOD1 gene, producing the ALS phenotype. Of the four studies, one study 
demonstrated that adequate vitamin D3 levels had a protective effect in ALS (Moghimi et 
al., 2015), another study, using the same study design, reported mixed results, showing that 
vitamin D deficiency decreases early disease severity and delays disease onset, but reduces 
performance in functional outcomes following disease onset (Solomon et al., 2011). The 
final two studies found no significant differences between high vitamin D diets when 
compared with adequate intake control animals (Gianforcaro et al., 2013; Gianforcaro and 
Hamadeh, 2012).  
The first two studies restricted vitamin D intake by reducing the level of vitamin D 
within chow to 0.025 IU/g compared to control animals receiving adequate levels of 
vitamin D at 1IU/g (Solomon et al., 2011; Moghimi et al., 2015). In one study, the spinal 
cords of both male and female mice were analysed for pathological markers of oxidative 
stress and inflammation as indicators of disease severity (Moghimi et al., 2015). Vitamin 
D3 deficiency exacerbated disease pathology through mechanisms that appeared to be sex-
specific, as deficient males were affected more than deficient females (Moghimi et al., 
2015). However, the second study, following the same restricted vitamin D diet showed a 
vitamin D deficiency reduced severity of disease and delayed onset, however, functional 
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performance in these animals was still impaired (Solomon et al., 2011). Indicting vitamin 
D deficiency may differentially affect functional and disease outcomes which was 
hypothesised to result from a gradual decrease in circulating pre-vitamin in the deficient 
animals, with a concomitant increase in circulating levels of active vitamin D (Solomon et 
al., 2011).  
The remaining two pre-clinical studies were performed by the same research group 
and examined enriched vitamin D in the diet using increasing levels of vitamin D3 
supplementation (Gianforcaro et al., 2013; Gianforcaro and Hamadeh, 2012). Neither study 
showed statistically significant differences in the functional outcome measures between 
groups. The first study in 2012 used a 10-fold increase in vitamin D, supplementing chow 
to 10 IU/g. Results were suggestive that vitamin D3 supplementation attenuated the decline 
in functional capacity, as indicated by impaired paw grip endurance and motor performance 
in the mouse model of ALS. However, this did not reach statistically significant levels. In 
the follow up 2013 study, vitamin D3 levels were enriched with a 50-fold increase to 
50IU/g,  and this attenuated the decline in paw grip endurance, but did not influence age of 
onset or disease severity. Suggestive of a tissue specific response to vitamin D in the CNS 
compared to skeletal muscles (Gianforcaro et al., 2013).  
4.4.6.2 Longitudinal cohort study 
The clinical study was a longitudinal cohort study investigating if vitamin D3 
supplementation for a period of 9 months reduced scores on the Amyotrophic Lateral 
Sclerosis Functional Rating Scale (ALSFRS-R) in ALS patients (Karam et al., 2013). The 
study population included 37 ALS patients with a median time since symptom onset of 61 
months. Participants were divided into patients receiving 2000 IU/d vitamin D3 
supplementation (n=20) and participants without supplementation (n=17). At the end of the 
9-month follow up period, the decline in the ALSFRS-R score was significantly smaller in 
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ALS patients receiving vitamin D3 compared to those who were not supplemented with 
vitamin D3. The result of this clinical trial indicate that increased vitamin D 
supplementation and increased vitamin D levels benefit ALS patients. 
In summary, very few studies have been published addressing vitamin D levels in 
the onset and progression of ALS. The pre-clinical data suggest that vitamin D depletion 
produces poorer disease outcomes, although the results have been mixed. Additionally, 
there were no increased protective effects from increasing vitamin D intake above adequate 
levels in the animal studies reviewed. However, the clinical study supplemented above 
adequate intake levels and reported no adverse events. No studies relating to ALS 
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4.5 Discussion 
In this systematic review, we explored the neuroprotective effects of vitamin D in 
neurodegenerative disorders. The focus was on comparing the effect of endogenously 
generated vitamin D, resulting from UV exposure, and different forms of exogenously 
derived vitamin D from synthetic supplementation. Additionally, we set out to identify 
whether vitamin D had a protective benefit on the onset or development of 
neurodegenerative diseases that was dependent on the route of administration.  
The results indicate that current data supporting vitamin D as a neuroprotective 
agent is predominately based on pre-clinical and observational studies and that solid 
clinical evidence is lacking. The majority of clinical MS trials supplementing with vitamin 
D did not show significant difference/improvements between treatment groups, while the 
few clinical studies in PD, AD and ALS did show some positive results yet fewer 
prospective studies were identified. Unfortunately, very limited research was available to 
discuss the impact of vitamin D as a result of sun exposure on neurodegenerative diseases. 
  Another, key finding of this systematic review is that sun exposure may protect 
against MS, but that there is insufficient data to support the use of oral vitamin D 
supplementation as a substitute for UV sourced vitamin D in MS. The lack of published 
clinical research relating to PD, AD and ALS results in insufficient evidence to draw 
conclusions regarding oral vitamin D supplementation versus UV derived vitamin D for 
these diseases. Further, these data draw into question if vitamin D is the mediator of the 
neurodegenerative disease protective effects of sun exposure or whether it is associated 
with increased outdoor activity, which may drive independent neuroprotective benefits or 
an as of yet unknown UV-related neuroprotective effect. 
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Though the complex aetiology of MS, PD, AD, and ALS remain largely unknown, 
the pre-clinical models of these diseases support the hypotheses that insufficient vitamin D 
likely contributes to neurodegenerative disease. Of the 31 pre-clinical studies reviewed, 21 
studies reported that vitamin D had a significant neuroprotective benefit in either delaying 
disease onset (Adzemovic et al., 2013; Spach and Hayes, 2005; Spach et al., 2006) or 
reducing disease symptoms (Bennett et al., 2013; Cass et al., 2014; Garcion et al., 2003; 
Kim et al., 2006; Landel et al., 2016; Nataf et al., 1996; Nashold et al., 2000; Nashold et 
al., 2013; Pedersen et al., 2007; Sanchez et al., 2009; Sloka et al., 2015; Soleimani et al., 
2014; Solomon et al., 2011; Taghizadeh et al., 2014; Tarbali and Khezri, 2016; Wang et 
al., 2001; Yu et al., 2011). The pre-clinical evidence suggests that route of administration 
does not influence neuroprotective benefits from vitamin D. However, only the MS and PD 
pre-clinical studies incorporated both preventative and treatment interventions and looked 
at different age-related timing for intervention and treatment, whereas, the pre-clinical AD 
and ALS studies looked at the effects of vitamin D manipulation after disease onset. Further 
exploration of vitamin D’s role in the onset of disease as well as in varying degrees of 
vitamin D deficiency are needed in these animal models to better understand potential 
protective benefits from vitamin D. 
The pre-clinical literature for all disease types varied significantly in the way in 
which vitamin D was administered to animals and the vehicle substrates used. 
Independently, each of these factors are cause for significant variation in outcomes and this 
may in part contribute to the lack of clinical translation, as the bioavailability would vary 
between different delivery methods. Intraperitoneal injection was the most common form 
of administration in pre-clinical models, particularly in PD research, whereas oral 
supplementation was the predominate route in the clinical literature for all disease types. 
 
 121  
 
The lack of consistency between groups means it is difficult to identify the best vitamin D 
intervention/treatment strategy to design clinical trials.   
Therefore, whilst the majority of pre-clinical data reported a positive outcome 
attributed to vitamin D, this same positive association does not translate clinically, 
particularly for MS. Drawing into question whether animal models adequately reflect the 
human pathologies in this scenario or if there are other important considerations to be made 
when using pre-clinical models to investigate vitamin D in neurodegenerative diseases. 
 
The observational data largely suggest that vitamin D may have a causative role in 
the pathogenesis of neurodegenerative diseases, with 15 of 21 studies highlighting that low 
serum vitamin D levels are associated with increased risk of neurodegenerative disease. 
Though, evidence from the observational research reported here, is not sufficient on its own 
to support the formal recommendation that a person’s brain health would benefit from 
increased serum vitamin D concentrations. Rather, quality use of medicine mandates that 
any recommendations should be grounded in causal evidence from clinical trials (Thacher 
and Clarke, 2011). Observational studies, while useful for generating hypotheses, cannot 
prove causality and often involve many confounding factors (e.g. season, ageing, 
geographical latitude, body mass index (BMI), physical activity, diet, and smoking) that 
are difficult to fully control for and independently relate to vitamin D status and health 
outcomes (Antico et al., 2012). If vitamin D were causatively associated with increased 
risk of neurodegenerative disease, then results from oral supplementation would be 
expected to significantly improve disease outcomes. Yet, as the MS literature shows this is 
not the case, suggesting that disease development and progression is not solely dependent 
on vitamin D. The MS literature demonstrates that sun exposure is linked to decreased 
prevalence of MS although the seven clinical trials, with a total population size of 368 
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participants, showed oral vitamin D supplementation failed to provide neuroprotective 
benefit. This may indicate that, mechanistically, an additional factor, such as UVR, may be 
responsible for the benefits from sun exposure on disease outcomes (Knippenberg et al., 
2014). The limited number of clinical studies available for PD, AD and ALS means it is 
not possible to determine from the systematically reviewed study results whether route of 
administration is a key factor in the neuroprotective benefits associated with vitamin D 
based on this review. 
Information gained from the pre-clinical and observational studies should be used 
in designing clinical trials investigating a role for vitamin D in development and 
progression of a range of neurodegenerative diseases. 
 
The current mechanistic model used to explain the relationship between increased 
UV exposure and decreased neurodegenerative disease is that UVR is critical for the 
production of vitamin D3. Sufficient vitamin D is thought to decrease the risk of 
neurological diseases by supressing pathological mechanisms through increases in anti-
inflammatory properties (Mpandzou et al., 2016; Holick, 2011). However, the data 
presented here show synthetic vitamin D supplementation does not meet neuroprotective 
expectations for MS and more research is needed to support its use in the other diseases. It 
was expected that the different forms of vitamin D would provide a possible explanation 
as to why supplemented vitamin D may not adequately match UVR produced vitamin D. 
However, as most studies used vitamin D3 this is not likely a contributing factor.  It is 
therefore possible that vitamin D may not be associated with neurodegenerative disease 
onset or disease progression but is merely an associative marker of sun exposure. As UV-
B wavelengths contribute to the production of vitamin D, any increases in sun exposure 
will likely result in elevated serum vitamin D levels (Garcion et al., 1998). Yet, UVR has 
 
 123  
 
other inflammatory properties that suppress the immune system through pathways 
independent of vitamin D, including the inhibition of antigen presenting cells, inducing 
suppressor T-cell populations, and altering inflammatory cytokine levels (Norval et al., 
2008). Prospective studies need to consider that vitamin D may be an associative marker 
and ensure to design experiments that are able to separate vitamin D dependent and 
independent contributions from UVR.  
There may be unintentional biases in the clinical studies, which cause an 
overestimation of the impact of sun exposure and vitamin D. For example, patients with 
less disability are more likely to have increased time in the sun participating in outdoor 
activities and therefore have increased levels of vitamin D when compared to those with 
greater disease severity. Moreover, increased physical activity correlates with increased 
time spent outdoors (Gray et al., 2015) and may be a confounding factor in the studies 
reviewed.  People who are more physically active and spend more time outside consistently 
present with improved health outcomes (Bauman et al., 2016; Mead, 2008). Independently, 
physical activity in an important preventative factor against disease with supporting 
evidence for both PD and AD (Paillard et al., 2015). Diet is another potentially cofounding 
variable that may have contributed to unintentional bias.  People who eat meat and fish 
have higher plasma concentrations of circulating vitamin D than those who follow a 
vegetarian or vegan diet (Crowe et al., 2011).  
Regardless of any statistical adjustment for potential interactions between co 
variables including sun exposure, physical activity and vitamin D status residual confounds 
may exist in the observational studies reported here. Adequate control variables of factors 
that may impact disease severity and vitamin D status are needed when designing clinical 
trials. Including physical activity, mood, diet and actual time outdoors/ UV index, which 
as the present time are predominately dependent on the patient’s subjective evaluation and 
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may not be reliable. Future prospective studies would have the potential to overcome this 
through sunlight detection sensors and the use of activity monitors.  
 
Definitions of vitamin D insufficiency/deficiency determined by serum levels of 
25(OH)D also varied across studies. As such, it is evident that there is no consensus on the 
appropriate supplemented vitamin D dose or required level. Nor is there an apparent dose-
to-target plasma concentration of 25(OH)D relationship employed. Amongst the literature 
reviewed here, a variety of oral vitamin D doses were used, ranging tenfold, from 1200 IU 
to 12,000 IU per day. The majority (9/12) of prospective clinical studies included in this 
systematic review supplemented vitamin D doses above the current recommendation of 
800 IU per day (Institute of Medicine Standing Committee on the Scientific Evaluation of 
Dietary Reference, 1997), and often for only short periods of follow up. Another major 
problem with clinical trials regarding nutrients, such as vitamin D, is that they follow 
guidelines that have been designed for pharmaceutical drugs without taking into 
consideration important differences between them. For example, the drug model assumes 
a liner-dose response relationship and that the only source of the agent is in the trial, 
however, nutrients such as vitamin D do not follow these assumptions (Heaney, 2014). 
Furthermore, all clinical studies utilised a standard vitamin D dose rather than individual 
vitamin D dosing to research a desired final concentration, which is suggested to be more 
relevant than dose, per se, in regard to health outcomes (Grant and Boucher, 2017). 
Moreover, the principle method to determine an individual’s vitamin D status currently is 
to measure serum levels of (25(OH)D), which may not be reflective on the active 
metabolite (1,25,(OH)2D), compounding limitations further (Holick, 2009). And finally, 
similar with the pre-clinical studies, the concoctions of oral vitamin D capsules also varied 
between groups which would likely impact on the bioavailability and rate of absorption 
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and therefore introduce a source of uncontrolled variation between studies (Grossmann and 
Tangpricha, 2010).  
 
In conclusion, strong recommendations relating to the potential therapeutic benefit 
attributed to vitamin D in neurodegenerative disease cannot be made based on the evidence 
systematically reviewed and presented here. The available pre-clinical and observational 
literature indicated vitamin D may play a causal role in development of neurodegenerative 
disease. However, minimal evidence from clinical trials exists to suggest oral vitamin D 
supplementation improves disease outcomes in AD, PD and ALS. Moreover, the clinical 
evidence relating to MS indicates that therapeutic benefits from sun exposure could be 
attributed to independent UV factors, rather than solely vitamin D. If vitamin D 
supplementation is equipotent to UVR derived vitamin D, as research assumes, then 
vitamin D supplementation would be expected to improve disease outcome to the same 
extent. The evidence from our systematic review suggests any UVR driven beneficial effect 
in neurological disease, such as MS, cannot be attributed to vitamin D alone. To properly 
address this gap in the literature, further research should consider what other UVR mediated 
factors might be generated in the skin that could be signalling to the brain through the 
development of specialized sensors with advanced sensitivity and the ability to detect all 
signalling mediators induced by UVR. Research would also benefit from the development 
of techniques sufficient to detect and distinguish not only the different forms of vitamin D, 
but vitamin D in both an inactive and active state, in order to more accurately reflect actual 
bioavailable vitamin D levels. A key recommendation of this systematic review is to 
establish a consensus dose and dosing regimen for vitamin D supplementation; 
additionally, future studies should aim to quantify serum vitamin D and metabolites 
concentrations to ensure compliance and bioavailability. It is also important to properly 
 
 126  
 
address the large number of confounding variables that may influence variation in vitamin 
D status, disease severity and any underlying interactions that may skew results. The use 
of high quality prospective or clinical trials is important to build the literature base for (or 
against) the use of vitamin D in AD, PD and ALS. It is also advised that future studies 
employ tests that go beyond the neurological deficit alone and include measures of other 
factors that may impact on vitamin D status, such as physical activity and diet. 
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Chapter 5. Discussion  
5.1 Summary of thesis outcomes 
The primary focus of this thesis has surrounded UV light as a biologically relevant 
initiator of cutaneous responses that have the capacity to affect the brain. UVR is an 
important environmental hazard across the globe, and greater understanding of the broader 
implications from UVR exposure are needed to fully elucidate and manage the potential 
for harm associated with overexposure/avoidance of UVR.   
Chapter 2.  A link between ultraviolet radiation and addiction 
Certain individuals show the behavioural characteristics of addiction following 
frequent exposure to UVR. Additionally, pre-clinical studies have demonstrated that UVR 
exposure, in mice, leads to the activation of neurological pathways that are associated with 
addiction pathology. Together, providing compelling evidence that UVR can influence 
central neuronal circuits and affect behavioural outcomes in a manner that is comparable 
to addiction. However, clear understanding of the physiological mechanisms by which 
UVR can elicit downstream consequences is lacking and more research is needed to 
develop these concepts further. This includes exploring additional aspects of addiction 
pathology, such as the role of the immune system which is now recognised to increase the 
vulnerability to addiction. Thus, this thesis has investigated the converging lines of 
evidence surrounding cutaneous exposure to UVR, immune activation, and addiction, 
aiming to gain greater insights as to how UVR can access central tissue and influence 
neuronal circuitry. This has led to the development of a novel hypothesis that neuroimmune 
signalling, initiated by UV-damaged skin cells, contributes to potentiated signalling within 
the cortico-mesolimbic pathways and a subsequent addiction phenotype.  This work has 
 
 128  
 
been published in Brain, Behaviour and Immunity and raises the following questions; 1) is 
UVR driving a form of addiction and 2) is this mediated by peripherally induced alarmin 
signalling induced from damage sustained by UVR. These research questions were 
explored in Chapter 3.    
Chapter 3. Does UV-induced alarmin signalling influence dopaminergic transmission 
and increase motivation? 
In succession to the literature review undertaken in chapter 2, a research proposal 
detailing planned experiments to explore the role of the immune system in the reward-
related behaviour following UV exposure is presented. The designed experimental works 
aims to examine whether UVR induced alarmin signalling, arising from UV-damaged skin 
cells, leads to increased reinforcement or motivation by effecting dopamine transmission 
within the NAc. The completion of this study will shed light on the role of the immune 
system and dopamine transmission in mediating the reinforcing effects of persistent UVR 
exposure. If a correlation between TLR4 activation and dopaminergic modification is 
found, this could have further ramifications for understanding how the immune system 
contributes to addictive and motivational behaviours. 
Chapter 4. Does source of vitamin D influence neurological effects? 
An important consideration to UV-related research is that UV-B wavelengths are 
responsible for the cutaneous production of vitamin D. As such, virtually all UVR exposure 
will result in increased vitamin D synthesis. Vitamin D exerts a number of biological effects 
throughout the body through interactions with the VDR. In particular, vitamin D has been 
suggested to protect against several neurological disorders. Thus, a systematic review was 
performed to explore if the neuroprotective benefits from vitamin D, in neurodegenerative 
disease, were dependent on the route of administration, by comparing published studies 
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that either supplemented with vitamin or provided a measure of sun-derived vitamin D. The 
findings indicated that there was insufficient data to comprehensively reflect on the 
neuroprotective potential for vitamin D and whether this is dependent on the route of 
administration. Solid clinical evidence supporting vitamin D as a neuroprotective agent is 
lacking, and the majority of current supportive data are based on preclinical and 
observational studies. Therefore, formal recommendations regarding therapeutic use of 
vitamin D, in neurodegenerative disease, cannot be made. The evidence presented in this 
systematic review also raises the question if vitamin D is the true mediator of the presumed 
therapeutic benefits associated with UVR exposure, or if other independent UVR factors 
are involved. To adequately address this gap in the literature, future research needs to 
consider alternative cutaneous responses to UVR, such as the alarmin response discussed 
in Chapter 2, and the potential for these mediators to also impact on neuronal tissues. The 
hypothesis and accompanying research proposal presented in Chapters 2 and 3 may shed 
light on potential independent UVR factors and their downstream effects.  
5.2 General discussion and future directions 
As UVR is biologically active, contributing to both positive and detrimental 
outcomes, UVR is relevant to health of individuals across the globe. The importance of 
UVR has been highlighted in recent years with factors such as migration and changes in 
lifestyle presenting with increased challengers associated with insufficient or over-
exposure to UVR (Diffey, 2003; Jablonski and Chaplin, 2017). These factors also create 
the  potential for new and diverse challenges to health and wellbeing that may be attributed 
to UVR but have previously been disregarded (Iacopetta et al., 2018). Furthermore, as the 
physiological responses to UVR are not limited to point of contact, but can reach distant 
sites, particularly the brain, the question of how UVR related signals travel throughout the 
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body is raised. Thus, the major theme throughout this thesis has surrounded the potential 
mechanisms by which peripheral, cutaneous UVR may influence central circuitry to modify 
behaviour and impact brain health.  
 
The current body of work has suggested possible pathways by which UVR exposure 
may signal to the brain, affecting neurotransmission, through contact with the 
integumentary system. The skin receives continual UVR through daily exposure as it forms 
the body’s outer protective layer, thus skin is the largest gateway for UVR penetrate the 
body and exert an effect (Autier et al., 2014; Becklund et al., 2010; Slominski, 2015).  The 
interaction of UVR with skin cells contributes to an inflammatory state through UVR 
induced damage as well as causing endogenous production of vitamin D. Both 
inflammatory alarmins and vitamin D can travel throughout the body in the circulation, 
reaching distant sites, including the brain, rendering them prime candidates to facilitate 
UVR-mediated skin-to-brain communication. Throughout this thesis, clinically relevant 
examples have been established, demonstrating the potential for these overlapping 
pathways to modulate central tissue. Yet, exact molecular and cellular mechanisms by 
which cutaneous UVR results in neuronal modification remain elusive. More research is 
needed to define specific pathways and neural routes that are involved in translating 
peripheral-to-central signalling induced by UVR. The discovery of a clear molecular or 
cellular pathway by which UVR can lead to central modulation will advance the fields of 
photoimmunology and neuroscience. This may help to develop greater understanding of 
the systematic effects of UVR and broader implications for health and disease. The 
proposed experimental work presented in Chapter 3 is the first step in addressing if the 
immune system facilitates central alterations induced by UVR exposure. The completion 
of this study will provide clear insights on whether UVR influences dopaminergic systems 
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within the brain to increase motivated behaviour; and if this is driven, at least in part, by 
inflammatory signalling arising from UVR damaged skin cells. 
 
To progress knowledge further and best investigate systemic UVR responses, whole 
systems that can be pharmacologically manipulated are needed in order to identify UVR 
induced changes that occur within living tissues. Providing the opportunity to observe 
peripheral responses to UVR, such as the photochemical reactions resulting in the release 
of alarmins and the production of vitamin D, and then track corresponding signalling 
pathways that result in  central alterations. Thus, animal models are a critical tool to gain 
further insights to improve this understanding. Yet, it is important to identify that animal 
models are not without limitations.  In the proposed study design presented in Chapter 3, 
Sprague Dawley rats were selected as they are cost effective, accessible and can be 
routinely trained to perform behavioural tasks. However, as Sprague Dawley rats are albino 
and nocturnal animals with limited melanin production, it is possible that UVR induced 
changes may not be directly translational to human responses and crucial components of 
the pathway could be unalike or missing completely. Hence, caution must be taken when 
interpreting results and additional studies may be needed to further validate identified 
mechanisms.  
 
  Traditionally, methods of administering UVR in animal models has been to suspend 
a UV emitting bulb which illuminates the entire cage, shining on the dorsal surface of 
shaved or hairless animals (Fell et al., 2014; Johnson et al., 2013; Skobowiat and Slominski, 
2015). However, factors such as the distance of the light from the cage, the angle of light 
emissions, the presence of objects that may reflect or block light and differences in the 
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emission spectrum of individual light bulbs can lead to substantial variability in the amount 
of actual UVR received (Goettsch et al., 1999). For these reasons, making comparisons of 
the biological reactions induced by different UVR set ups is near impossible. In order to 
control variability and ensure we are reporting precise quantities of the UVR  administered 
in our model, we have designed a new apparatus that guides UV light directly onto the skin 
via a dispersing cone, securely fitted to the animal (see Appendix A). The benefit of guiding 
the light guiding UVR directly onto the skin is that we can definitively say how much UVR 
the animal received within a given time period as no radiance is lost. Thus, this may provide 
a more accurate assessment of biological changes induced by different quantities of UVR.  
Designing a secure-fitting apparatus was also paramount to minimise harm by 
protecting the most sensitive areas of the animal (eye, ears and paws) from exposure. As 
the light is guided directly onto a contained and target area of the skin, the animal is 
protected and potential confounding variables are eliminated. For example, existing models 
can be profoundly stressful if precautions to protect they eyes are not taken, due to the 
inescapable brightness unaccustomed to nocturnal animals (Bouwknecht et al., 2007; 
Nathiya and Vanisree, 2010). As much remains unknown about the role of the immune 
system in pathological conditions, it is necessary to control for variables such as stress 
which can also influence immune function (Liu et al., 2014). 
 
A major challenge in all health-related UVR research has been to formulate a 
quantitative radiation-based dose-response relationship for UVR exposure and disease 
(Lucas and Ponsonby, 2002). Consequently, the optimal dose or amount of UVR exposure 
a person should receive remains unknown. This is partly due to epidemiological studies 
relying on recalled sun-exposure or actinic damage as measures of past exposure, which 
are highly subjective. It is also likely that for certain diseases, including melanoma and 
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basal cell carcinoma of the skin, there is not a simple linear equation between exposure and 
disease; factors such as the timing and pattern of exposure may critically influence disease 
outcomes (Armstrong and Kricker, 2001). Defining a relationship between UVR exposure 
and disease is further complicated as there is often a long lag period between risks factors 
and  development of disease (Lucas et al., 2006). In addition, behavioural factors and skin 
pigmentation make it difficult to directly equate personal doses of UVR from physical 
measures of ambient UVR. Skin pigmentation alone can substantially alter the dose-
response relationship, darker skin has a 33-fold higher minimal erythemal dose compared 
to fairer skin (Clydesdale et al., 2001). Whereas, behavioural factors such as clothing 
choices, the use of sun-screens and intentional sun-exposure can cause a 100-fold 
difference in personal UVR exposure (Gies et al., 2004).  
 
Considerable advances need to occur in the vitamin D field to adequately address 
knowledge gaps and truly recognise the role of vitamin D in health and disease. Presently, 
there are a number of uncertainties surrounding the physiological function of vitamin D, 
the effects of long-term high/low doses of vitamin D, and the efficacy of different vitamin 
D metabolites. Moreover, vitamin D research is often limited due to the number of 
confounding variables associated with circulating vitamin D levels (e.g. physical activity, 
weight, age) and that definitions of vitamin D insufficiency/deficiency are not standardised 
(Taylor et al., 2017). The future of vitamin D research needs to improve detection methods 
in order to distinguish the different vitamin D metabolites (i.e. vitamin D2/D3) and better 
monitor active vitamin D levels. Future research would also benefit from designing studies 
that can separate vitamin D-dependent and -independent contributions from UVR.  
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5.3 Concluding remarks  
In conclusion, UVR is an important modifiable risk factor for a range of diseases 
affecting human health. Despite the fact that UVR only comes in contact with two 
peripheral ports of entry, through the skin and eyes, it is evident that the effects from UVR 
extend systemically and can influence neuronal circuitry. Although, physiological 
mechanisms remain unclear, this thesis has explored two pathways by which the 
integumentary system may facilitate skin-to-brain signalling induced by UVR, and the 
implications of this for neurological disorders. The outcomes of this thesis have identified 
that in order to overcome the limitations associated with UVR and vitamin D-related 
research, more consistency is needed surrounding experimental design and controlling for 
the wide number of confounding variables associated with UVR exposure and with 
circulating levels of vitamin D. The work contained in this thesis has significant 
implications for progressing the understanding of how peripheral UVR, potentially via the 
immune system or the vitamin D pathway, can access central circuits and affect neuronal 
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Appendices 
Ø Appendix A: Design of a novel apparatus for 
the safe delivery of targeted UVR on the skin 
Ø Appendix B: Pilot study results  
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The proposed study design described in Chapter 3 reflects a body of work that was 
planned with the intention of designing a new experimental protocol for the safe and targeted 
administration of UV light to animals; to test potential motivational properties associated with 
exposure. This included the comprehensive design of a new apparatus that enabled plasma light 
to be administered directly onto an area of the skin via a fibre optic cable, and extensive 
research and planning of experimental protocols to address the research questions described in 
section 3.2. However, during initial pilot tests and training phases the candidate and lead 
investigator experienced a serious injury that had ongoing complications, significantly 
impacting on progression of the research. The uncertainty surrounding the longevity of 
personal treatment and unpredictable circumstances ultimately restricted the capacity of 
completing the research goals within the given time frame of candidature. Thus, the research 
focus was shifted away from the proposed study design and the project was not completed. 
Detailed in the Appendices is the design of the UV light apparatus, protocols and preliminary 
results from initial pilot tests, and the source codes that were developed for behavioural testing. 
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Appendix A: Design of novel apparatus for the delivery of targeted ultraviolet radiation 
on the skin 
As detailed in section 3.7.2, a novel UV light apparatus was developed that guides UVR 
directly onto a target area of skin. In this design, UV light is emitted from a plasma light source 
and then travels along a fibre optic cable connected to a titanium dispersing cone that is worn 
by the animal (displayed in Figure A.1). Designing a secure-fitting UV light apparatus was 
paramount for the outlined research project as it enables precise quantities of UVR to be applied 
to a designated area. This serves to remove ambiguity surrounding the amount of radiation 
received by the animal as no radiance is lost, thus providing greater clarity of subtle differences 
in the physiological response to a range of UVR intensities. Additionally, reducing the UVR 
exposure to a targeted area of the skin eliminates unnecessary exposure to the eyes, ears and 
paws, minimising harm to highly sensitive tissues. Furthermore, containing the light within the 
dispersing cone eliminates a potential stress response triggered by an inescapable bright light 
(Barker et al., 2010) and any associated harm which could significantly impact on results.  
 
  The dispersing cone (Figure A.2A) was designed modelling the curvature of a Sprague 
Dawley rat, and using titanium, was 3D-printed by the Australian National Fabrication Facility 
at the University of Adelaide. UVR was generated with an EQ-99 laser-driven light source 
(Energetiq Technology Inc., Wilmington, MA, United States) known to produce high 
brightness, broad band light. The emission spectrum captured (Figure A.2B) resembles solar 
emission spectrum recorded at sea level including light wavelengths from ~290nm to above 
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Figure A.1. Photograph of the UV light administration using the novel apparatus. UV 
light from a plasma light source (not shown) is delivered to the scapular region of the animal 
along a fiber optic cable (a.). The cable connects to a light weight titanium dispersing cone (b) 
that is sits within a material vest, worn by the animal (c.). All experimental procedures were 
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Figure A.2. (A.) Image of the dispersing cone designed to be worn by the animals for the 
administration of UVR.  (B.) The output spectra of wavelength emissions from the UV light 
apparatus. Demonstrating that the spectra of light emitted is comparable to solar emissions 
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Appendix B: Pilot results  
Pilot 1A: Acute ultraviolet exposure to assess skin response  
The UV light apparatus employs a new method for delivery of UVR, therefore a pilot 
study was undertaken to assess different levels of exposure (amount of UVR received) in an 
acute setting. This was necessary to ensure the light apparatus was effective, without causing 
excessive skin damage and to test study protocols.  Animals were exposed to either 0, 2 or 4 
kj/m2 of UVR and then tissues were collected four hours post-exposure. Histological changes 
in the skin were assessed with routine H&E staining. This pilot study also provided the 
opportunity to test the backpack design for fitting the dispersing cone to the scapular region of 
the animal.  
 UVR exposure 
Ø 0 kj/m2  - equating 1800s (30m) of sham UVR 
Ø 2 kj/m2  - equating to 868s (14.4m) of  UVR and 939s (15.6m) of sham UVR 
Ø 4 kj/m2  - equating to 1736s (28.9m) of UVR and  66s (1.1m) of sham UVR 
Animals: N=9 (3 per group) 
Ø Tissue collection +4 hours post UVR to capture mid-range of the expected 2-6 
peak elevation of alarmin/inflammatory mediators (Catania et al., 1999; Peltz 
et al., 2009).  
Protocol 
Day 1.  
1. Anesthetise animal using isoflurane inhalation (1.5-2% in O2) 
2. Shave scapular region with clippers 
3. Tail-vein blood collection  
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Day 2. 
1. Ensure UV light barrier is in place  
2. Turn on light source, cooling fan and operant box 
3. Collect animals from home cages, as per experiment guide 
4. Fit animal with light cone apparatus and position within operant box, 
attaching fibre cable to the dispersing cone 
5. Double check animal ID and exposure time with experiment guide 
6. Remove UVR filter (if applicable) set timers  (UVR timer and 30-minute 
test timer) and simultaneously remove light barrier. 
7. Once UVR timer has elapsed, apply filter for remainder of test  
8. At 29 minutes (after UVR filter has been applied) save spectrum analysis  
9. Block light source with barrier 
10. Disconnect fibre, remove UV apparatus and return animal to home cage.  
11.  Set a 4-hour timer for post exposure tissue collection  
12. Clean operant box for next use 
 
13. Set up work bench for cardiac perfusion, tissue dissection and collection 
(saline, ice, labelled tubes, liquid nitrogen) 
14. Anaesthetise animal using isoflurane 
15. Perform cardiac bleed and store blood in EDTA tubes 
16. Transcardial saline perfusion until tissues are clear of blood 
17. Collect brain, spinal cord and skin tissue (exposed and unexposed site) 
and place in labelled tubes.  
a. Half of skin samples to be placed in 10% formalin for histology   
18. Freeze tissue immediately in liquid nitrogen 
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Histological analysis with H&E  
Skin samples from the irradiated site and a proximal non-irradiated site were prepared 
for histological assessment following the protocol described in section 4.5.5. Scanned image 
files were analysed using ImageJ software and assessed for:  
a. Cell morphology (length of basal keratinocytes) 
b. Epithelial layer thickness (as a portion of total thickness) 
c. Layer intensity (i.e. were cells becoming more compressed due to 
the UV light and therefore increasing the intensity (number of 
pixels) within a set parameter from each layer) 
To facilitate analysis, images were converted to 8bit, black and white images, and 
then a standardised “region of interest” was selected to obtain measurements of pixel 
intensity and quantity within each region. Comparisons were then made between the UVR 
exposure site and the non-UVR exposure site for each animal and between different exposure 
groups (Figure B.1). Despite extensive analysis, no significant differences in all measures 
between the UVR and non-UVR tissue or UVR quantity were found (Figures B.2-B.4). 
Leading to the conclusion that a single acute exposure of UVR at 0, 2 or 4 kj/m2 in this 
model, was not inducing detectable histological changes in the skin. This was consistent with 
visual assessment of the skin tissue immediately after exposure and at four hours post-
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Figure B.1. Histological assessment acute UVR study. (A.) Cell length (upwards from the 
basement membrane) was recorded from 10 individual cells per image to detect if UVR 
contributed to alterations in keratinocyte morphology. (B.) Analysis of layer thickness by 
measuring three adjacent regions of the epidermis the stratum basale, stratum spinosum and 
stratum granulosum (as a proportion to total thickness) to determine if UVR contributed to 
layer differences. (C.) Layer intensity was measured by looking at the ratio of light/dark pixels 
of each layer, including the dermis, to detect a potential shift in density induced by UVR. (D.) 
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Figure B.2. Analysis of cell morphology of basale keratinocytes. Skin samples were 
collected from the irradiated site and a proximal non-irradiated site, following exposure with 
either 0, 2 or 4 kj/m2 of UVR (n=3 per group). Measurements of basale keratinocytes length 
(upwards from the basement membrane) were then compared between groups to detect UVR-
related changes. Statistical significance was not reached (p>0.05). Statistical calculations were 
performed using liner mixed-effects model fit from R software (R Core team, 2016) comparing 
the mean intensity (length of cell) with the treatment dose.  
 




Figure B.3. Layer thickness as proportion of total thickness. Skin samples were collected 
from the irradiated site and a proximal non-irradiated site, following exposure with either 0, 2 
and 4 kj/m2 of UVR (n=3 per group). The proportional length of the basale, granulosum and 
spinosum layers of the epidermis were determined from the samples collected. An ANOVA 
with Tukey multiple comparisons was performed using GraphPad Prism 7 software (GraphPad 
Software Inc.; California, USA). Statistical significance was not found (p>0.05).  
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Figure B.4. Layer intensity. Skin samples were collected from the irradiated site and a 
proximal non-irradiated site, following exposure with either 0, 2 or 4 kj/m2 of UVR (n=3 per 
group). A standardised area was measured within each layer of skin tissue, representing the 
stratum granulosum (layer 1), the stratum spinosum (layer 2), the stratum basale (layer 3) and 
the dermis (layer 4) from which the ratio of light/dark pixels were compared to detect a 
potential shift in density (increased dark pixels) induced by UVR. No significant detectable 
changes were observed in any layer between the UVR and the sham UVR exposed skin.   
 
 
 172  
 
Outcomes 
1. This method of UVR administration, at physiologically relevant doses, was not 
causing harm/distress to the animals. 
2. A single cutaneous dose of UVR did not induce changes to skin tissue, using H&E 
analysis, four-hours following UVR exposure.  
3. Re-design of the backpack is necessary to ensure secure fitting of the dispersing 
cone to the animal.  
 
Pilot 1B: Repeated ultraviolet exposure to assess skin response after 7 days 
Following the acute pilot study, increased UVR exposure, over consecutive days was 
undertaken aiming to elicit detectable UVR-induced changes to skin tissue. This study 
followed the same protocol as the acute study, however exposure was repeated for 7 days. 
Tissue was collected four-hours post exposure on day 7. Only 0 and 4 kj/m2 of UVR exposures 
were used to allow for larger group sizes. Tissue analysis was performed using HMGB1 
antibody staining, as HMGB1 is a prominent alarmin released from cells during times of injury.  
UVR exposure 
Ø 0 kj/m2  - equating 1800s (30m) of sham UVR 
Ø 4 kj/m2  - equating to 1736s (28.9m) of UVR and  66s (1.1m) of sham UVR 
Animals: N=9 (4-5 per group) 
Ø Tissue collection  +4 hours post UVR exposure 
Protocol 
This study followed the same protocol as the acute UVR study repeating “day 2” 
procedures for seven consecutive days. There was a minor amendment in that the spectrum 
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analysis was recorded at two time points, an initial recording prior to removing the UVR 
filter and then again at the end of the test. The dispersing cone was also more securely fitted 
to the animal with the new fabric vest design as displayed in Appendix A.   
Histological tissue analysis with H&E  
Skin samples were once again collected as described in section 4.5.5 and were stained 
with routine H&E, as in the acute study. However, as there were no evident differences 
between each site (UVR and non-UVR areas) and between UVR and sham UVR groups 
detected during preliminary screening, no further analysis of H&E slides was performed and 
H&E staining was determined insufficient to detect variance in these samples.  
Immunohistochemistry  
Immunohistochemistry was performed to analyse the presence of the alarmin HMGB1 
in skin tissue following UVR and sham UVR exposure. HMGB1 was expected to be 
downregulated in the UVR treated animals, therefore reduced HMGB1 staining in the UVR 
tissue, as there would be less HMGB1 in the tissue once it was released from damaged skin 
cells. A general immunohistochemistry staining procedure has been detailed in section 4.5.6. 
Briefly, antigen retrieval was completed using citrate buffer and endogenous peroxidase 
activity blocked with 3% hydrogen peroxide in methanol. Non-specific binding was blocked 
using 10% normal horse serum in phosphate buffered saline (PBS). Slides were then incubated 
overnight at room temperature in primary antibodies for HMGB1 (Abcam #Ab19256 1:5000). 
Sections were washed in PBS and incubated in a corresponding biotinylated secondary 
antibody for 60 minutes and then incubated in avidin horseradish peroxidase solution for 60 
minutes. Staining was developed with 3,3’ Diaminobenzidine (DAB) and sections were 
washed in running water before counterstaining with hematoxylin, and coverslips applied.   
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Scanned slides were initially assessed using the DAB colour deconvolution function in 
Image J Fiji software to calculate the optical density (max intensity/mean intensity) of the DAB 
separated file image. Optical density analysis was performed on the epidermis and dermis 
together, the epidermis only and the dermis only, however, significant differences between the 
exposure site and not-exposure sites, as well as between UVR and sham UVR was not detected 
(Figure B5).   
Next, manual cell counts of all positively stained cells in either the epidermis, dermis 
(portion of the dermis just below the epidermis) and sub dermis (remaining portion of the 
dermis) regions were obtained to detect possible differences in the number of cells showing 
HMGB1 staining. Image files were blinded and the average number of cells per µm2 were 
determined. Cell counts from each area were then compared between exposure groups (Figure 
B6). However, no significant differences were detected.  
In a final effort to capture an effect, semi-quantitative graded analysis was performed 
on both the epidermal and dermal sections of tissue. For this analysis, blinded images were 
assessed by three independent persons and staining intensity was graded as follows: 0, no 
staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Any discrepancies in 
grading were discussed until a consensus was reached. Still, a significant effect was not 
distinguishable between groups (data not shown).  
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Figure B5. Optical density of HMGB1 staining using DAB colour deconvolution function 
in Fiji ImageJ software. Skin samples were collected from the irradiated site and a proximal 
non-irradiated site, following exposure with either 0 (sham UVR) or 4 kj/m2 of UVR (n=3-5 
per group).  Colour deconvolution allows separation of an image file into channels, so the 
intensity of DAB staining can be assessed within a selected area. GraphPad prism software 7 
(GraphPad Software Inc.; California, USA) was used to perform a two-way ANOVA to analyse 
the mean intensity of the DAB stain within the epidermis, dermis and the two regions 
combined, yet, results were non-significant (p>0.05). 
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Figure B6. Cell counts of HMGB1 positively stained cells per µm2 for the different layers 
of skin tissue. Skin samples were collected from the irradiated site and a proximal non-
irradiated site, following exposure with either 0 (sham UVR) or 4 kj/m2 of UVR (n=3-5 per 
group).  The number of positively stained cells per mm2 from epidermis, dermis and sub dermis 
were determined and used for a two-way ANOVA between the exposure groups and the 
irradiated and non-irradiated sites using GraphPad Prism 7 software (GraphPad Software Inc.; 
California, USA). However, no significant differences were observed between groups 
(p>0.05). 
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Outcome 
1. Daily exposure of skin tissue to 4kj/m2 of UVR for 7 days did not induce 
detectable changes in either H&E staining or HGMB1 immunohistochemistry 
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Appendix C: Source code written for operant conditioning boxes 
Outlined below are the source codes developed for the behavioural testing within the 
operant conditioning boxes described in section 4.5.2. The experiment aimed to investigate if 
UVR administration had an effect on motivational drive determined with performance in the 
progressive ratio/concurrent choice behavioural paradigm described by Randell et al 2012. In 
this experiment the animal has the option to engage in lever pressing for a highly desirable 
sugar pellet or to eat the freely available standard rodent chow, after administration of either 
UVR or sham UVR.  
Three separate codes were required to facilitate the appropriate training regime needed 
to train the animals to engage in lever pressing. The first phase of training, coded as magazine 
training, involved automatic delivery of a sugar pellet every 2 seconds, necessary to expose 
the animal to the chamber and delivery of sugar pellets. Next, animals progressed to the second 
phase, using the code fixed ratio (FR) reinforcement schedule. During this phase, animals are 
required to press a lever in order to trigger the release of a sugar pellets The FR schedule begins 
at 1 (1 lever press for 1 sugar pellet) but is gradually increased across training days to an FR5 
schedule (5 lever presses for 1 sugar pellet). This was implemented by changing the “SET R = 
#” number, corresponding with the reinforcement counter, to the desired ratio at the beginning 
of each training day. Animals remain on an FR5 schedule until a steady output is reached. The 
final phase introduces the progressive ratio reinforcement schedule that will be used for the 
duration of the behavioural tests. During this phase there is an incremental raise in the number 




Magazine training  
\Magazine Training 
\By Krystal Iacopetta 
\March 03, 2017 
\Automatic delivery of pellet every 2 seconds 
 
\Input ; Output ---> Response 
 
\this section is for outputs 
^lever = 2          \left lever operate 
^feeder= 3          \pellet dispenser operate 
^house = 7          \house light 
^light = 9          \cue light 
 
 
S.S.1,     \Main Logical operator delivers pellet every 2 seconds 
 
S1, 
  #START: ---> S2 
 
S2, 
   0.1": ON 3, 9, 2; Z1  ---> S3 
 
S3, 
   6": OFF 3 ---> S2 
 
S.S.2            \minute counter 
 
S1, 
 #START: SHOW 1, Minutes, X; SHOW 4, Seconds, S ---> S2 
 
S2, 
  1': ADD X; SHOW 1, Minutes, X ---> SX 
 
S.S.3            \show pellets on screen 
 
S1, 
   #Z1: ADD B; SHOW 3, Pellets, B  ---> SX 
 
S.S.4,             \Session Timer 
 
S1, 
   #START: SET M=30; ---> S2 
 
S2, 
 1": ADD S; Show 4, Seconds, S; 
      IF S/60 >= M [@true, @false] 
          @true: ---> S3 
          @false: ---> SX 
S3, 




Fixed ratio reinforcement schedule 
\ Fixed Ratio Schedule 
\ By Krystal Iacopetta 
\ March 5 2017 




^leveron=2          \ out for lever 
^lever=3            \ input for responding 
^feeder=3           \ output for reinforcement 






\ A = Total Lever Presses While Time-In 
\ B = Total Pellets Received 
\ C = Pellets Delivered in Grams 
\ D = Highest Ratio Achieved 
\ E = DIM of 5 Minute Response Bins 
\ F = Time-Out Timer 
\ G = 5 Minute Blocks of Responding 
\ H = Time Out Clock 
\ I = Ratio Increment 
\ J = Time-Out Variable - 1 = timed out 
\ K = Total Lever Presses While Time-Out 
\ L = Time of Last Response 
\ M = 
\ N = Number of Reinforcements Before Ratio Increase 
\ O = 
\ P = 
\ Q = Time to Complete Each Ratio 
\ R = Reinforcement Ratio 
\ S = Ratio Time Bin Incrementer 
\ T = Ratio Time Timer 
\ U = FR Counter - Resets after each reinforcement 
\ V = Reinforcement Counter - Resets after N reinforcements 
\ W = 
\ X = Session Timer (in seconds) 
\ Y = Session Duration 




\ Z1: off feeder, counts pellets, Time-Out Timer Reset 
\ Z2: Ratio Incrementer 
\ Z3: Time-Out Controller 
\ Z4: Ratio Time Controller 
 
 

















  #Z3: ---> s1 








  0.01": IF U >= R [@true, @false] 
    @true: ON ^feeder; Z1; SET U = 0 ---> s2 
    @false: ---> s2 
 
 








  #Z3: ---> s1 












   #R^lever: IF (X<=300) [@firsttrue, @firstfalse] 
         @firsttrue: ADD G(0) ---> s1 
         @firstfalse: IF (X>300) AND (X<=600) [@secondtrue, 
@secondfalse] 
                 @secondtrue: ADD G(1) ---> s1 
                 @secondfalse: IF (X>600) AND (X<=900) [@thirdtrue, 
@thirdfalse] 
                       @thirdtrue: ADD G(2) ---> s1 
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                       @thirdfalse: IF (X>900) AND (X<=1200) 
[@fourthtrue, @fourthfalse] 
                              @fourthtrue: ADD G(3) ---> s1 
                              @fourthfalse: IF (X>1200) AND 
(X<=1500) [@fifthtrue, @fifthfalse] 
                                     @fifthtrue: ADD G(4) ---> s1 
                                     @fifthfalse: IF (X>1500) 
[@sixthtrue, @sixthfalse] 
                                             @sixthtrue: ADD G(5) --
-> s1 
















  0.01":  IF X>=1800 [@END,@CONT] 
                 @END: ---> s4 
                 @CONT: ---> s2 
s4, 









Progressive ratio reinforcement schedule 
\ Progressive Ratio Schedule 
\ By Krystal Iacopetta 
\ March 5, 2017 
\ Starts on FR1 and increments by 1 for every 15 reinforcements with 
no limit 
\ Coded with Time-Out Quit when no reinforcements for 2 minutes, 
indicated by lights-out 
 
^leveron=2          \ out for lever 
^lever=3            \ input for responding 
^feeder=3           \ ouput for reinforcement 






\ A = Total Lever Presses While Time-In 
\ B = Total Pellets Received 
\ C = Pellets Delivered in Grams 
\ D = Highest Ratio Achieved 
\ E = DIM of 5 Minute Response Bins 
\ F = Time-Out Timer 
\ G = 5 Minute Blocks of Responding 
\ H = Time Out Clock 
\ I = Ratio Increment 
\ J = Time-Out Variable - 1 = timed out 
\ K = Total Lever Presses While Time-Out 
\ L = Time of Last Response 
\ M = 
\ N = Number of Reinforcements Before Ratio Increase 
\ O = 
\ P = 
\ Q = Time to Complete Each Ratio 
\ R = Reinforcement Ratio 
\ S = Ratio Time Bin Incrementer 
\ T = Ratio Time Timer 
\ U = FR Counter - Resets after each reinforcement 
\ V = Reinforcement Counter - Resets after N reinforcements 
\ W = 
\ X = Session Timer (in seconds) 
\ Y = Session Duration 




\ Z1: off feeder, counts pellets, Time-Out Timer Reset 
\ Z2: Ratio Incrementer 
\ Z3: Time-Out Controller 
\ Z4: Ratio Time Controller 
 
 
DIM G = 6 
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DIM Q = 50 
 













  #Z3: ---> s1 








  0.01": IF U >= R [@true, @false] 
    @true: ON ^feeder; Z1; SET U = 0 ---> s2 












  #Z3: ---> s1 
















  0.01": IF V>=N [@true, @false] 
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        @true: ---> s3 

















  #Z1: ---> s4 
  1": IF R>2 [@true, @false] 
        @true: ADD F; SHOW 5, T TIMER, F ---> s3 
        @false: ---> s2 
s3, 
 
  0.01": IF F>=120 [@true, @false] 
         @true: OFF ^light; ADD J; Z3 ---> sx 













   #R^lever: IF (X<=300) [@firsttrue, @firstfalse] 
         @firsttrue: ADD G(0) ---> s1 
         @firstfalse: IF (X>300) AND (X<=600) [@secondtrue, 
@secondfalse] 
                 @secondtrue: ADD G(1) ---> s1 
                 @secondfalse: IF (X>600) AND (X<=900) [@thirdtrue, 
@thirdfalse] 
                       @thirdtrue: ADD G(2) ---> s1 
                       @thirdfalse: IF (X>900) AND (X<=1200) 
[@fourthtrue, @fourthfalse] 
                              @fourthtrue: ADD G(3) ---> s1 
                              @fourthfalse: IF (X>1200) AND 
(X<=1500) [@fifthtrue, @fifthfalse] 
                                     @fifthtrue: ADD G(4) ---> s1 




                                             @sixthtrue: ADD G(5) --
-> s1 














  #Z3: SHOW 6, TO, H ---> s1 












  0.01": IF J>=1 [@true, @false] 
            @true: ADD K ---> s1 
            @false: ---> s1 
 
 
S.S.8,             \ Time Since Last Response 
 
s1, 
   #START: ---> s2 
s2, 
   #R^lever: SET L = X; SHOW 5, LAST, L ---> s2 
 
 

















    #Z4: SET Q(S) = T; ADD S ---> s2 
 
s2, 
    0.1": SET T = 0 ---> s1 
 












  0.01":  IF X>=1800 [@END,@CONT] 
                 @END: ---> s4 
                 @CONT: ---> s2 
 
s4, 
3": OFF ^light, ^leveron ---> STOPABORTFLUSH 
 
 
 
 
 
